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Abstract 
The Endosomal Sorting Complexes Required for Transport (ESCRT) machinery 
controls key cellular processes, including multivesicular body (MVB) biogenesis, 
retroviral release, division between daughter cells, and closure of small plasma 
membrane wounds, all of which require the budding of membrane away from the 
cytosol.  The ESCRT proteins function by binding membrane, generating 
curvature, and through the enzymatic activity of an AAA-ATPase Vps4, executing 
membrane scission.  Both the localization and oligomerization state of Vps4 are 
important mechanisms that control Vps4 activity.  The ESCRT-III proteins are 
themselves substrates of Vps4 activity but also participate in regulating Vps4 
function.  These proteins are structurally related, and contain a unique protein-
interaction motif known as the MIT-interacting motif (MIM) that engages the Vps4 
microtubule-interacting and trafficking (MIT) domain.  Through this MIT-MIM 
interaction, the ESCRT-III proteins are thought to drive oligomerization and 
recruit Vps4 to the site of action. 
Vps4 regulation is further expanded by its co-factor Vta1, which itself 
contains two tandem MIT domains that bind to the ESCRT-III proteins.  Two 
yeast ESCRT-III proteins, Did2 and Vps60, were initially found to bind the second 
Vta1 MIT domain that stimulates Vps4 via Vta1 binding.  Biochemical analysis 
showed that Did2 does not bind to the second MIT domain as previously thought, 
but in fact binds to the first MIT domain.  The crystal structure of the LIP5-
 xvi 
CHMP1B complex (human orthologs of Vta1 and Did2) showed that this mode of 
interaction is conserved.  Interestingly, the binding interface of Vps60 to Vta1 has 
diverged in higher species.  It appears that LIP5 has evolved different structural 
requirements for VPS4 stimulation as well, and that CHMP5 (human ortholog of 
Vps60) has also gained an inhibitory function for LIP5 stimulation, which is in 
contrast to yeast Vps60.  Another interesting difference between the human and 
yeast systems is that yeast harbor a novel ESCRT-III protein Vfa1.  Vfa1 
regulates Vps4 through a high-affinity MIT-MIM interaction that can greatly 
stimulate Vps4 ATPase activity.  Taken together, these results suggest that while 
the basic mechanism of ESCRT function is conserved, there is a significant 
divergence in the regulatory mechanism of ESCRT action, with Vps4 as a prime 
example.
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Chapter 1 Introduction 
Maintenance of cellular membrane is one of the most important aspects of 
cell viability.  Not only do biological membranes define “self” from “not self”, but 
also are key for the homeostasis of a variety of cellular processes.  Twenty years 
ago, the mechanism of how membrane buds away from the cytosol was 
essentially unknown.  Then emerged the endosomal sorting complexes required 
for transport (ESCRT) proteins, a series of complexes that function to carry out 
this unique topological event (Figure 1.1).  Classically discovered from yeast 
genetics, they were found to be essential in the endolysosomal trafficking 
pathway.  The ESCRT machinery directs cell-surface receptors into multi-
vesicular bodies (MVBs), which fuse with the lysosome to degrade these 
receptors. The ESCRT proteins are also responsible for the membrane-
restructuring event that generates MVBs. As a result, defects in the ESCRT 
machinery have serious implications for development of cancer and other 
pathological states through the deregulation of its client proteins.  It was also 
observed that many enveloped viruses hijack the host ESCRT proteins to help 
them egress from infected cells, a process topologically similar to MVB 
biogenesis.  Another critical cellular role for the ESCRT proteins is to complete 
abscission between daughter cells during cytokinesis, with failure to do so having 
direct ties to cancer progression.  While most of our understanding of ESCRT 
function comes from studying their roles in processes described above, it does 
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not diminish the fact that the ESCRT proteins have also been implicated in: 
plasma membrane repair, autophagosome maturation, exosome biogenesis, and 
the shedding of microvesicles.  Due to the complex role of the ESCRT machinery 
in cell viability and prevention of pathogenic states, there has been an extensive 
effort to understand how the ESCRT proteins work. 
 
Figure 1.1 ESCRT-controlled biological processes 
The ESCRT machinery controls a wide variety of membrane restructuring events 
in the cell, which are labeled in the figure.  All of these processes are related by 
the fact that they require the budding of membrane away from the cytosol. 
1.1 ESCRT and Human Disease 
Given that dysfunction in the ESCRT machinery leads to human diseases, 
understanding its cell biology will likely provide tractable pharmacological targets.  
The ESCRT machinery is best understood in its role in endolysosomal trafficking, 
which controls the degradation of cell surface receptors.  Clearly, dysfunction in 
controlling receptor homeostasis can lead to disastrous effects for an 
organism(1).  For example, many adherens and tight junction proteins are 
degraded via the MVB pathway(2-4).  Imbalance of the degradation of these 
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proteins can lead to the loss of proper cell polarization, which is particularly 
important for epithelial cells.  When epithelial cells lose polarity, the result is the 
epithelial to mesenchymal transition (EMT).  When epithelial cells enter EMT, 
they become migratory, which is thought to promote metastasis(5-7).  In addition, 
the MVB pathway controls the degradation of cellular signaling receptors, such 
as epidermal growth factor receptor (EGRF).  Loss of ESCRT function can cause 
the accumulation of EGFR on the plasma membrane, which leads to hyper-
activation of its downstream targets and generates a proliferative, cancerous 
state(8). Targeting the EGFR and its downstream targets has been used as a 
therapeutic measure for some lung cancers, and thus understanding the biology 
of the MVB pathway may potentially lead to new treatments(9). 
 
In mammalian cells, ESCRT function is also tied to cancer biogenesis 
through their control of abscission during cytokinesis.  Incomplete division of 
daughter cells can lead to multinucleated cells, which are believed to be a source 
of tumorigenesis and aid in resistance to treatments(10,11). The ESCRT proteins 
function to resolve the intercellular bridge which separates the cells and releases 
the midbody (a protein-rich structure in the middle of the intercellular bridge)(12).  
Interestingly, this appears to be the most ancient function of the ESCRT proteins 
as a family of crenarchaea, Sulfolobus, have a subset of the ESCRT proteins, but 
lack an endosomal system(13,14).  It has been shown that these ESCRT 
homologs localize at the site of cell division, in a similar manner as their 
mammalian counterparts, to aid in the completion of cell division(15,16).  Most 
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components of the ESCRT machinery are recruited to the intercellular bridge to 
complete abscission by providing the force necessary to close off the 
membrane(17-19).  Many of these ESCRT proteins are indispensible for their 
roles in cytokinesis, however, our understanding of their specific functions for 
abscission is still unclear. 
 
Many viruses have insidiously evolved the ability to coax the ESCRT 
machinery to aid in their egress from their cellular hosts.  ESCRT proteins control 
the membrane fission event to allow fully matured viruses to be released from 
cells.  While it is best understood for retroviruses (e.g. HIV-1), many other types 
of viruses use a similar strategy(20).  Viral proteins are often sufficient for 
generating membrane curvature, and as such, they only recruit a subset of the 
ESCRT proteins to complete membrane fission(21,22).  These viruses produce 
viral proteins with “late-assembly domains” in order to engage early ESCRT 
components, which can then prompt ESCRT-mediated membrane fission(23).  
For example, HIV-1 Gag proteins contain a motif that specifically recognizes the 
ESCRT nucleating complex, ESCRT-I.  In turn, ESCRT-I recruits only 
downstream ESCRT components that are necessary for membrane fission 
(ESCRT-III and VPS4), but bypasses others (ESCRT-II)(21,24).  Deconstructing 
how these viruses utilize the ESCRT proteins to release from host cells will allow 
us to directly target and prevent viral infection. 
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1.3 Function of the ESCRT Machinery 
1.3.1 Multivesicular body pathway 
ESCRT function is best understood within the context of the 
endolysosomal trafficking pathway and I will use this as a reference for 
describing our current understanding of how the ESCRT machinery functions. 
 
MVBs are unique endosomal organelles that play a critical role in 
maintaining cellular homoeostasis.  They were first observed in the 1950s from 
electron micrograph studies, although their exact nature was unknown(25-27).  
Sotelo and Porter later described MVBs as “a vesicular structure, containing a 
large number of small vesicles” inside the lumen of an endosomal structure(28).  
These intralumenal vesicles (ILVs) were partially egressed from the limiting 
membrane, which was the first evidence that ILV formation has an unusual 
topology and can be described as budding away from the cytosol(27).  More 
importantly, ILVs were later found to contain epidermal growth factor receptor, 
which effectively silences the activity of the receptor(29).  It has since been 
demonstrated that an array of integral membrane proteins are sorted into ILVs(2-
4,30,31).  Once mature, MVBs fuse with the vacuole (lysosome in metazoan), 
which leads to the degradation of its luminal contents as the final step in the 
endolysosomal pathway(32)(Figure 1.2).  
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Figure 1.2 Cell surface receptor down-regulation via the MVB pathway 
A cartoon showing the process of cell surface receptor down-regulation via the 
MVB pathway.  Receptors are colored green and purple.  Through endocytosis, 
cell surface receptors are brought into the early endosome.  Some receptors, like 
the one colored in green, are recycled back to the plasma membrane.  Others, 
like the one colored in purple, become ubiquitinated (orange star), which serves 
as a signal for internalization of this receptor into an ILV and formation of the late 
endosome or the MVB.  The MVB then fuses with the lysosome to degrade its 
luminal contents 
Genetic screens in Saccharomyces cerevisiae were performed to identify 
mutations in gene products that caused vacuolar protein sorting (vps) defects(33-
37).  Tom Stevens and colleagues observed that mutations within a certain 
subclass of vps genes gave rise to a unique vacuolar phenotype, which they 
termed as “class E” genes(38).  The class E phenotype is characterized by the 
appearance of an aberrant structure, comprised of stacked cisternae with 
accumulated proteins and lipids that have not been properly delivered to the 
vacuole for degradation(39,40).  Seminal work by Scott Emr’s group identified 
that the products of several of the “class E” genes work together in a molecular 
complex to target cellular receptors for degradation via the MVB pathway in a 
 7 
ubiquitin-dependent manner(41).  This complex was called the endosomal 
sorting complexes required for transport-I (ESCRT-I). 
 
Further work revealed that other “class E” gene products form additional 
ESCRT complexes, which work as distinct molecular assemblies, with each 
having a clearly defined role in MVB biogenesis.  Currently, the ESCRT 
machinery can be grouped into five sub-complexes: ESCRT-0, -I, -II, -III and the 
AAA-ATPase Vps4.  They are thought to be recruited in a sequential manner to 
the endosomal membrane for their function(42-44).  In terms of yeast MVB 
biogenesis, the ESCRT machinery functions in the following steps: cargo 
selection and sequestering, membrane deformation, and abscission.  Here, I 
define cargo as any protein that gets sorted into the MVB by the ESCRT 
complexes.  While much of the early understanding of the ESCRT complexes 
was achieved in yeast, it has been subsequently demonstrated that they are well 
conserved across eukaryotes (45-47).  Therefore, MVB biogenesis in yeast has 
served as an excellent model of ESCRT function by eliminating much of the 
complexity from possible redundancy, due to isoform and splice variants seen in 
higher species.  
 
For a cell receptor to be targeted for degradation via the MVB pathway, it 
first must be ubiquitinated(31,48,49).  Monoubiquitination of the cytoplasmic tail 
of a receptor has been shown to be sufficient for entering the MVB pathway(50-
52).  The trafficking of polyubiquitinated substrates has also been observed in 
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some cases(53,54).  However, recent data has emerged that suggested cargo 
could enter the MVB in a ubiquitin-independent manner as well.  For example, 
aquaporin AQP2, the G-protein-coupled receptor PAR1, and interleukin-2 
receptor #-chain can all be efficiently sorted into ILVs without ubiquitination(55-
57).  These data suggested that interaction with the ESCRT proteins alone could 
directly result in a protein being identified as an ESCRT cargo.  Indeed, using a 
chimeric substrate, Mageswaran et al. showed that binding to the limiting 
membrane of the endosome while having a loose association with the ESCRT 
proteins was sufficient for proteins to be delivered into ILVs(58).  This model also 
helps explain why some soluble, yet ubiquitinated, proteins can also be targeted 
as cargoes for the ESCRT machinery, since membrane association was initially 
thought to be essential for cargo processing(59-61).  It seems that ubiquitination 
only serves to increase the affinity for the ESCRT machinery, since most early-
acting ESCRT proteins (ESCRT-0, -I, and –II) contain ubiquitin-binding 
domains(62-64).  Membrane proteins at the limiting membrane of the endosome 
can thus avoid ESCRT processing, unless their interaction is increased through 
ubiquitination.  While ubiquitination may not be an absolute requirement for cargo 
processing, more often than not, it serves as a signal for the ESCRT proteins to 
identify cargoes.  
1.3.2 ESCRT-0   
The first critical step in the MVB pathway is the selection of ubiquitinated 
cargo by the ESCRT-0 complex (65).  Two proteins comprise the ESCRT-0 
complex, Vps27 and Hse1 (has symptoms of E class-1) (in human: Hrs 
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(hepatocyte growth factor-regulated tyrosine kinase substrate) and STAM1/2 
(signal transducing adaptor molecule1/2)) (Table 1.1).  The complex functions as 
an ~8 nm long heterodimer of a 1:1 stoichiometry that binds through coiled-coil 
interactions and two domain-swapped GAT (GGAs and Tom1) domains(66-68) 
(Figure 1.3).  Loss of either protein causes defects in MVB biogenesis(69-71).  
Between the two proteins, there are five ubiquitin-binding sites –three ubiquitin 
interacting motifs (UIM)s and two VHS (Vps27, Hrs, and STAM1/2) domains - 
that can mediate selection and clustering of cargo(68,72) (Figure 1.3).  
Hrs/Vps27 contains a FYVE (Fab-1, YGL023, Vps27, and EEA1) domain towards 
its N-terminus that has a unique affinity for PI(3)P (phosphatidylinositol 3-
phospate)(73,74).  PI(3)P is specifically enriched on the late endosomes (the site 
of cargo sorting) as well as on ILVs(75).  The FYVE domain helps the ESCRT-0 
complex localize to the endosomal membrane(76).  STAM/Hse1 has a SH3 
domain that can recruit deubiquitinating enzymes (DUBs), such as AMSH 
(associated molecule with the SH3 domain of STAM) and UBPY (ubiquitin-
specific processing protease Y)(77,78).  Loss of the deubiquitinase activity of 
either enzyme can greatly influence cargo fate(79-82).  This adds an additional 
regulatory step in cargo processing due to the fact that these DUBs can alter the 
ubiquitination state of various cargoes, where loss of a ubiquitin tag allows the 
cargo to diffuse away from the site of ILV formation.  Another interesting 
observation about the ESCRT-0 complex is that it forms higher oligomeric 
structures on the membrane, effectively increasing the multiplicity of ESCRT-0 
function(83).  This could form a lattice around cargo to cluster them on a specific
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Table 1.1 ESCRT proteins in yeast and human and their structural moieties
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zone on the endosomal membrane.  Together, ESCRT-0 uses a variety of 
mechanisms to control the proper sorting of cargo at the endosomal membrane. 
     
Figure 1.3 Structures of proteins that form the ESCRT machinery 
(A) A modeled ESCRT-0 complex.  Pieced together from the Hrs FYVE domain 
(PDB code: 1DVP), the tandem UIM domains of Vps27 (PDB code: 1Q0V), the 
STAM2 VHS domain (PDB code: 1X5B), the Vps27 UIM1 domain (PDB code: 
1O06), the STAM2 SH3 domain (PDB code: 1UJ0), and the Vps27/Hse1 
complex structure (PDB code: 2PJW). 
(B) A modeled ESCRT-I complex.  Pieced together from the Vps23 UEV domain 
(PDB code: 1UZX), the Vps28 CTD (PDB code: 2J9V) and the ESCRT-I complex 
structure (PDB ID: 2P22). 
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(C) A modeled ESCRT-II complex.  Pieced together from the ESCRT-II complex 
(PDB code: 3CUQ) and the Vps36 GLUE domain (PDB code: 2J9V) 
(D) ESCRT-III protein structures.  On the left is the partial structure of CHMP3 
with the helices labeled !1-!5 (PDB code: 2GD5).  Note the position of the !5 
helix, which suggests an “open” conformation.  On the right is the partial structure 
of Ist1 with helices labeled !1-!5 (PDB code: 3GGY).  Note position of the !5 
helix, which abuts !2 helix and suggests a “closed” conformation.  The ESCRT-III 
fold is represented by !1-!4 of both structures. 
(E) A modeled Vps4 monomer structure.  Pieced together the Vps4 MIT domain 
(PDB code: 2V6X) and the Vps4 AAA ATPase domain (PDB code: 2QPA).  The 
MIT domain is colored green, the large AAA subdomain in blue, the small AAA 
subdomain in cyan, the " domain in red, and the C helix in orange. 
(F) A modeled Vta1 dimer structure.  Pieced together from the Vta1NTD structure 
(PDB code: 2RKK) and the Vta1 VSL structure (PDB code: 2RKL).  The MIT1 
domain is colored in cyan, the MIT2 is colored in green, the VSL is colored in red.  
The corresponding modeled in dimer is colored in gray. 
1.3.3 ESCRT-I 
The ESCRT-I complex has been well studied in yeast, as it was the first 
ESCRT sub-complex to be identified(41).  It is comprised of four proteins: Vps23, 
Vps28, Vps37 and Mvb12 (multivesicular body 12) that exist in a complex with 
1:1:1:1 stoichiometry(41,84,85).  This complex is conserved in human as well: 
Tsg101, hVps28, Vps37, and hMvb12, respectively, although Vps37 has three 
isoforms and hMvb12 has two isoforms(46,86-89) (Table 1.1).  UBAP1 
(Ubiquitin-associated protein 1) has also been shown to have an overlapping 
function with hMvb12 in the MVB pathway, however it is more prominently 
involved in processing ubiquitinated cargo(90,91).  Based on structural studies, 
we can build a complete model of the yeast ESCRT-I complex.  It consists of a 
“stalk” formed by Vps23, Vps37 and Mvb12 via antiparallel coiled-coil 
interaction(92) and a globular ‘head’ group formed by Vps23, Vps28 and Vps37 
at one end of the complex(93,94) (Figure 1.3).  This complex can engage 
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ubiquitin, through the Vps23 UEV (ubiquitin E2 variant) domain on its N-terminus.  
A current model suggests that this ESCRT-I interaction with ubiquitin influences 
cargo sorting(41,95,96).  Further structural studies with small-angle X-ray 
scattering (SAXS) revealed that the ESCRT-I complex is elongated (~22.5 #m) 
and highly flexible relative to the stalk(97).  The elongated structure contributes 
to the bifurcation of function, as one end needs to engage ESCRT-0 while the 
other can bind ESCRT-II.   
1.3.4 ESCRT-II 
The ESCRT-I complex recruits the next complex in the pathway, ESCRT-
II.  ESCRT-II itself is a heterocomplex: one subunit of Vps22 (in human: EAP30 
(ELL-associated protein of 30 kDa)), one subunit of Vps36 (EAP45) and two 
subunits of Vps25 (EAP25)(98-101) (Table 1.1).  The ~5 nm complex adopts a Y-
shaped structure, where Vps22 and Vps36 form the base of the complex and 
each arm binds a copy of Vps25 (Figure 1.3).  As highlighted above, binding of 
ubiquitinated cargo is a critical function for early-acting ESCRT complexes.  
While both yeast and human ESCRT-II homologs, Vps36 and EAP45, harbor a 
GLUE (GRAM-like ubiquitin-binding in EAP45) domain that recognizes ubiquitin, 
it apparently does so by two different mechanisms (Figure 1.3).  Within the 
Vps36 GLUE domain, there are two NZF (NpI4-type zinc finger) inserts, where 
one binds to ESCRT-I and the other binds to ubiquitin(102,103).  However, for 
human EAP45, the GLUE domain does not contain NZF inserts, but can still bind 
to ubiquitin directly(104-106).  Through its interaction with ubiquitin, it is thought 
that ESCRT-II can influence cargo selection. 
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Also essential for ESCRT-II function, the two Vps25 arms directly bind to 
Vps20, a core ESCRT-III protein, to activate the ESCRT-III complex(107).  This 
is most likely to be the most critical role of ESCRT-II in MVB biogenesis, as 
ESCRT-II overexpression can rescue ESCRT sorting defect for ESCRT-I deletion 
mutants(108).  In addition, perturbations to one of the Vps25 binding sites can 
lead to the retrograde trafficking of cargo proteins(109).  These data highlight the 
importance of ESCRT-II in cargo sequestering. 
 
Recent work has put forward the idea that ESCRT-I and ESCRT-II work 
together in a supercomplex.  From in vitro reconstitution experiments with GUVs 
(giant unilamellar vesicles), recombinantly purified ESCRT-I and ESCRT-II 
appeared to co-localize and cause membrane deformation(110).  This suggested 
that the supercomplex can provide a mechanism for nascent vesicle budding.  
However, the field remains unconvinced of ESCRT-I and –II’s role in membrane 
deformation in the cell, as argued by Schuh and Audhya(44).  While purified 
yeast ESCRT–I and –II form a stable complex in vitro(102), this complex has not 
been detected in yeast cell extract (41,108).  Attempts to reproduce GUV 
membrane restructuring with an ESCRT-I and –II supercomplex from either C. 
elegans or human failed to induce bud formation(44,111).  Additionally, the size 
of the budding neck formed by the yeast supercomplex in vitro is two orders of 
magnitude larger than what is typically seen in vivo(112).  Experiments 
investigating the effect of other ESCRT proteins in the presence of GUVs also 
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see spontaneous membrane structural change(113,114).  Thus, it appears that 
membrane deformation is not the primary role of the ESCRT-I and –II 
supercomplex. 
 
Instead of controlling membrane deformation, it is more likely that the 
early-acting ESCRT complexes (-0, -I and –II) are more important for cargo 
selection and sequestration.  As discussed above, at least one component of 
each early ESCRT complex contains ubiquitin-binding domain.  The fact that 
these ESCRT complexes are recruited sequentially suggests that this process 
has delineated steps.  ESCRT-0 nucleates the entire process by recognizing 
ubiquitinated cargo.  The recruitment of ESCRT-I and subsequently ESCRT-II 
can then begin to define the geometry of the nascent vesicle.  Since ESCRT-I 
can form higher order oligomeric species on the membrane, the early-acting 
ESCRT complexes can expand greatly outside of their predefined geometry to 
encapsule/capture cargo.  The precise stoichiometry of the early ESCRT 
complexes is currently unknown and remains of great interest to the field. 
1.3.5 ESCRT-III 
The ESCRT-III complex is made up of four “core” proteins, in yeast they 
are Vps20, Vps32 (Snf7 (sucrose non-fermenting 7) is the name I will use), 
Vps24, and Vps2(115) (Table 1.1).  The deletion of core ESCRT-III proteins 
yields a strong class E phenotype(38).  Other “non-core” ESCRT-III proteins 
have been subsequently identified and will be discussed later.  In human, the 
ESCRT-III proteins are called CHMPs (charged multivesicular body proteins), 
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with the analogous core ESCRT-III proteins being: CHMP6, CHMP4, CHMP3, 
and CHMP2, respectively (Table 1.1).  As seen with the early-acting ESCRT 
complexes, in human, various isoforms expand the complexity of the system.  
CHMP2 has two isoforms CHMP2A and -2B, and CHMP4 has three isoforms 
CHMP4A-C.  These different isoforms are generally assumed to function 
redundantly to each other, but emerging evidence suggests tissue specific roles 
for different isoforms(116).  Moreover, recent data has shown that CHMP4B 
functions predominantly in viral budding, whereas CHMP4C is more involved in 
cytokinesis(117). 
 
All ESCRT-III proteins adopt a similar structure fold.  There have been 
crystal structures for truncated CHMP3 and CHMP4B(118-120).  The ESCRT-III 
proteins adopt an ~7 nm bundle of !-helical hairpins, where helices 1 and 2 form 
the length and base of the protein (Figure 1.3).  Helices 3 and 4 fold back as an 
anti-parallel bundle stacked on top of the first two helixes to create a compact 
fold.  These four helixes form the “ESCRT-III fold,” and based on secondary 
structure prediction, are present in all of the ESCRT-III proteins.  The fifth helix 
can then fold back and abut against the ESCRT-III fold opposite helices 3 and 
4(120,121).  The position of the fifth helix is critical for determining whether the 
ESCRT-III protein is in an active or inactive state.  When helix 5 binds to the 
ESCRT-III fold, the protein is in a “closed”, autoinhibited, monomeric and 
cytosolic state (Figure 1.3).  Conversely, when helix 5 is relieved from contact 
with the ESCRT-III fold, the ESCRT-III protein is in an active, “open” 
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conformation and polymerizes on the endosomal membrane(115,119-122) 
(Figure 1.3).  This is evidenced by the fact that ESCRT-III truncations lacking 
regions outside of the ESCRT-III fold form spiral filaments on the membrane that 
cause exaggerated membrane deformation(123,124).  To return to the closed 
state, ESCRT-III proteins are removed from the membrane through the 
enzymatic action of Vps4.  Vps4 contains a microtubule interacting and trafficking 
(MIT) domain that binds to the MIT-interaction motif (MIM) within the ESCRT-III 
proteins.  ESCRT-III MIMs are located C-terminal to helix 5 and are free to bind 
MIT domain-containing proteins in solution when ESCRT-III proteins are in active 
states(125).  There have been a number of MIMs described since their discovery 
and the core ESCRT-III proteins are categorized into two subclasses defined by 
the type of MIM they contain.  Briefly, Vps20 and Snf7 contain a MIM2 and 
Vps24 and Vps2 contain a MIM1(126,127).  The nature of MIT-MIM interactions 
is of great interest for this thesis, and will be discussed in more detail later. 
 
While structurally similar, different ESCRT-III proteins function with distinct 
roles within the ESCRT-III oligomeric complex.  The ESCRT-III proteins work in a 
sequential manner, beginning with Vps20/CHMP6 nucleating ESCRT-III polymer 
formation(128).  Snf7/CHMP4 is the next subunit to be recruited.  Snf7 is the 
most abundant ESCRT-III protein and is considered to be the major driving force 
in membrane deformation via its homo-oligomerization(128,129).  To abridge 
polymerization, Vps24/CHMP3 is thought to act as a cap to Snf7 polymerization 
as it can attenuate Snf7 filament structure(128,129).  Finally, Vps24 recruits Vps2 
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to the membrane, where Vps2 is then able to bring Vps4 to the membrane to 
promote ESCRT-III disassembly(128,129).  The recruitment of Vps4 seems to be 
solely dependent on its interaction with Vps2, even though the other ESCRT-III 
members can also directly interact with Vps4(113,124). 
 
Much work has gone into understanding the nature of the ESCRT-III 
polymer(113).  It has been observed that many ESCRT-III proteins can form 
polymers, by themselves or with another ESCRT-III 
protein(109,123,124,130,131).  For example. wild-type yeast Snf7 forms various 
oligomeric structures on the membrane, including patches, rings and long 
filaments(123).  CHMP4, the human homolog of Snf7, can polymerize as well, 
since the removal of the inhibitory C-terminus causes CHMP4 to form planar 
spirals and circular arrays on a lipid membrane, which are flat in nature.  At high 
concentrations, CHMP4 can form three-dimensional projections from 
membrane(109,131).  This suggests that once in an active conformation, 
ESCRT-III proteins can assemble into a functional tubular and then a dome-like 
structure.  A similar theme is seen with CHMP3 and CHMP2, which, when in their 
open conformation, can co-assemble into a helical structure about ~40 nm in 
diameter(124).  As seen with CHMP4, overexpression of CHMP2 generates 
tubular extensions that bud away from the plasma membrane(130).  Interestingly, 
the addition of CHMP3 and CHMP2 to a planar CHMP4 array can convert it to a 
tubular structure with a dome cap(109).  Whichever the situation, it seems that 
ESCRT-III proteins are competent to form oligomeric, tubular protrusions.  
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However, each experimental condition seems to generate structures with slightly 
differently morphologies.  A likely scenario is that, in vivo, the ESCRT-III polymer 
is a conglomerate of all the morphologies, and that there is a highly precise 
oligomer structure needed for proper ILV formation.  In fact, recent work using 
deep-etch electron microscopy confirms this(132).  Expression of CHMP4 or 
CHMP2 alone produces distinct polymer assemblies, yet interestingly, co-
expression of the two proteins yielded a completely new morphology.  
Furthermore, the final ESCRT complex, Vps4, has also been implicated in having 
a direct role in shaping the ESCRT-III oligomer through direct interaction or by 
removing components from the membrane(109,131,133).  These data highlight 
the fact that ESCRT-III proteins efficiently deform membrane, but high-resolution 
structural studies are clearly needed to understand how the ESCRT-III oligomer 
is constructed under physiological conditions. 
1.3.6 Vps4 
Of all the class E proteins, Vps4 has always gathered a great deal of 
attention due to the fact that it is the only enzyme within the ESCRT 
machinery(134).  Vps4 is highly conserved, from archaea to human, and 
functions in all known ESCRT mediated processes(13-15,135).  In both yeast 
and human, removal of Vps4 causes severe defects in MVB biogenesis and fails 
to recycle the ESCRT machinery from the endosomal membrane(136,137).  
Human has two isoforms of Vps4, VPS4A and VPSB, which are 80% identical to 
each other and 60% identical to yeast(138)(Table 1.1).  In fact, VPSB can 
compliment Vps4 function in !vps4 yeast strains(139).  Due to its high level of 
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conservation and the critical function in the ESCRT pathway, much focus has 
gone into understanding the molecular mechanism of how Vps4 works. 
 
Vps4 belongs to a family of proteins known as the ATPase Associated 
with various cellular Activities (AAA ATPases).  As such, hydrolysis of ATP 
allows the ATPases to exert a mechanical force to physically restructure their 
substrates in some capacity(140-143).  AAA ATPases fall into one of the two 
classes, type–I or type–II, where they contain either one or two ATP binding 
cassettes.  A number of groups have determined crystal structures of the Vps4 
ATPase binding domain in different nucleotide states and from various 
sources(144-147).  Vps4 contains one ATPase binding cassette, comprising of a 
large and small AAA subdomain, and is therefore a type-I AAA ATPase (Figure 
1.3).  The ATP binds between these two subdomains, similar to other AAA 
ATPases, via a Walker A/B motif(148).  The Walker motifs are conserved 
structural elements that bind ATP or GTP(149).  Inserted within the small AAA 
subdomain is a small motif of a three anti-parallel beta sheets.  This “"-domain” 
is unique to Vps4 when compared with other AAA ATPases, and functions to 
bind a cofactor of Vps4, Vta1 (Vps twenty associated-1)(147) (Figure 1.3).  Vps4 
orthologs from simpler organisms that do not contain Vta1 also lack a "-domain, 
indicating a clear evolutionary relationship for this protein-protein 
interaction(144,150).  Beyond the small AAA subdomain is a C-terminal helix that 
abuts the large AAA subdomain (Figure 1.3). The C-terminal helix is critical for 
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the stability of the large AAA subdomain, and perturbations to the structure of this 
helix completely destabilize Vps4(146,147,151). 
 
There are two other structural components to Vps4 outside of the ATPase 
domain, the MIT domain and a linker.  To date, there has been no successful 
attempt at crystallizing a full-length Vps4 protein.  The MIT domain is at the N-
terminus of Vps4 and is responsible for binding to ESCRT-III proteins(152).  The 
Vps4 MIT domain can bind to two different structural motifs with ESCRT-III, 
MIM1 and MIM2 (126,127).  The linker has recently emerged as having a critical 
role in Vps4 function.  It is thought to act in an inhibitory capacity to Vps4 ATPase 
activity.  Substrate binding to the MIT domain relieves this 
autoinhibition(153,154).  In addition, the linker may contain a secondary binding 
site for ESCRT-III proteins(154).  Current models predict that the MIT domain 
and the linker work together to coordinate the removal of ESCRT-III proteins 
through their direct interactions. 
 
Key to Vps4 function is its ability to self-assemble into a higher oligomeric 
structure.  In the absence of nucleotide, Vps4 remains in a catalytically inactive, 
monomeric state and upon ATP binding forms a catalytically active oligomer.  
While there has been some discrepancy whether inactive Vps4 actually exists as 
a dimer(145,148,155), our group has been able to observe only the monomeric 
form of Vps4(121,146).  Regardless of the quaternary structure in the absence of 
ATP, this state is the non-functional form of Vps4. Attempts at capturing a stable 
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oligomer have proven difficult, since Vps4 readily converts ATP into ADP and 
then would disassemble into the monomer structure(148).  To overcome this 
challenge, a mutant form has been used in many studies, with a mutation in the 
Walker B motif, E223Q, which is able to bind but not hydrolyze ATP 
(134,156,157).  This traps the Vps4 in its oligomeric state.  Electron microscopy 
study showed that the Vps4 E233Q mutant could assemble into a two-ringed 
dodecameric structure(155,158,159).  However, recent work has found that the 
E233Q oligomer is non-physiological and that the preferred structure of Vps4 
oligomer is in fact a hexametric ring(144).  This is a more logical structure of the 
oligomer, as other type-I AAA ATPases also adopt single-ringed hexamers in 
their functional states(160,161).  Furthermore, it is easier to reconcile how all the 
MIT domains in Vps4 can orient in the same direction for ESCRT-III interaction in 
a single-ring hexameric structure(162).   
 
Unfortunately, a high-resolution structure of the Vps4 oligomer still 
remains elusive.  The current model of the Vps4 oligomer is based on the p97 (a 
AAA ATPase whose D1 domain forms a single-ringed hexameric structure) 
oligomeric structure(146,161).  While the p97 based model is useful in certain 
ways, we cannot truly understand the mechanism by which Vps4 removes 
ESCRT-III proteins from the membrane without a high-resolution structure.  
Other AAA ATPases, like ClpX (caseinolytic peptidase X), remodel their 
substrate by moving the protein substrate through a central pore in the 
hexamer(163,164).  It has been proposed that Vps4 does so in a similar manner.  
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Mutating residues that are predicted to be in the central pore of the Vps4 
oligomer (modeled from the p97 structure) have been shown to disrupt its 
function in HIV budding(145).  Perturbations in the central pore of human VPS4A 
have also been shown to cause deficiency in ATPase activity due to a loss of 
ESCRT-III interaction(154).  While these data do support a model where the 
ESCRT-III proteins are threaded through a central hole, they do not rule out other 
possible mechanisms(165). 
1.3.7 Vta1 
While Vps4 can self-assemble, this is not an efficient process and, in vivo, 
it is aided by its co-factor Vta1 (in human: LIP5 (lyst-interacting protein 
5))(156,166) (Table 1.1).  Vta1 contains two domains that are connected by a 
flexible linker (Figure 1.3).  At the N-terminus are two tandem MIT domains that 
also bind to various ESCRT-III proteins(167,168).  The first MIT domain is only 
competent to bind MIM1 elements(169,170) and the second MIT domain 
uniquely binds Vps60, an ESCRT-III protein, by a distinct MIT-MIM5 
interaction(167,171).  At the C-terminus is the VSL (Vta1-SBP1-LIP5) domain 
that allows for the dimerization of Vta1 and directly binds to the Vps4 "-
domain(147,156,168,172,173).  Vta1 dimer formation is critical for binding to 
Vps4 and the interaction between the two proteins is ATP-dependent in 
yeast(168).  Recent work has also identified new interactions that further 
stimulate Vps4 ATPase activity, called the VSE (Vps4 stimulatory 
element)(174,175).  The VSE is proximal to the VSL and could be thought of as 
one continuous domain.  However, it is unclear whether there is a VSE-like 
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region in the human LIP5.  Through its interaction via the VSL domain and the 
VSE, Vta1 greatly stimulates Vps4 activity by stabilizing the oligomer.  
Interestingly, the Vta1 linker region inhibits Vps4 stimulation, but this inhibition is 
relieved upon ESCRT-III binding to the N-terminal domain(175,176).  These data 
suggest an important role for the linker in communicating inputs at the N-terminal 
MIT domains and conferring the information to the VSL.  The mechanism by 
which this occurs is unknown and whether it is conserved in human will be 
discussed in Chapter 3. 
 
Given that Vta1 is effective in driving Vps4 ATP hydrolysis, it can be 
thought of as an inherent part of a functional complex with Vps4 in vivo.  For 
yeast Vps4 to self-assemble and have significant ATPase activity in vitro, protein 
concentrations must be greater than ~0.5 µM, but Vps4 concentration in the 
yeast cell is ~0.2 µM(148).  This suggests that additional factors aid in Vps4 
oligomerization in vivo such as Vta1.  This process is conserved in plants as well, 
as the Arabidopsis thaliana(At) ortholog of Vps4 undergoes a five fold increase in 
ATPase activity in the presence of AtVta1(177).  Human VPS4 is a much weaker 
ATPase at a similar protein concentration, which suggests that human LIP5 is 
necessary to promote oligomer formation in vivo, as well(154).  Through its own 
MIT domains, Vta1 can also potentially aid in the recruitment of Vps4 to the 
endosomal membrane(178).  Therefore, the role of Vta1 in the ESCRT pathway 
is to help recruit Vps4 to the endosomal membrane and drive Vps4 oligomer 
assembly(133). 
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Like other ESCRT proteins, Vta1 depletion in yeast cells causes a class E 
phenotype, albeit to a much milder degree(156,179).  Deletion of non-core 
ESCRT-III proteins in conjunction with a Vta1 deletion, however, yields a 
synthetic phenotype that is comparable to a classic class E phenotype(180).  
Further studies using electron tomography found that Vta1 deletion mutant alone 
perturbed MVB formation and is exacerbated by synthetic mutations with other 
ESCRT-III proteins(133).  In mammalian cells, LIP5 seems to have an integral 
role in other processes as well.  Polarization of epithelial cells requires rapid 
turnover of cell-surface receptors, and interestingly, LIP5 has a pronounced 
increase of expression in these cells suggesting a link between these two 
observations(181).  ESCRT proteins control HIV-1 release, but this can be 
prevented by the expression of the interferon-stimulated gene 15 (ISG15), a 
ubiquitin-like moiety.  The Leis group has identified that LIP5 becomes 
conjugated with ISG15.  It was suggested that conjugation prevents association 
of LIP5 with VPS4 and stops viral proliferation(182,183).  These observations 
offer exciting possibilities for targeting LIP5 for therapeutics.  In mammalian cells, 
it has been shown that LIP5 also has a direct role in cargo processing, a role that 
has been classically associated with early-acting ESCRT complexes.  Depletion 
of LIP5 by siRNA caused altered kinetics for ubiquitinated cargo processing(184).  
Two cargos, epidermal growth factor receptor and aquaporin 2, have been 
suggested to have a physical interaction with LIP5 that facilitated their trafficking 
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through the ESCRT pathway(55,184).  It will be interesting to explore whether 
other cargos enter ILVs by this non-canonical mechanism. 
1.3.8 Current model of vesicle formation 
The degree of conservation for different ESCRT complexes gives clues for 
their relative importance in vesicle formation.  Phylogenetic analysis can only 
identify ESCRT-0 homologs in the broad clade of opisthokonts (animal, fungi and 
unicellular eukaroyotes), suggesting alternative mechanisms for cargo clustering 
in other organisms(185).  This is not entirely unexpected as - even in human - 
alternative factors can activate downstream ESCRT complexes for some 
ESCRT-mediated events.  A mammalian protein called ALIX has been shown to 
directly recruit ESCRT-III components in both cytokinesis and viral budding while 
completely bypassing ESCRT-I and –II function(17,19,186,187).  In other 
species, ESCRT-I and –II are dispensable as three taxa of apicomplexan 
(parasitic protist) are completely devoid of any ESCRT-I or ESCRT-II 
components(47).  However, all eukaryotes contain at least one ESCRT-III core 
protein from each subclass (containing a MIM1 or MIM2) and Vps4(47).  This 
suggests, at least evolutionarily, that ESCRT-III and Vps4 are the minimal 
machinery to accomplish vesicle formation. 
 
As discussed above, there is a growing consensus that early-acting 
ESCRT complexes (-0,-I, and –II) primarily function to sequester cargo and that 
membrane deformation and abscission is carried out by late-acting ESCRT 
complexes (ESCRT-III and Vps4-Vta1).  When understanding ESCRT mediated 
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vesicle formation, two facts should be considered: first, the control of vesicle 
formation must be precise since it consistently generates uniformly-sized 
ILVs(39,133); second, the process is amenable to generate vesicles in 
topologically related but geometrically distinct events (MVB biogenesis, viral 
budding, cytokinesis, etc.).  Our current understanding of the ESCRT-III 
polymerization process may shed light on these two observations.  Snf7, in vitro 
or in vivo, has been shown to be potent at membrane deformation and Vps24 or 
a Vps24-Vps2 complex can form filament structures as well.  Interestingly, co-
expression of human Snf7 and Vps2 yielded polymer structures distinct from 
polymers formed by the individual component(132).  The diversity in oligomeric 
structures of ESCRT-III suggests that there may be an optimal oligomeric 
geometry for abscission.  The fact that in vivo Vps4 is necessary for the final 
steps of abscission also suggests that removal of ESCRT-III proteins by Vps4 
may play an important role for the precise timing of abscission(18,188,189). 
 
Studies with human Vps24-Vps2 heteropolymer gave insights to a 
structure that was capable of generating vesicles.  Recombinant human Vps24-
Vps2 formed helical tubes that are ultimately capped by a “dome”-like 
structure(124).  This structure gave rise to a computational model where the 
predicted tension generated by ESCRT-III proteins binding to the highly curved 
membrane could lower the activation energy barrier for membrane scission(190).  
Due to the propensity of Snf7 to generate or stabilize tubular membrane 
curvature(131,191), it would form the base of the dome that is capped by the 
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Vps24-Vps2 filaments to complete the dome hemisphere.  What is attractive 
about this model is that Snf7 would define the boundaries of the nascent vesicle 
through its interaction with upstream components.  The ESCRT-II-Vps20 
complex has been shown to have a preference for binding highly curved 
membrane(114).  Furthermore, both “arms” of the Y-shaped ESCRT-II complex 
nucleate ESCRT-III polymerization and this action is thought to help encircle 
cargo proteins(109).  Therefore, once cargo is properly clustered, Snf7 can 
polymerize and define the area of membrane that will eventually become a new 
vesicle.  Consistent with this model is that loss of Snf7 allows for the retrograde 
trafficking of cargo back to the plasma membrane, where loss of Vps24 does 
not(128). 
 
The necessity of Vps4 ATPase activity also indicates that dome formation 
alone is not sufficient for vesicle formation in vivo.  There are a few models that 
offer insight to the role that Vps4 ultimately plays in the process.  One is that the 
Vps4-Vta1 complex selectively removes ESCRT-III substrates to achieve an 
optimal geometry for dome-mediated scission, if dome assembly alone is 
sufficient for membrane scission as in vitro experiments seem to have 
suggested(110).  There is evidence that Vps4 could affect the dome structure, 
since Vps4 binding to Snf7 polymers has been shown to induce curvature(131).  
Furthermore, Vps4 has a preference for the MIMs of Snf7 and Vps2 for ILV 
formation indicating a coordinated restructuring of the dome(192).  Along the 
same line another model suggests that, due to the high affinity of the ESCRT-III 
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polymer for the membrane and for each other, removal of any protein might 
destabilize the highly curved membrane and cause membrane “buckling(193).”  
Dynamin, a GTPase responsible for endocytosis, follows a similar mechanism, 
where the release of a dynamin polymer from a membrane tubule is sufficient to 
generate the nascent vesicle(174).  Interestingly, several other AAA-ATPases 
use an analogous strategy for disassembly of polymeric substrates.  Eerily 
similar to the Vps4-ESCRT relationship, the N-terminal MIT-domains of Katanin 
and Spastin bind the C-terminal acidic tail of !/" tubulin, and through ATP 
hydrolysis, exerts a mechanical force sufficient to disassemble 
microtubules(160,194).  In the type VI secretion system of gram-negative 
bacteria, the AAA-ATPase ClpV is responsible for the breakdown of large 
VipA/VipB polymers(195).  Analogous to the Vps2, Snf7 and Vps4 relationship, 
ClpV only engages VipB for disassembly of the VipA/VipB heteropolymer(196).  
Current models are not mutually exclusive and further experiments are needed to 
help deconvolute this complex process. 
1.4 Regulators of Vps4 Function 
Outside of the “core” ESCRT-III proteins, a number of “non-core” ESCRT-
III proteins that a similar fold, but do not seem to be essential for MVB 
biogenesis.  However, these other non-core ESCRT-III proteins, Did2, Ist1, 
Vps60 and Vfa1 do have subtle effects on MVB biogenesis and other ESCRT-
mediated processes.  This discussion will now shift to these other regulatory 
ESCRT proteins and describe what functions these proteins may have in the 
ESCRT-controlled functions. 
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1.4.1 CHMP1-IST1 (Did2-Ist1) 
First characterized in human, CHMP1 was found to engage in the MVB 
biogenesis.  Its depletion caused enlarged MVBs, which is the predominant 
hallmark of MVB dysfunction in human(197).  Bioinformatics analyses identified 
that CHMP1 contains two isoforms in human, CHMP1A and -1B(198)(Table 1.1).  
While some functional differences have been identified, these two proteins are 
thought to be redundant for their function in the MVB pathway.  The yeast 
homolog of CHMP1 is Did2, and was not initially identified as an ESCRT protein 
due to its weak class E phenotype upon deletion.  Later, yeast two-hybrid 
analysis found that Did2 interacts with the Vps4-Vta1 complex, suggesting a role 
as an important player in the MVB pathway(199). The interaction between Did2 
and the Vps4-Vta1 complex is thought to bring Vps4-Vta1 complex to the 
endosomal membrane(39,173).  Did2 interaction with either Vps4 or Vta1 
stimulates Vps4 ATPase activity, presumably by stabilizing the Vps4 oligomeric 
structure directly or through Vta1(154,176).  For Vta1-dependent stimulation of 
Vps4, Did2 binding is thought to cause a conformational change in Vta1 N-
terminal domain to relieve the autoinhibition by the Vta1 linker(180).  Since loss 
of Did2 in yeast only leads to a moderate defect in MVB biogenesis, it suggests a 
nuanced role for Did2, most likely regulation of Vps4 function(39,133).  
 
The Did2-Vps4 interaction has been characterized extensively.  One of the 
first structures of a MIT-MIM interaction came from human CHMP1A-VPS4A 
complex(200).  The molecular details of this interaction are well conserved 
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between human and yeast.  For the Did2-Vta1 interaction, however, the picture 
seems a bit unclear.  The Did2-Vta1 interaction binds using a MIT-MIM type of 
interaction, where the Did2 MIM binds to the second of the two MIT domains in 
Vta1 N-terminal domain(176).  Interestingly, human CHMP1B binds to the first 
MIT domain in LIP5(167).  The nature of CHMP1B/Did2 binding to LIP5 (Vta1) 
will be addressed in Chapter 2. 
 
Further pursuits in understanding Did2 function revealed that it works with 
another late-acting ESCRT-III protein Ist1.  Ist1 was initially identified as a Vps4 
interacting protein and further characterization found that it contains two Vps4 
binding sites(201).  One is at the C-terminus, which contains a MIM that strongly 
associates with Vps4 and the other is a lower affinity interaction site within the 
ESCRT-III fold that inhibits Vps4 oligomerization(201).  During starvation 
trafficking through the MVB pathway is at its highest, and interestingly, Ist1 
expression is at its lowest further supporting an inhibitory role for Ist1 in 
yeast(202).  So far, Ist1 is the only ESCRT-III protein shown to have an inhibitory 
affect on Vps4.  Structural pursuits of Ist1 have been quite fruitful(120,121).  
Along with Vps24, all of our structural understanding of the ESCRT-III fold comes 
from these two proteins.  In the crystal structure of Ist1, it was revealed that helix 
!5 interacts with the ESCRT-III fold, which provided the first structural evidence 
of the conformational switch between active and inactive conformation of 
ESCRT-III proteins.  Outside of the ESCRT-III fold, human IST1 is thought to 
contain two MIMs, a proximal MIM2 and a more distal MIM1.  While it is been 
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suggested that the MIT domain of human Vps4 could engage both MIMs 
simultaneously, this has only been determined somewhat indirectly(120). 
 
Within the ESCRT pathway, most evidence indicates that Ist1 and Did2 
function as a heterodimer to regulate Vps4(120,121,169,180,201).  In both 
human and yeast, deletion of Ist1 does not have a large effect on the 
ubiquitinated cargo processing, but electron tomography reveals that their 
respective deletion perturbs MVB biogenesis(133,169).  When examining Ist1 
function with other late-acting ESCRT-III proteins, Ist1 exhibits a synthetic 
phenotype in a !ist1!vta1 or !ist!vps60 strain but not a !ist1!did2 strain(180).  
This suggests that Did2 and Ist1 work in a complex for Vps4 recruitment.  
Furthermore, ablation of the Did2-Ist1 interface has a measureable effect on 
cargo sorting(121).  Ist1 has a high affinity for Vps4 when compared to other 
ESCRT-III proteins, most likely due to its two binding sites (through the ESCRT-
III fold and the C-terminal MIM), and has been proposed to bind a monomeric 
Vps4 in the cytoplasm(201).  This was supported by the fact that the recruitment 
of Ist1 to the endosome is dependent on its interaction with Did2(178,201).  
Together, the Ist1-Did2 complex would hold Vps4 in the cytoplasm, and once 
ESCRT processing reaches a certain time point or step, this complex is then 
recruited to the endosomal membrane to allow for Vps4 activation. 
 
A low-resolution crystal structure has been determined for the Ist1-Did2 
complex(121).  As predicted by yeast two-hybrid analyses, the Did2 MIM binds to 
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the Ist1 ESCRT-III fold.  It binds in a perpendicular fashion to the ESCRT-III fold 
and in parallel to the Ist1 !5.  This suggests Did2 MIM may bind Ist1 by 
displacing the MIM of IST1 (helix !6) and allow for a tripartite complex to form 
with Vps4.  This has been proposed to be the inhibitory state of Vps4, in complex 
with Did2 and Ist1(178).  When recruited to the membrane, the ESCRT-III 
polymer would displace the Did2-Ist1 complex from Vps4 due to avidity from the 
membrane localized ESCRT-III MIMs.  Another interesting observation is that 
human Ist1 and Did2 can form polymer structures in vitro(120).  It is possible that 
once free from Vps4, Ist1 and Did2 could join the ESCRT-III polymer structure 
and contribute to vesicle formation.  Further studies are needed to understand 
the exact role the Ist1 and Did2 polymers play in vivo.   
 
In addition to its important role in MVB biogenesis, the human IST1 and 
CHMP1 complex is essential in two other ESCRT controlled processes, 
cytokinesis and viral release.  In a similar fashion to MVB biogenesis, IST1 and 
CHMP1 are essential for VPS4 recruitment to the midbody (the site of 
cytokinesis).  Loss of either component leads to multinucleated 
cells(120,121,203).  In addition to VPS4 recruitment, CHMP1 and IST1 can also 
bring other MIT containing proteins to the midbody.  AMSH, UBPY, Spastin, 
Spartin, and MITD1 all have MIT domains and can participate in cytokinesis by 
removing ubiquitin(169,204-206), proteolytic cleavage of microtubules(169,207-
209) or limiting the association with VPS4(210,211).  With regard to HIV viral 
release, IST1 function seems to be dispensable while CHMP1 has an essential 
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role(24,111).  This has been seen for human cytomegalovirus as well, suggesting 
the role for CHMP1 in viral release may be conserved(212).  It is thought that 
CHMP1 recruits VPS4 to the plasma membrane to complete abscission for 
budding viruses, just like in MVB biogenesis.  It will be interesting to see why the 
requirements for viral release are different from the other ESCRT-mediated 
processes. 
 
Recent work has identified ESCRT function to be important in the repair of 
micro-wounds to the plasma membrane(213).  Briefly, small wounds that occur in 
the plasma membrane must be excised to retain membrane integrity.  When the 
hole is produced, there is an influx of calcium into the cell due to the 
concentration gradient.  The calcium influx, through a cascade of events whose 
mechanisms are unknown, brings the ESCRT machinery to the site of damage 
and buds the damaged membrane away as a microvesicle into the extracellular 
matrix.  Interestingly, CHMP1B and IST1 form a ternary complex with the 
autolytic protease Calpain-7, a protein that can possibly bind calcium(214).  
Calpain-7 contains tandem MIT domains, and is the binding site for IST1 
MIM(215).  Calpain-7 also binds to the !2 helix of CHMP1B in an unconventional 
manner(214).  Binding to this region of CHMP1B allows for the formation of a 
ternary complex between Calpain-7. IST1 and CHMP1B.  Indeed, it has been 
shown that the presence of both IST1 and CHMP1B elevated Calpain-7 protease 
activity as compared to with just one ESCRT-III component or Calpain-7 
alone(214).  It is unknown whether the calcium binding of Calpain-7 is important 
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for plasma membrane repair, but it would offer an attractive model where the 
three-protein complex senses the calcium influx and is recruited to the site of 
damage.  Additional work on Calpain-7 further revealed that ALIX, a protein that 
nucleates ESCRT-III polymerization in membrane repair, can act as a substrate 
and aid in Calpain-7 recruitment to the site of damage(213,216).  IST1 and 
CHMP1B would then recruit VPS4, which is necessary to complete microvesicle 
release of the damaged membrane (Figure 1). 
 
Interestingly, the CHMP proteins were not originally identified as members 
of the ESCRT pathway, but for their roles in chromatin remodeling.  CHMP1 was 
initially called chromatin modifiying protein-1, but whether it actually carries out a 
specific chromatin remodeling event has not been explicitly tested(217).  
However, CHMP1A does have tumor suppressive properties, and this has been 
directly tied to its localization to the nucleus(218).  Higher expression levels have 
been shown to inhibit tumor growth in both pancreatic and renal tumors(218-
220).  Similarly, in zebrafish cell proliferation has been directly linked to CHMP1A 
nuclear localization(221).  While none of these observations has been directly 
linked to ESCRT function, it expands potential for understanding CHMP1 
regulation as a tumor suppressor gene. 
1.4.2 CHMP5 (Vps60) 
Early work identified that loss of Vps60 in yeast caused mild endosomal 
trafficking defects.  Through sequence analysis, it was classified as a bona fide 
ESCRT-III protein(222).  Unlike other ESCRT-III proteins, Vps60 is found to bind 
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to only one ESCRT protein, Vta1(176).  They function together in MVB 
biogenesis (133,176,179,180).  Deletion of Vps60 and Ist1 or Did2 leads to a 
synthetic class E phenotype, while a !vps60!vta1 strain does not exacerbate 
vacuolar defects(180).  This result supports the model that these two proteins 
function as a complex in the ESCRT pathway.  This interaction is conserved in 
human as well, in a LIP5-CHMP5 complex.  Indeed, CHMP5 and LIP5 interact 
with high-affinity and forms a stable complex in the cytoplasm(170).  Loss of 
CHMP5 has been reported to have different outcomes for cargo processing.  
Early reports did not see a dramatic effect in receptor trafficking with a loss of 
CHMP5(184).  Subsequent studies, however, did find that CHMP5 depletion in 
human cells could alter both MVB biogenesis and the kinetics of cell surface 
receptor down regulation(223).  More indirect evidence for CHMP5’s role in MVB 
biogenesis comes from the fact that a loss of CHMP5 function causes abnormal 
morphogenesis of epithelial cells in Drosphilila(224).  It is presumed that 
alteration of the MVB biogenesis kinetics, and consequently cell surface receptor 
down regulation, is the cause of this morphological change.  As with yeast, 
deletion of Vps60 only yields subtle defects in membrane protein trafficking and 
this phenotype is only observed under stringent experimental conditions. 
 
Much work has gone into understanding the nature of the Vta1-Vps60 
interaction.  As with all other ESCRT-III proteins, Vps60 is predicted to have an 
ESCRT-III fold consisting of five alpha helices.  Vps60 binds to the second MIT 
domain of Vta1, but to achieve maximal binding, two helices !4 and !5, are 
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required in yeast and human(168,170).  This is unique as for all other previously 
studied ESCRT-III interactions, a single helix or extended coil was sufficient for 
MIT binding(225).  This interaction regulates Vps4 ATPase activity through 
Vta1(176).  Like Did2, Vps60 binding to Vta1 is thought to cause conformational 
changes that relieve the inhibitory properties of the Vta1 linker to stimulate Vps4 
at least in yeast(175).  
 
At the beginning of this thesis study, only the N-terminal ESCRT-III 
binding domain of Vta1 (Vta1NTD) had been structurally determined.  In 
collaboration with Prof. Chunyang Cao’s group at Institute of Organic Chemistry, 
Chinese Academy of Science, we determined an NMR solution structure of the 
Vta1NTD-Vps60 (!4-!5) structure that is discussed in the appendix.  The 
Sundquist group determined the NMR structure of the LIP5NTD-CHMP5 
(residues 139-195) complex, while were we able to determine a ternary complex 
crystal structure of CHMP1B (MIM)-LIP5NTD-CHMP5 (residues 139-195).  
These two structures will be discussed further in Chapter 3.  There is also a 
reported structure of the extreme C-terminus of CHMP5, a region outside of the 
LIP5 binding interface, bound to Brox, a protein with an unclear role in HIV-1 
release(226,227).  This peptide fragment of CHMP5 forms a small "-hairpin that 
was unpredicted by secondary structure predictions.  Unfortunately, no functional 
assessment has been attributed to this complex, but it will be interesting to see if 
it can form larger complexes with LIP5 and other ESCRT proteins. 
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CHMP5 also has regulatory functions outside of MVB biogenesis.  
Currently, no study has explicitly examined what role CHMP5 has in cytokinesis, 
but CHMP5 is recruited to the site of abscission(226,227).  For HIV-1 viral 
release, CHMP5 silencing increased the amount of released viral particles(184).  
However, subsequent studies saw that loss of CHMP5 had little effect on viral 
release(24).  While CHMP5’s role in HIV-1 release remains unclear, it contributes 
to the release of avian sarcoma leukosis virus.  Just like with LIP5, ISG15ylation 
of CHMP5 inhibits the release of viral particles(183).  Several ESCRT 
components can be ISG15ylated, but many of them require the ISG15ylation of 
CHMP5 first(182).  The fact that CHMP5 functions in an upstream role in this 
process warrants more investigation.  CHMP5 has been shown to have another 
role outside of MVB biogenesis, as it has been reported to be an oncogene in 
acute myeloid leukema (AML).  Regulation of CHMP5 levels was correlated with 
cascade of caspase activation, which ultimately controls apoptotic cell 
death(228).  In AML, CHMP5 expression is upregulated, and its silencing causes 
cell death for the cancerous cells(229). The mechanism by which CHMP5 
functions as an oncogene is unclear or if its deregulation functions in a similar 
manner as CHMP1B in a cancer-activating pathway. 
1.4.3 Vfa1 
Vfa1 was initially identified in a novel approach to look for proteins that 
affect vacuolar transport.  By overexpressing all the proteins in the yeast 
genome, the Ungermann group observed many genes whose perturbation can 
lead to altered receptor trafficking.  The product of one of the identified genes 
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interacted with Vps4, and was thus termed Vfa1 (Vps4-associated-1).  
Overexpression of Vfa1 causes swollen vacuoles, a class D phenotype – as 
opposed to a class E phenotype that is typically observed in ESCRT 
dysfunction(230).  Vfa1 can also be recruited to an aberrant class E structure in a 
dominant-negative ESCRT background, but its localization to this compartment 
was dependent on its interaction with Vps4(230).  Therefore, the nature of the 
Vps4-Vfa1 relationship added a previously unknown layer of complexity to the 
ESCRT system.  The biochemical and biophysical properties of Vfa1 regulation 
of Vps4 are detailed in Chapter 4. 
1.5 Communication between ESCRT Complexes and Membrane 
One of the most critical aspects of ESCRT function is the ESCRT 
complexes respective ability to sequentially recruit one another to the endosomal 
membrane.  Interpreting and defining how each complex can bind and associate 
with downstream complexes has been an important focus for the field.  I will now 
focus on our current understanding of the communication between various 
ESCRT complexes and membrane.  
1.5.1 Early-acting ESCRT complexes 
After cargo selection and clustering, ESCRT-0 must recruit the next 
ESCRT complex, ESCRT-I, to the membrane.  Hrs/Vps27 of the ESCRT-0 
complex directly binds to the ESCRT-I complex through its distinct and internal 
proline-rich motif(62,70,231,232), where it recognizes the UEV of Tsg101/Vps23 
(70,93) (Figure 1.3).  In both metazoa and yeast, this interaction is essential for 
ESCRT-I localization(69,70) and any perturbation to this interaction decreases 
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the efficiency of MVB biogenesis(62,70).  Through its FYVE domain, ESCRT-0 
also maintains high-affinity interaction with the endosomal membrane, but 
ESCRT-I only directly associates with the membrane via weak electrostatic 
interaction.  The prevailing model is that ESCRT-0 is responsible for anchoring 
the ESCRT-I complex to the endosomal membrane(76,92). 
 
At the other end of the ESCRT-I complex, the CTD (C-terminal domain) of 
Vps28 nucleates the downstream ESCRT-II complex formation(94,102) (Figure 
1.3).  The Vps36/EAP45 GLUE domain from the ESCRT-II complex directly binds 
to Vps28(94,102) (Figure 1.3).  Importantly, the GLUE domain also binds 
specifically to PI(3)P that helps partially localize the ESCRT-II complex to the 
endosomal membrane(104).  Within the Vps36 GLUE domain, there are two NZF 
(NpI4-type zinc finger) inserts, where one binds to ESCRT-I and the other binds 
to ubiquitin(102,103).  However, for human EAP45, the GLUE domain lacks NZF 
inserts(104-106). Vexing to the field, it is still not known how human EAP45 can 
directly interact with ESCRT-I.  Although the specifics of this interaction remain 
nebulous, it is clear that the GLUE domain is an essential factor for maintaining 
the ESCRT-I and ESCRT-II interface. 
1.5.2 Late-acting ESCRT complexes 
As mentioned above, the two arms of the ESCRT-II complex, Vps25, 
nucleate ESCRT-III oligomerization.  A high-resolution crystal structure revealed 
that Vps25 contains a winged-helix domain that provides the minimal binding 
surface for ESCRT-III(107).  Vps25 binds to the first helix of the ESCRT-III 
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protein Vps20 with micromolar affinity, but does not contribute significantly to 
Vps20’s affinity for endosomal membrane(107).  Furthermore, while this 
interaction is important for normal MVB biogenesis, data suggest that its role for 
directing ESCRT-III membrane association can be circumvented, as seen in HIV-
1 budding or cytokinesis(98,233). 
 
In order to be active, the ESCRT-III complex must be associated with the 
endosomal membrane.  The ESCRT-III proteins do not have a ubiquitin-binding 
domain, so cargo is unlikely to contribute to ESCRT-III membrane association.  
Instead, the bottom of the ESCRT-III fold is highly basic, contrary to the acidic 
helix 5 and MIM, and aids in membrane binding(191).  Besides ESCRT-II 
recruitment of Vps20 to the membrane, Vps20 can also undergo myristoylation to 
further tether itself to the membrane(234).  Recently, a new mechanism for 
anchoring ESCRT-III proteins to the membrane has emerged.  At the very N-
terminus of ESCRT-III proteins is a small ANCHR (amphipathic N-terminus 
containing hydrophobic residues) motif(191).  One half of the helix is polar and 
can electrostatically interact with the negatively charged lipid head groups of the 
membrane.  The other hydrophobic half inserts itself into the lipid bilayer, and is 
functionally important for sensing membrane curvature as well(191).  
Understanding how ESCRT-III proteins interact with the membrane has yielded 
significant clues as to how the ESCRT-III polymer sculptures the membrane. 
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1.5.3 MIT-MIM interactions 
A predominant feature of the ESCRT-III complex regulation is the 
communication between their MIMs and with various MIT domains.  This is 
primarily understood through ESCRT-III interaction with Vps4, but has been 
described for other MIT containing proteins as well.  To date, four MIT-MIM 
interactions have been described.  A fifth unique MIT-MIM interaction has been 
found between the second MIT domain of Vta1/LIP5 and Vps60/CHMP5, and will 
be discussed further in Chapter 3 and the appendix.  The MIT domain was first 
described as a putative domain within the SNX15 protein.  It was noted that this 
domain had homology with a variety of other proteins loosely associated with 
ESCRT function(235,236).  Later, a MIT domain was found within Vps4 and is 
the domain by which it recognizes ESCRT-III proteins(152).  The first structure of 
the MIT domain showed it is approximately 80 amino acids long and is folded into 
an antiparallel three-helix bundle(127,152,200).  It was postulated that each 
groove between the helices is capable of binding ESCRT-III ligands.  The first 
MIT-MIM structures were determined for the VPS4A-CHMP1A complex and the 
Vps4-Vps2 complex, and both structures showed that the MIM bound as an 
amphipathic three-turn helix between helixes !2 and !3 of the MIT domain(200). 
Sequence alignment predicted that many ESCRT-III proteins have a similar 
sequence at their C-terminal ends, including Vps24, Vps2, Did2, and Ist1.  The 
consensus sequence motif is (D/E)xxLxxRLxxL(K/R), where x is any residue.  
This type of MIM is defined a MIM1.  As seen in all MIT-MIM1 structures, a 
majority of the binding energy comes from the Van der Waals contacts made by 
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the conserved leucines with the hydrophobic grove formed by the MIT helices !2 
and !3(127,200).  The peripheral hydrophilic contacts also contribute a modest 
amount of affinity, but are more critical for specificity for a particular MIT domain. 
 
Vps4 MIT also recognizes another type of MIM using the groove between 
the !1-!3 helices.  Here, ESCRT-III proteins Vps20 and Snf7 bind using a 
different sequence motif called MIM2.  The MIM2 has a conserved sequence of 
(L/V)Px(V/L)P motif, which binds to the grove as an extended coil, and not as a 
small helix(126).  In the structure of MIT-MIM2, the prolines make extensive 
hydrophobic contacts with the groove.  Comparing the two binding sites, the !1-
!3 groove is much narrower than the !2-3 groove and presumably prevents 
helical MIMs from binding.  To date, a binding partner for the !1-!2 helical 
groove has not been identified and will be interesting to see if one exists.   
 
MIT domains within other proteins utilize similar binding sites to interact 
with MIMs but use distinct mechanisms.  CHMP1B recruits the protein Spastin 
via a MIM-MIT interaction to the midbody during cytokinesis to cleave 
microtubules(237).  Interestingly, the same CHMP1B residues that bind to VPS4 
as a MIM1 bind to Spastin as well.  However, instead of binding at the groove of 
!2-!3, CHMP1B binds between !1-!3 of Spastin MIT, which would be the site of 
MIM2 binding for Vps4(207).  Since CHMP1B binding to Spastin is different from 
either MIM1 (wrong site) or MIM2 (as a helix), this type of MIT-MIM interaction 
has been defined as a MIM3.  The Spastin !1-!3 groove is wider than the Vps4 
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groove and thus can accommodate a helical MIM.  Furthermore, CHMP1B forms 
a five-turn helix when interacting with Spastin, which is much longer than what is 
necessary for CHMP1B to bind as a MIM1.  Spartin, a protein related to Spastin, 
is also recruited to the midbody, and is thought to interact with IST1 through a 
MIT-MIM3 interaction(208).  Work from our group has now shown that IST1 does 
interact with the Spartin MIT at the !1-!3 groove, but as a much shorter helix 
than CHMP1B (E. Guo, unpublished data).    
 
The fourth type of MIT-MIM interaction is seen in a complex between 
CHMP3 and AMSH.  AMSH, a deubiquitinase recruited by ESCRT proteins 
during cytokinesis, contains a MIT domain that binds CHMP3(193,223).  CHMP3 
uses the same residues to bind AMSH as for VPS4.  While CHMP3 binds to the 
equivalent !2-!3 pocket of AMSH, just as it would for Vps4, the critical residues 
for this interaction are polar not hydrophobic(238).  This different binding mode 
was called a MIM4 with the consensus binding sequence being 
ExxxExx$xx$xxRLxTLRx, where x represents any residue and $ is any 
hydrophobic residue. 
 
A common theme of MIT-MIM binding is that it serves to recruit factors in 
the cell to carry out various functions.  Evolution has diversified the MIT domains 
to bind similar peptide sequences in a variety of different ways.  In fact, most MIT 
domains are not easily detectable by sequence homology alone and it often 
requires structure determination to conclusively categorize a MIT domain.  Thus, 
 45 
more effort is needed to understand and decode the complex MIT-MIM 
interactions.  
1.6 Scope of the Thesis 
The ESCRT machinery serves to complete a distinct set of membrane 
restructuring events, which is essential for a variety of cellular processes.  
Deregulation of ESCRT protein can lead to various pathogenic states, particularly 
in the case of Vps4.  Since all ESCRT processes require Vps4 activity, it has 
been a great source of interest to the field to detail how it is regulated.  Currently, 
there is a dearth of understanding concerning how ESCRT-III proteins work with 
Vps4 to control ESCRT function.  My thesis has focused on how the ESCRT-III 
proteins either directly, by binding to Vps4, or indirectly, through interactions with 
Vps4’s cofactor LIP5, regulate Vps4 using biochemical and structural methods.  
In Chapter 2, I will examine the structure of LIP5 and LIP5 in complex with 
CHMP1B and compare how this interaction contributes to VPS4 regulation.  In 
Chapter 3, I will detail how the ternary complex of LIP5-CHMP1B-CHMP5 
uncovered a novel mechanism of LIP5 regulation, and explore the structural 
requirements of LIP5 stimulation of VPS4.  In Chapter 4, I will describe how Vfa1 
is a bona fide ESCRT-III protein that can potently stimulate Vps4 ATPase 
activity.  Finally in Chapter 5, I will discuss the insights we have gained on Vps4 
function, and expand on how this might relate to Vps4 function within the cell.  I 
believe that this thesis work has contributed to our knowledge of Vps4 regulation 
by ESCRT-III proteins, and has allowed us to better understand how these 
proteins collectively work together to control ESCRT function in the cell. 
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Chapter 2 Structural Conservation of Vps4 regulation by its co-
factor Vta1 and ESCRT-III proteins 
2.1 Abstract 
Disassembly of endosomal sorting complexes required for transport 
(ESCRT) machinery from cellular membrane is a critical final step in multi-
vesicular body biogenesis, retroviral release, abscission during cytokinesis and 
plasma membrane repair.  This process requires the interaction of the ESCRT-III 
complex with the enzymatic Vps4-Vta1 (VPS4/LIP5 in human) complex.  While it 
has been extensively studied in yeast, there has been a lack of understanding 
whether the specifics of these interactions are conserved in human proteins as 
well.  Here we present the crystal structures of the LIP5 N-terminal domain 
(LIP5NTD), the region that interacts with the ESCRT-III ligands, alone and in 
complex with a fragment of an ESCRT-III protein, CHMP1B.  The LIP5NTD 
contains two microtubule-interacting and trafficking (MIT) domains.  We saw that, 
thematically, LIP5NTD and Vta1NTD share the same fold, but there are subtle 
differences between the two structures particularly in the second MIT domain.  
These differences may explain the different binding properties for yeast and 
human ESCRT-III proteins to this domain.  Furthermore, we identified that for 
both yeast and human, CHMP1B interacts with the first MIT domain of LIP5.  The 
MIT-interacting motif (MIM) of CHMP1B binds via a canonical MIT-MIM1 mode 
as seen for other MIT-ESCRT-III interactions.  Our data redefine how the 
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ESCRT-III proteins bind to LIP5, and suggest a lack of conservation for ESCRT-
III binding to the second MIT domain of LIP5. 
2.2 Introduction 
The Endosomal Sorting Complexes Required for Transport (ESCRT) 
proteins control and complete many essential biological processes, such as 
multi-vesicular body (MVB) biogenesis, enveloped virus budding, abscission 
during cytokinesis, and repair of small membrane wounds (1-4).  These events 
are all topologically related by the fact that they require the budding of cellular 
membrane away from the cytosol, which is distinct from other well-studied 
protein-membrane reconstructing events like clathrin-mediated endocytosis (5).  
MVB biogenesis is the best understood process of all the ESCRT-controlled 
functions, and was initially characterized in yeast (6).  Although predominantly 
studied in this context, it has been shown that the ESCRT proteins are well-
conserved from archaea to human and are thought to function through similar 
mechanisms regardless of protein origin (7). 
 
The ESCRT proteins function as a series of macromolecular complexes 
during the long process of vesicle formation (8,9).  Working at the later stage of 
vesicle formation are two ESCRT complexes, ESCRT-III and Vps4 (in human: 
VPS4).  The ESCRT-III complex is comprised of similarly folded proteins, whose 
job is to bind and deform membrane (10,11).  The ESCRT-III proteins, when 
bound to the membrane, are thought to undergo conformational changes that 
expose a C-terminal region that can now bind to the AAA-ATPase Vps4.  Vps4 
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contains a microtubule-interacting and trafficking (MIT) domain at its N-terminus 
that can engage with the ESCRT-III proteins (12).  Structurally, MIT domains are 
comprised of a small three-helix bundle capable of binding ligands in the grooves 
between its helical grooves.  In fact, the ESCRT-III proteins have evolved to bind 
at discreet grooves on the surface of the Vps4 MIT domain using two different 
sequence motifs, commonly referred to as MIT-interacting motifs (MIMs) (13-15).  
Through this MIT-MIM interaction ESCRT-III recruits Vps4 to the membrane, and 
where ATP hydrolysis provides the energy necessary to complete membrane 
scission(16). 
 
Vps4, however, is an inefficient enzyme that must undergo oligomerization 
to form a functional and active species (17).  Upon ATP binding, Vps4 monomers 
form a high-ordered, hexameric, and single-ringed species that is functionally 
active (18).  Biochemical studies have shown that this oligomer is unstable and 
requires additional factors to be stabilized in this conformational state (19).  One 
such factor is Vta1 (LIP5), an ESCRT protein that binds to a unique domain 
within the ATPase domain of Vps4 (20).  The Vps4-Vta1 interaction has been 
shown to dramatically increase Vps4 ATPase activity.  It is thought that Vta1 
interaction helps stabilize the oligomer, which in turn increases ATPase 
throughput (19).  Vta1 may also aid in Vps4 regulation by controlling its 
localization.  Vta1 contains two tandem MIT domains at its N-terminus (19).  The 
multiplicity of MIT domains within the Vps4-Vta1 complex increase its avidity in 
 71 
binding the ESCRT-III ligands, thus allowing the complex to be recruited to the 
membrane. 
 
Two ESCRT-III proteins, Did2 (CHMP1A and CHMP1B) and Vps60 
(CHMP5) are thought to have specialized roles in recruiting the Vps4-Vta1 
complex.  Loss of either Did2 or Vps60 leads to altered kinetics for receptor 
degradation through the MVB pathway, presumably due to the development of 
MVBs with unusual morphology (21,22).  Did2 can bind to either the Vps4 MIT or 
the Vta1 MIT domains, and both interactions increase Vps4 ATPase activity 
(23,24).  It seems that Vps60 can only interact with Vta1 and not with Vps4 
(25,26).  With regards to VPS4 binding in human, the CHMP1A MIM was found 
to form a small helix that binds between the second and third helices of the Vps4 
MIT, which has since been classified as a MIT-MIM1 interaction (15).  The 
specifics of this interaction are thought to be conserved in yeast as well.  In 
yeast, Did2 binding to Vta1 has been mapped to the second MIT domain where it 
is assumed to interact by a canonical MIT-MIM1 mechanism (23).  Although, it is 
not known whether the human orthologs of Did2 and Vta1 bind using the same 
mechanism.   
 
Currently, there is a significant gap between our understandings of 
ESCRT function in yeast versus in human.  Vta1 and LIP5 have low sequence 
homology, which suggests the possibility that ESCRT-III proteins regulate Vta1 
and LIP5 by different mechanisms.  To this end, we determined the crystal 
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structure of the LIP5 N-terminal domain (LIP5NTD).  We found that, overall, the 
N-terminal domains of LIP5 and Vta1 adopt a similar fold.  However, some 
structural differences indicate a possible alternative mechanism of regulation.  
We also investigated the nature of interaction between Did2 and Vta1, and 
between CHMP1B and LIP5.  To our surprise, we found that regardless of 
protein origin, the ESCRT-III protein bound to MIT1 of Vta1/LIP5, while Vps60 
binds to MIT2.  The high-resolution crystal structure of LIP5NTD-CHMP1B 
showed that this interaction indeed occurs via a canonical mode of MIT-MIM1 
interaction.  From our biochemical and structural analysis, regulation by the 
ESCRT-III proteins for the Vta1/LIP5 MIT1 domain seems to be conserved, while 
regulation of MIT2 is divergent. 
2.3 Results 
2.3.1 The crystal structure of the N-terminal domain of LIP5 
Due to the low sequence homology between yeast Vta1 and human LIP5 
(approximately 22% identity) (Figure 2.1), we sought to determine the crystal 
structure of the N-terminal domain of LIP5 (LIP5NTD, residues 1-162) to identify 
the extent of conservation between the two structures.  The LIP5NTD structure 
was determined by single-wavelength anomalous diffraction (SAD) method and 
refined to a 3.0Å resolution with an R-factor of 24.8% and a free R-factor of 
28.6% (Table 2.1). 
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Figure 2.1 Sequence alignment of Vta1/LIP5 
Vta1 residues predicted to be important for binding the ESCRT-III proteins to the 
MIT1 are colored in yellow.  Vta1 MIT2 residues that are important for Vps60 are 
colored in red. 
 In the crystal structure, there are three molecules in the asymmetric unit 
(ASU).  The electron density quality for the three molecules varies at different 
regions of the protein structure.  Only molecule A had sufficient electron density
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Table 2.1 Crystallographic data statistics  
 LIP5NTD  LIP5NTD/CHMP1B 
 Native SeMet Native 
Data Collection    
Space group P6522 P6522 P212121 
Unit cell parameters:    
a, b, c (Å) 76.4, 76.4, 355.9 76.1, 76.1, 355.1 52.8, 55.2, 194.9 
!, ", # (°) 90.0, 90.0, 120.0 90.0, 90.0, 120.0 90.0, 90.0, 90.0 
Molecules/ASU 3 3 2 
Wavelength (Å) 0.9792 0.9792 0.9787 
Resolution (Å) 3.0 3.3 2.2 
Unique reflections 13124 9907 29702 
Redundancy1 6.9 (7.1) 18.3 (19.0) 7.3 (7.4) 
Completeness (%) 98.8 (99.8) 98.2 (99.1) 99.9 (100) 
Average I/$ (I) 18.8 (3.6) 22.4 (5.0) 19.4 (3.2) 
Rmerge  0.10 (0.60) 0.16 (0.56) 0.11 (0.55) 
Refinement    
Residues in the structure    
LIP5 3-158  1-162 
CHMP1B   183-199 
Resolution range (Å) 50.0-3.0  50.0-2.2 
Rwork (%) 25.0  19.6 
Rfree (%) 28.7  22.7 
RMS deviations    
Bond lengths (Å) 0.010  0.009 
Bond angles (°) 1.06  1.22 
B-factor average (A2) 71.1  37.6 
Ramachandran plot    
Most favored (%) 97.7  98.0 
Allowed (%) 1.2  1.7 
Outliers (%) 1.2  0.3 
PDB accession code 4TXP  4TXQ 
1 Values in parentheses are for the specified high-resolution bin. 
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to build a continuous model.  In the final model, residue 4 is missing for molecule 
B and residues 4 and 7 are missing for molecule C.  By aligning molecule A to B, 
A to C and B to C based on their visible C! positions, we determined that the root 
mean squire deviations (r.s.m.d) were 0.22, 0.37, and 0.36 Å2, respectively 
(Figure 2.2B).  In the following structure description and analysis, we use 
molecule A as a structure representative for the LIP5NTD structure. 
A 
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Figure 2.2 The crystal structure of LIP5NTD 
(A) Overview of the LIP5NTD structure.  Cartoon representation of LIP5NTD (1-
162) in three orthogonal views.  MIT1, MIT2 and the short linker between the two 
MIT domains of LIP5NTD are colored cyan, green and white, respectively.  
Helices of LIP5NTD are labeled !1-!7.  (B) Molecules in the asymmetric unit 
have good agreement with each other.  Molecules in the asymmetric unit were 
aligned to one another based on their C! positions, where the root mean squared 
deviation is noted above the alignment (RMSD, Å).  Molecule A has the same 
coloring scheme described in Figure 1A, molecule B is colored in magenta, and 
molecule C is colored in orange. (C) An example of van der Waals contacts at 
MIT domain interface with the same coloring scheme as described in Figure 1 
except atoms are colored as such: carbon atoms of MIT1, cyan; carbon atoms of 
MIT2, green; oxygen, red; nitrogen, blue.  Side chains that are found to make 
hydrophilic intramolecular interactions are represented as sticks, except critical 
side chains are shown as sticks with their van der Waals surfaces in dot 
representation. (D) Hydrophillic intramolecular interactions stabilize MIT1-MIT2 
interface.  Left panel, overview of loop representation of LIP5NTD.  Right panel, 
zoom-in view of the side chains involved in hydrophilic interactions and uses the 
same coloring scheme as described in Figure 2C.  Hydrogen bonds are 
represented by dashed lines.   
Not surprisingly, LIP5NTD contains two easily identifiable MIT domains, 
MIT1 and MIT2.  Each MIT domain contains a three-helix bundle that is oriented 
nearly perpendicular to each other (Figure 2.2A).  MIT1 contains helices !1-!3 
(residues 16-74) and MIT2 contains helices !5-!7 (residues 83-162).  
Connecting these two domains is a small one-turn helix (!4, residues 75-82). 
Interestingly, we observed an N-terminal extended loop (residues 3-15) 
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positioned in the groove between helices !1 and !3 that could occlude any 
possible ligand binding to this groove. 
 
MIT1 and MIT2 interact through an extensive surface area, where many of 
the residues from !1-!2 of MIT1 and !5-!6 of MIT2 contribute to stabilize the 
interface.  Hydrophobic interactions predominate, for example Tyr41 from the 
MIT1 makes van der Waals contacts with three residues from the MIT2: Asp126, 
Val127 and Val130 (Figure 2.2C).  Additional contributions to the stability of this 
interface come from several hydrophilic interactions as well.  Three histidines 
from the MIT1, His19, His20, and His27, form hydrogen bond interactions with 
Tyr119, Asp126, and Tyr93, respectively, from the MIT2 (Figure 2.2D).  A salt 
bridge between Glu26 and Lys116, which is conserved across metazoa, is also 
seen at the interface (Figure 2.1 and Figure 2.2D).  The high conservation of this 
salt bridge indicates a potential functional importance for this interaction.  A list of 
all the intramolecular interactions between MIT1 and MIT2 can be found in Table 
2.2. 
2.3.2 Comparing the LIP5NTD crystal structure to the Vta1NTD crystal structure 
and the LIP5NTD solution structure 
The crystal structure of the N-terminal domain of yeast Vta1 (Vta1NTD, 
residues 1-167) was reported previously (19,23).  While the sequence 
conservation between Vta1 and LIP5 is low, the overall structural folds are 
similar.  We aligned the Vta1NTD structure (pdb code: 2RKK) with our LIP5NTD  
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Table 2.2 Tabulation of the intramolecular interactions within LIP5 
MIT1 MIT2 
Hydrogen bond interactions  
H19 ND1 Y119 OH 
H19 NE2 Y119 OH 
H20 NE2 D126 OD2 
E26 OE1 K116 NZ 
E26 OE2 K116 NZ 
H27 NE2 Y93 OH 
Van der Waals interactions  
H19 Y119, L123 
T23 T120 
H27 Y93 
V34 Y93 
Y37 L90, V127 
C38 V127 
Y41 D126, V127, V130, 
 
structure (Figure 2.3A).  The Vta1 structure contains two molecules in the ASU.  
By aligning the C! positions between these two structures and LIP5NTD, we saw 
the r.m.s.d between the structures was 3.4 Å and 3.8 Å, respectively. 
The high r.m.s.d suggests that there are some outstanding differences 
between the two structures.  Due to the low-resolution (~3Å) of both structures, 
we only note major structural differences.  These differences are localized to four 
major areas.  First is the aforementioned N-terminal extended loop that exists in 
the LIP5NTD structure (Figure 2.3A).  This stretch of sequence is a conserved 
feature in metazoan LIP5 but not yeast Vta1 (Figure 2.1).  In addition, the !4 
linker that connects the two MIT domains is significantly longer and disordered in 
the Vta1 structure, but we saw clear electron density for a one-turn helix in the 
LIP5 structure (Figure 2.3A).  We also observed that in the MIT2 fold, the turn 
between helices !6-!7 occurs much earlier in LIP5 by about 4.6Å.  Beyond that, 
we saw other subtle helix positional differences between the two structures.  The 
 80 
A 
 
B 
 
 81 
C 
 
Figure 2.3 Structural differences and similarities between the LIP5NTD 
crystal structure, the Vta1NTD crystal structure and the LIP5NTD solution 
structure 
(A) Two orthogonal views of the superimposition of Vta1NTD and LIP5NTD.  
LIP5 is colored in the same schematic as described in Figure 2A and Vta1 (PDB 
code: 2RKK) is colored similarly but pale.  Positional differences between the 
structures are labeled with arrows.  Helices are labeled !1-!7.  (B) Two 
orthogonal views of the superimposition of the LIP5NTD crystal structure and the 
LIP5NTD solution structure.  LIP5 from the crystal structure is colored in the 
same schematic as described in Figure 2A and LIP5 from the solution structure 
(PDB code: 2LXL) is colored similarly but pale.  Positional differences between 
the structures are labeled with arrows.  Helices are labeled !1-!7.  (C) Residues 
predicted to be essential for ESCRT-III binding.  The left panel shows the 
superimposition of !2-!3 groove surface of LIP5 and Vta1.  Side chains that 
were structurally conserved and predicted to prevent MIM1 binding are shown, 
with LIP5 residues in cyan and Vta1 residues in pale cyan.  The right panel 
shows the superimposition of the MIT2 domains of LIP5 (green) and Vta1 (pale 
green).  Vta1 residues that are important for Vps60 binding and residues from 
LIP5 that are structurally conserved are shown. The following atoms are 
additionally colored: oxygen, red; nitrogen, blue; sulfur, orange. 
 
two MIT1 domains superimpose very well, where we only saw helix !1 of LIP5 
being about 2.6Å closer to the MIT2 (Figure 2.3A).  However, there is larger 
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positional difference in the MIT2.  Helix !7 of LIP5 seems to be the driving force 
behind the relative shift of its MIT2, where it is about 4.8Å closer to the MIT1.  
This positions !6 in a more perpendicular orientation relative to the MIT1 by 
4.5Å, and consequently forces helix !5 to shift outwards by 3.1Å relative to the 
overall structure. 
 
We also compared our LIP5NTD crystal structure to a recent solution 
NMR structure of LIP5NTD (PDB code: 2LXL) (27).  Aligning the two structures 
based on their C! positions generates a r.m.s.d. of 1.3 Å, which suggests good 
agreement between the two independently determined LIP5NTD structures.  For 
the MIT1 domain, the two structures are nearly superimposable except for a 2.3Å 
positional difference in helix !1 (Figure 2.3B).  In MIT2, we saw more substantial 
conformational differences.  Helices !5 and !6 in the crystal structure have a 3.6 
Å and 2.3 Å shift, respectively, relative to their solution structure counterparts 
(Figure 2.3B).  There is also positional difference in the position of helix !7 
between the two structures, where it shifts by 6.6Å.  While some differences exist 
we propose that thematically, these two structures are the same 
2.3.3 ESCRT-III binding to LIP5/Vta1 
Previous work has mapped the binding sites of Did2 and Vps60 to the 
second MIT domain of Vta1 ((23), appendix).  By comparing our LIP5 structure to 
Vta1, we looked to see whether the binding surface for these ESCRT-III proteins 
is conserved in human.  Vta1 Lys152 has been previously shown to be critical for 
binding both Did2 and Vps60 (23).  From the alignment, we see that LIP5 Lys143 
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is oriented in an equivalent position, suggesting the residue can be utilized to 
bind CHMP1B and CHMP5 by LIP5 in a similar manner.  However, when site-
directed mutagenesis and binding analysis were used to investigate the 
contribution of this residue for binding the two ESCRT-III proteins, no effect was 
seen for K143A mutation (data not shown).  Therefore, we made an additional 
mutation of a highly conserved tyrosine, Y144A, hoping to further perturb the 
binding interface (Figure 2.3C).  We termed these MIT2 domain mutations LIP5-
MUT2 (K143A, Y144A).  The equivalent mutations on Vta1 are K152A, Y153A 
(Figure 2.3C).  We also made a series of alanine mutations to residues in the 
MIT1 domain (E68A, K71A, K72A), termed LIP5 MUT1.  Based on the 
assumption that LIP5 can bind the ESCRT-III proteins via a MIT-MIM1 binding 
mode, these residues would be essential for maintaining the LIP5 and ESCRT-III 
interaction. (14,15) (Figure 2.1 and Figure 2.3C). 
Using Glutathione S-Transferase (GST) pulldown analysis, we tested 
whether GST-tagged CHMP1B or CHMP5 could interact with LIP5, LIP5 MUT1 
or LIP5 MUT2 (Figure 4A).  To our surprise, CHMP1B failed to bind LIP5 MUT1, 
but retained full capacity to bind LIP5 MUT2 compared to the wild-type protein.  
The LIP5 MUT1 mutations block binding to the LIP5 !2-!3 helical groove, 
suggesting CHMP1B binds as a MIM1 (14,15).  We also saw that neither LIP5 
MUT1 nor LIP5 MUT2 seemed to dramatically affect CHMP5 binding.  Further 
studies investigating the LIP5-CHMP5 interaction clearly showed that LIP5 
Lys143 and Tyr144 are not involved in the LIP5-CHMP5 binding interface ((27), 
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also in Chapter 3), and could explain why we do not see a loss of binding in our 
assay. 
A 
 
B 
 
Figure 2.4 GST-pulldown analysis of LIP5/Vta1 for ESCRT-III binding 
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(A) ESCRT-III binding to LIP5.  GST-CHMP1B and GST-CHMP5 were used to 
analyze their interactions with LIP5, LIP5 MUT1, and LIP5 MUT2 (listed 1-3).  (B) 
ESCRT-III binding to Vta1.  GST-Did2 and GST-Vps60 were used to analyze 
their interactions with Vta1, Vta1 MUT1, and Vta1 MUT2 (listed 1-3). Proteins 
retained on the beads were analyzed by SDS-PAGE and visualized by 
Coomassie staining. 
Since the mechanism of binding was different between yeast and human 
proteins, we wanted to validate the binding site of Did2 and Vps60 on Vta1 by 
GST pulldown analysis.  A similar experiment was performed as described 
above, but this time we used Vta1, Vta1 MUT1 (E57A, K60A) and Vta1 MUT2 
(K152A, Y153A), which are equivalent to the LIP5 mutations (Figure 2.3B).  We 
observed again, that Did2 failed to bind Vta1 MUT1, but could interact with Vta1 
and Vta1 MUT2 (Figure 2.4B).  As expected, the Vps60 binding site of Vta1 
appears to be on MIT2, as only mutations on MIT2 (Vta1 MUT2) lead to loss of 
interaction with GST-Vps60 (Figure 2.4B).  These data suggest that the previous 
notion that both Did2 and Vps60 bind to MIT2 of Vta1 needs to be reexamined 
and that the interaction between CHMP1B/Did2 and LIP5/Vta1 is well-conserved, 
but the CHMP5/Vps60 binding interface seems to be divergent. 
2.3.4 The Crystal structure of LIP5NTD-CHMP1B 
To determine whether CHMP1B does in fact bind LIP5 as a MIM1, we 
determined the crystal structure of LIP5NTD in complex with CHMP1B176-199, a 
fragment that is necessary and sufficient for binding LIP5NTD.  The LIP5NTD-
CHMP1B176-199 complex structure was solved by molecular replacement using the 
above-determined crystal structure of LIP5NTD as a search model (Table 2.1).  
The structure was refined to 2.2 Å with an R-factor of 19.3% and a free R-factor 
of 22.7%.  Binding of CHMP1B does not cause significant change in the overall 
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structure of LIP5NTD.  When the LIP5NTD molecules in the apo- and CHMP1B-
complex structures were compared, the alignment showed an RMSD of 0.34 Å 
between the C! positions of the two structures. 
2.3.5 CHMP1B binds to the MIT1 domain of LIP5 
The CHMP1B binding site of LIP5 is located on the MIT1 domain.  
CHMP1B forms a three-turn helix and sits on the surface groove formed by 
helices !2 and !3 of the LIP5 MIT1 (Figure 2.5A).  The binding mode of 
CHMP1B to LIP5 is similar to the binding observed in the VPS4A-CHMP1A 
complex structure (15), which is also more generally known as the MIT-MIM1 
binding mode.  As seen in other MIT-MIM1 structures, the cognate MIT domain 
presents an overall hydrophobic surface, which is necessary for tight binding 
(Figure 2.5B).  The binding between the two molecules buries approximately 624 
Å2 of surface area. 
A 
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Figure 2.5 The crystal structure of LIP5NTD-CHMP1B complex. 
(A) An overview of the LIP5NTD-CHMP1B complex structure. Cartoon 
representation of LIP5NTD (residues 1-162) in complex with CHMP1B (residues 
176-199) in two orthogonal views. CHMP1B is colored in yellow and LIP5 is 
colored the same as in Figure 1A. Helices of LIP5NTD are labeled !1-!7. (B) 
The CHMP1B-binding surface of LIP5NTD is hydrophobic. LIP5NTD is shown as 
a surface representation and colored based on the underlying atoms: 
hydrophobic side chain atoms, orange; polar and charged side chain atoms, 
blue; and main chain atoms, white. CHMP1B is shown as a yellow coil. (C), (D) 
Detailed interactions at LIP5NTD-CHMP1B interface. Zoom-in cartoon 
representation showing residues involved in hydrophobic (C) and polar (D) 
interactions between LIP5NTD and CHMP1B. Residues that make distinct 
contacts are shown as stick models. Hydrogen bonds are denoted as dashed 
lines. Coloring schemes are the same as in (A) except for the following atoms: 
oxygen, red; nitrogen, blue; sulfur, orange. 
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The bound peptide in the canonical MIT-MIM1 structure often utilizes a 
series of conserved aliphatic residues, in many cases leucines, for binding 
(14,15).  In the LIP5NTD-CHMP1B176-199 structure, Leu188, Leu192, and Leu195 
of CHMP1B make intimate contacts with LIP5, whose binding surface consists of 
Tyr36, Leu40 and Met47 from helix !2 and Leu60, Met64, Leu67 from helix !3 
(Figure 2.5C).  In addition to the leucines, two polar residues of CHMP1B, 
Arg191 and Arg196, are also seen at the binding interface, with their aliphatic 
portion of the side chains contributing to hydrophobic binding and terminal 
groups contributing to polar interactions (Figure 2.5D).  Arg191 forms two salt 
bridges with Asp65 and Glu68 of LIP5, and Arg196 makes one hydrogen bond 
interaction with Gln44. Interestingly, Arg196 also makes a lone interaction with 
the MIT2 domain.  Here, a hydrogen bond is formed between its side chain and 
the main chain carbonyl oxygen atom of Val130. A tabulated list of all interactions 
is shown in Table 2.3. 
Table 2.3 Interaction table for LIP5NTD-CHMP1B MIM structures 
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To evaluate the contribution of individual residues to the overall stability of 
the LIP5-CHMP1B complex, site-directed mutagenesis and GST pulldown 
analysis were performed.  We used GST-tagged CHMP1B176-199 to test its 
binding to LIP5 and various LIP5 mutants including LIP5 L40A, LIP5 Q44A, LIP5 
M64A, LIP5 E68A and LIP5 MUT1.  Among the mutants, M64A has been 
previously shown to disrupt CHMP1B binding (27).  We observed that both L40A 
and E68A affected CHMP1B binding to a similar extent as M64A, whereas Q44A 
had little effect on CHMP1B binding (Figure 2.6A).  However, to completely 
abolish the binding of CHMP1B, multiple mutations were required on the LIP5 
surface. 
A 
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Figure 2.6 Critical residues at the LIP5NTD-CHMP1B interface. 
(A) Critical residues on LIP5. GST-CHMP1B176-199 was used to analyze its 
interaction with LIP5 and various LIP5 mutants (listed as 2-6). (B) Critical 
residues on CHMP1B. GST-CHMP1B176-199, GST-CHMP1B176-199, L195D or GST-
CHMP1B176-199, R196A was used to analyze its interaction with LIP5.  
 
We also mutated two CHMP1B residues, Leu195 and Arg196, to evaluate 
their importance to LIP5 binding.  The ability of GST-tagged CHMP1B176-199, 
CHMP1B176-199/L195D or CHMP1B176-199/R196A to bind LIP5 was examined.  As seen 
in Figure 2.6B, L195D was not able to bind LIP5, demonstrating the importance 
of hydrophobic interaction to the overall binding.  In contrast, R196A bound LIP5 
to the same extent as the wild-type protein, suggesting that the peripheral polar 
interaction contributes to a lesser degree to the overall stability of the complex. 
2.4 Discussion 
ESCRT function is central to MVB biogenesis, where the final steps are 
regulated by the AAA-ATPase VPS4.  VPS4 has evolved a cofactor, LIP5, which 
can increase its activity and promote its association with the ESCRT-III 
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components.  While much of our knowledge about human LIP5 function was 
originally derived from studies in yeast, there is always the question how 
conserved the mechanism of VPS4 regulation really is.  Here, we have 
investigated the structure of LIP5NTD and revealed it to be structurally 
homologous to its yeast counterpart, Vta1.  However, our studies also showed 
that the mechanism by which it binds to some of the ESCRT-III components may 
have diverged.  The crystal structure of LIP5NTD in complex with CHMP1B MIM 
revealed canonical MIT-MIM1 binding mode between the two proteins.  Together, 
this work has identified key similarities and differences between Vta1 and LIP5, 
pointing to the potential mechanistic differences that may exist between yeast 
and human systems. 
2.4.1 LIP5NTD comparison to Vta1NTD 
Our structural analysis was able to see that, despite low conservation 
between LIP5 and Vta1, the N-terminal domains of each protein adopt a similar 
fold.  However, LIP5 contains a N-terminal extended coil that binds in the !1-!3 
helical pocket (Figure 2.2A).  This structural feature potentially has physiological 
consequences.  In the case of Vps4 MIT domain, it can bind two ESCRT-III 
ligands, MIM1 in its !2-!3 pocket and MIM2 in its !1-!3 pocket (13-15,28).  The 
MIM2 uses the consensus sequence of "-P-X-"-P (where " is a hydrophobic 
residue, and X is any residue) to bind this pocket as an extended coil (28).  LIP5 
residues Leu2, Leu7, Pro8, Leu10, and Pro11 mimic the MIM2 sequence to 
make hydrophobic contacts in this pocket.  Other studies have shown that 
ESCRT-III MIM2 containing proteins cannot bind LIP5 (27).  Most likely, this N-
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terminal coil may function in vivo to prevent interactions with these MIM2-
containing ligands. 
 
Although similar, we have observed structural differences between 
Vta1NTD and LIPNTD.  As seen in Figure 2.3A, the LIP5 MIT2 globally 
undergoes approximately a 4 Å rotation relative to the Vta1 MIT2.  This 
movement increases surface area of the MIT1-MIT2 interface, which allows for a 
more extensive interaction.  In fact, this allows for the formation of a salt bridge 
between LIP5 Glu-26 and Lys-116, which we will describe in Chapter 3 to be 
important for sensing the binding of CHMP5.  While not explicitly tested, we 
believe that the structural differences between the two orthologous proteins may 
account for the functional differences. 
2.4.2 ESCRT-III binding to the MIT2 domain 
We also investigated whether the mechanisms of ESCRT-III binding are 
conserved in LIP5.  Yeast proteins, Did2 and Vps60, were initially found to bind 
to the Vta1 MIT2 (23).  We were keenly interested in seeing if LIP5 uses a similar 
binding strategy to interact with CHMP1B and CHMP5, the respective orthologs 
of Did2 and Vps60.  One of the key residues for this interaction, Vta1 Lys152, is 
structurally conserved in the LIP5 structure as residue Lys143 (Figure 2.3B).  
However, mutation of this residue and a structurally conserved tyrosine does not 
ablate CHMP5 binding (Figure 2.4A).  LIP5 and CHMP5 bind with a very high 
affinity, ~100 pm, so one could argue that our assay was not sensitive enough for 
detecting the effect of mutating these two residues even if they are part of the 
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binding interface (24,27).  However, our structural work on the LIP5-CHMP5 
complex as described in Chapter 3 will show that these residues are not in the 
binding interface.  While these residues are important for the Vta1-Vps60 binding 
, the same cannot be said true for LIP5 and CHMP5.  Clearly, the binding 
interface between Vta1-Vps60 and LIP5-CHMP5 has diverged during evolution. 
2.4.3 CHMP1B binding to LIP5NTD 
Our work led us to test whether CHMP1B binds to the MIT2 of LIP5 as 
well.  GST-pull-down analysis showed that GST-CHMP1B binds LIP5 MUT2 to a 
similar amount as wild-type (Figure 2.4A).  Interestingly, GST-CHMP1B failed to 
bind LIP5 MUT1 (Figure 2.4A).  Since residues mutated in LIP5 MUT1 stabilize 
MIM1-binding elements, this suggested that CHMP1B binds to LIP5 as a MIM1.  
This prompted us to test whether Did2 does in fact bind to Vta1 MIT2.  Sequence 
analysis predicted that Did2 would bind MIT domains as a MIM1, mainly through 
hydrophobic contacts (14,15).  MIM1 has been shown to bind between the !2-!3 
helical groove of the MIT domain.  This would correspond to helices !6-!7 in the 
MIT2 domain of Vta1.  If that were the case, Lys155 in the !6-!7 groove would 
prevent any binding by a hydrophobic MIM1 element.  Indeed, we found that 
Did2 binds to the Vta1 MUT2, but not Vta1 MUT1 (Figure 2.4B).  This establishes 
that CHMP1B and Did2 bind to the same region of LIP5/Vta1 and this interaction 
is well-conserved in MIT1.  These data are consistent with our current 
understanding of ESCRT-III regulation of MIT domain containing protein.  Most 
interestingly since the binding sites of MIM1 containing ESCRT-III proteins, like 
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Did2, and Vps60 do not overlap, it should be possible to explore how these 
proteins simultaneously regulate Vta1. 
 
A number of human MIM1-containing ESCRT-III proteins including 
CHMP1A, -1B, CHMP2, CHMP3 and IST1 have been previously shown to bind 
to LIP5 (24,29).  The crystal structure of the LIP5NTD-CHMP1B complex 
confirmed that CHMP1B binds to LIP5 MIT1 as a MIM1.  This predicts that other 
MIM1-containing ESCRT-III proteins will bind to LIP5 in the same way.  Since 
binding of CHMP1B MIM1 to LIP5 does not induce significant conformational 
change in LIP5, this suggests that interaction between LIP5 and MIM1-containing 
ESCRT-III proteins likely serve to recruit the VPS4-LIP5 complex to the ESCRT-
III bound membrane. 
 
Taken together, the structural analysis of LIP5NTD and the LIP5NTD-
CHMP1B MIM structures have illustrated important insights on ESCRT-III 
regulation of LIP5.  While previous work in understanding ESCRT-III function in 
yeast does not need to be dramatically reinterpreted, it does highlight that 
differences do exist between yeast and human systems. Earlier reports showed 
that Vta1 stimulation of Vps4 ATPase activity is potentiated by ESCRT-III 
binding, and it will be interesting to see whether this mechanism is conserved in 
human.  The fact that there appears to be two different binding mechanisms for 
binding to MIT2 by the two orthologs CHMP5/Vps60 suggests that the allosteric 
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regulation of the LIP5/Vps60 might be different.  Further functional assays are 
needed to deconvolute the complicated mechanism of LIP5/Vta1 regulation. 
2.5 Methods 
2.5.1 Cloning, Expression, and Purification 
DNA sequences encoding for various proteins and protein fragments were 
amplified from cDNAs (ATCC®) and cloned into a modified pET28b vector to 
generate N-terminal His6-SUMO tagged fusion proteins.  Point mutations were 
generated using a standard PCR mutagenesis protocol (Stratagene).  Proteins 
were expressed in Escherichia coli Rosetta(DE3), where cells were grown at 
37°C to log phase in standard LB media and induced with 0.2 mM Isopropyl #-D-
1-thiogalactopyranoside followed by an additional 16-20h growth at 16°C.  
Seleno-methionyl LIP51-162 derivative was expressed in E. coli B834(DE3) using a 
minimal medium where methionine was replaced with seleno-methionines. 
 
All proteins were purified using a similar protocol with adjustment made 
when necessary.  Cells were pelleted and lysed by sonication in buffer A (25 mM 
Tris pH 8.0, 300 mM NaCl, 5 mM 2-mercaptoethanol, and 10 µg/mL (w/v) 
phenylmethylsulfonyl fluoride).  Cell lysate was cleared by centrifugation and 
supernatant was loaded onto a Ni2+-nitrilotriacetic acid affinity column, washed 
with buffer A and eluted with buffer A supplemented with 250 mM imidazole.  
Eluate was collected, digested with ULP1 to cleave the His6-SUMO tag while 
being dialyzed against 50 mM Tris pH 8.0, 25 mM NaCl overnight.  A moderate 
precipitation formed for LIP51-162 during dialysis, which was determined to be 
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nucleic acid and could be cleared by centrifugation.  Dialyzed protein mixture 
was passed over a second Ni2+-nitrilotriacetic acid column to remove the His6-
SUMO tag.  Proteins that would be used for GST-pull-down analysis were stored 
directly in -80°C. 
 
Proteins used for crystallization were further purified.  LIP51-162  was further 
purified on a Source-S (GE Healthcare) cation exchange column using buffer C 
(50 mM HEPES pH 7.0, 50 mM NaCl, 1mM EDTA, 1mM DTT) as a loading 
buffer, and eluted via a gradient with buffer C supplemented with 1M NaCl.   
Fractions containing the protein were pooled, concentrated and loaded onto a 
HiLoadTM SuperdexTM 75 (GE Healthcare) column and eluted with buffer C.  For 
the LIP5NTD-CHMP1B complex, the CHMP1B fragment was mixed with LIP51-162 
in an approximately 2:1 ratio.  This mixture was concentrated and loaded onto 
the SuperdexTM 75 column, and eluted with buffer C.  Complex formation was 
confirmed by elution position change from the gel filtration column.  The 
CHMP1B peptide was not detectable by Coomassie blue staining.   
2.5.2 Crystallization and Data Collection 
Crystals of LIP51-162 were produced by hanging drop vapor diffusion 
method at 4°C.  Protein at 15 mg/ml was mixed in a 1:1 ratio with a reservoir 
solution of 7.5-9% PEG8000, 3% 1,4-butanediol, 0.1 M cacodylate pH 7.0, 0.2 M 
sodium acetate to a final volume of 4 µl and equilibrated against 500 µl of the 
reservoir solution.  Small hexagonal crystals appeared after approximately two 
weeks, which were then transferred into a solution containing 20% PEG8000, 
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20% glycerol, 8% butanediol, 0.1 M cacodylate pH 7.0, 0.2 M sodium acetate 
and immediately flash-frozen under liquid nitrogen.  The seleno-methionyl 
derived LIP51-162 crystals were produced and harvested in a similar manner.  
Data were collected at Advanced Photon Source beamline 21-ID, and processed 
and scaled using XDS (MPI for Medical Research). 
 
Complex crystals of LIP5-CHMP1B were grown by sitting drop vapor 
diffusion method at 4°C.  Protein complex at 12.7 mg/ml was mixed in a 1:1 ratio 
with a solution of 16% MPD, 0.1 M Tris pH 9.0 and equilibrated against 500 µl of 
a reservoir solution of 8% MPD, 0.1 M Tris pH 9.0.  Two crystals with different 
morphology appeared.  Long needle-like crystals would appear instantly and 
dissolve over time.  Stable diamond-like crystals would appear later and were 
ultimately used for data collection.  Crystals were micro-dialyzed (Hampton 
Research) against 30% MPD, 0.1 M Tris pH 9.0 for 16-24h before flash-freezing 
under liquid nitrogen.  Data were collected at Advanced Photon Source beamline 
21-ID, and processed and scaled using HKL2000 (HKL Research Inc.) 
2.5.3 Structure Determination and Refinement 
The LIP51-162 structure was determined using single-wavelength 
anomalous diffraction method using the data set collected at the peak 
wavelength ($=0.9792). There are three molecules in the asymmetric unit. Phenix 
autosol was able to find 12 out of the 15 expected selenomethionine sites (5 
sites/LIP5 molecule) (30). Phases were calculated and refined.  Autosol was able 
to build a model for one of the three molecules based on the initial electron 
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density map. This model was then used to search for the other two molecules 
against the native data set by molecular replacement as implemented in Phenix 
AutoMR. BUSTER was used for further structure refinement with NCS applied 
throughout (Global Phasing Limited). The LIP5NTD-CHMP1B structure was 
solved by molecular replacement as implemented in AutoMR using the refined 
LIP51-162 structure as an initial search model. Structure refinement was done in 
Phenix, with NCS restrictions applied to the LIP5-CHMP1B structure in the early 
rounds of refinement. COOT was used for model building and adjustment. 
Structural figures were generated with PYMOL (Schrödlinger). Structure 
refinement statistics are shown in Table 2.1. 
2.5.4 GST Pull-down Analysis 
GST pull-down analysis was performed following standard procedures in 
phosphate-buffered saline (PBS) solution supplemented with 1 mM DTT and 
0.1% (v/v) Tween 20(31). Specific samples were also supplemented with 2 
mM ATP as indicated in the figure. Purified proteins were incubated with GST 
alone or GST-tagged proteins immobilized on glutathione-agarose beads for 1 h 
at 4 °C. The beads were then washed extensively with the buffer before bound 
proteins were analyzed on SDS-PAGE and visualized by Coomassie blue 
staining. 
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Chapter 3 Structural Basis of VPS4 Regulation by the LIP5/ESCRT-
III Protein Complexes 
3.1 Abstract 
The AAA-ATPase VPS4 catalyzes the disassembly of the ESCRT 
machinery from cellular membrane, a critical final step in membrane vesiculation 
away from the cytoplasm.  LIP5 and regulatory ESCRT-III proteins bind VPS4 
and are essential for controlling its activity.  Here we present structure and 
functional analyses of molecular interactions between human VPS4B, LIP5 and 
ESCRT-III proteins.  The crystal structure of the LIP5 N-terminal domain 
(LIP5NTD) in complex with the MIT-interacting motifs (MIMs) of two ESCRT-III 
proteins, CHMP1B and CHMP5, was determined.  While CHMP1B MIM has no 
effect, CHMP5 MIM can strongly inhibit LIP5-dependent stimulation of VPS4.  
We found that binding of CHMP5 leads to a conformational change in LIP5NTD, 
which may result from the insertion of a conserved CHMP5 tyrosine residue 
(Tyr182) at the core of LIP5 structure.  We hypothesized a novel mechanism of 
VPS4 regulation, where CHMP5 binding disrupts a previously unknown critical 
interaction between LIP5NTD and VPS4. 
3.2 Introduction 
The endosomal sorting complex required for transport (ESCRT) 
machinery is responsible for catalyzing membrane fission reactions away from 
the cytoplasm, a process that has reverse topology as compared to classical 
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vesiculation processes such as endocytosis (1-4).  ESCRT was initially identified 
in the yeast multivesicular body (MVB) biogenesis pathway (5) and was later 
shown to be involved in additional biologically important events in higher 
eukaryotic cells, including enveloped virus budding from the plasma membrane 
(6), resolution of the mid-body structure during cytokinesis (7) and more recently 
repair of small plasma membrane wounds (8).  The core components of the 
ESCRT machinery have shown remarkable structure and functional conservation 
throughout eukaryotic cells.  Among them, late-acting complexes ESCRT-III and 
Vps4 catalyze the actual membrane fission event as well as the disassembly of 
the machinery at the end of each reaction cycle (9-12).  ESCRT-III and Vps4 are 
required for all known ESCRT-dependent cellular processes and are thought to 
constitute a minimal membrane fission machine. 
 
ESCRT-III consists of four core subunits: Vps20 (human ortholog: 
CHMP6), Snf7 (CHMP4), Vps24 (CHMP3), and Vps2 (CHMP2) (13,14).  They all 
exist as soluble monomeric proteins in their inactive states and polymerize into 
membrane-bound helical filaments when activated by upstream factors (15-19).  
ESCRT-III polymerization plays a critical role in membrane fission, and also 
exposes arrays of C-terminal tails that can bind microtubule interacting and 
transport (MIT) domain-containing proteins (20,21).  These MIT domain-binding 
sequences on the ESCRT-III proteins are also known as the MIT interacting 
motifs (MIM).  Two of the ESCRT proteins whose sequences contain MIT 
domains are Vps4 (VPS4) and its activator Vta1 (LIP5) (22,23). 
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Vps4 is an AAA-ATPase whose function in the cell is to extract the 
ESCRT-III subunits from the membrane-bound filaments and return them to their 
inactive states at the end of the membrane fission reaction cycle (24-28).  There 
is also evidence suggesting that Vps4 directly contributes to membrane fission in 
some cellular processes (8,29-31).  Vps4 contains an N-terminal MIT domain, a 
linker and a C-terminal canonical AAA-ATPase cassette (32-34).  Unique to the 
Vps4 structure is a small motif of three anti-parallel #-sheets called the “#-
domain”, inserted within AAA cassette.  Vps4 can exist in two quaternary 
structures, an inactive disassembled state and an active high-order oligomer 
(35).  Equilibrium between the two states represents a major step of regulation in 
the ESCRT machinery.  Binding of ATP shifts the equilibrium towards assembly 
and hydrolysis of ATP shifts the equilibrium towards disassembly (36).  
Furthermore, the ATP-dependent assembly of Vps4 is greatly promoted by Vta1 
(LIP5) (37-39). 
 
The structure of Vta1 contains two terminal domains that are connected by 
a ~100 residue long, non-conserved flexible linker (23,40).  The N-terminus 
consists of two tandem MIT domains (23) and at the C-terminus is the Vta1-
SBP1-LIP5 (VSL) domain that allows for the dimerization of Vta1, and which 
directly binds to the #-domain of Vps4 (40).  Vta1 dimer formation is critical for 
binding to Vps4 and the interaction between the two proteins has been shown to 
be ATP-dependent (23,41).  In yeast, Vta1 can stimulate the ATPase activity of 
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Vps4 by about three fold and this effect is largely attributed to the fact that 
interaction between the VSL domain and Vps4 stabilizes the active Vps4 
assembly structure (23).  The activity of Vps4 can also be regulated by other 
mechanisms.  Recent work has identified a region immediately N-terminal to the 
VSL domain in yeast Vta1 that can further stimulate Vps4 activity (named VSE) 
by increasing the catalytic efficiency of the ATPase (42). 
 
The ESCRT-III proteins display regulatory activity towards Vps4 as well.  
Binding of the Vps4 MIT domain to the high concentrations of MIM sequences 
displayed by membrane-bound ESCRT-III filaments can serve to recruit, 
assemble and activate the ATPase (25,29).  Furthermore, direct interactions 
between ESCRT-III and the MIT domain relieve auto-inhibition imposed by the 
linker of Vps4 (43).  Beyond the four core ESCRT-III subunits, there exist several 
proteins whose structural folds are similar to ESCRT-III but loss of their function 
does not cause severe defects in the MVB pathway (10,44).  These include Did2 
(CHMP1), Vps60 (CHMP5) and Ist1 (IST1), which have been implicated in the 
regulation of Vps4 activity and in some cases are thought to aid in the 
recruitment of Vps4 to the membrane (45).  The regulatory role of the Did2, 
Vps60 and Ist1 in particular overlaps with that of Vta1.  Biochemical analysis of 
protein-protein interactions has shown that Did2, Vps60 and Ist1 can all bind to 
the N-terminal domain of Vta1 (23,46).  Works in the yeast have suggested that 
Did2 and Vps60 are allosteric ligands of Vps4 activity (38,42). 
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Since metazoan ESCRT machinery perform a series of additional 
functions not described in yeast, it is essential that the molecular mechanism of 
Vps4 regulation be studied in its native contexts.  To this end, we performed 
structural and functional analyses of molecular interactions between human 
VPS4B, LIP5 and regulatory ESCRT-III proteins CHMP1B and CHMP5 to gain 
mechanistic insights into the regulation of metazoan ESCRT machinery.  The 
atomic-resolution crystal structure of the LIP5-CHMP1B-CHMP5 complex was 
determined and they revealed that binding of CHMP5 leads to disruption of the 
interface between the two MIT domains of LIP5.  Induction of this conformational 
change precludes LIP5 stimulation of VPS4 via a previously uncharacterized 
interaction, and helps explains the mechanism by which CHMP5 allosterically 
regulates LIP5 function in metazoan. 
3.3 Results 
3.3.1 Binding of CHMP5 to LIP5 inhibits its stimulatory activity towards VPS4 
Yeast regulatory ESCRT-III proteins, Did2 and Vps60, have been shown 
to regulate the MVB pathway by stimulating Vps4 ATPase activity in a Vta1-
dependent manner (38).  We asked whether a similar effect could be observed in 
metazoan orthologs CHMP1B and CHMP5.  Earlier studies on human Vps4 
orthologs (VPS4A and VPS4B) indicated that they have much weaker ATPase 
activity than yeast Vps4 (43).  Using the Malachite Green ATPase assay, we 
observed a similar result but our study also indicated that VPS4B is slightly more 
active than VPS4A and also more stable under experimental conditions (data not 
shown).  Therefore, VPS4B was used for the rest of our experiments.  To 
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eliminate any potential stimulation through direct interaction between VPS4B and 
the ESCRT-III proteins via the MIT domain, we used a MIT domain truncation 
mutant of VPS4B (VPS4B79-444 or VPS4B%MIT) which has a similar basal and 
LIP5 stimulated activities as the full-length protein (data not shown). 
 
The ATPase activity of VPS4B is concentration-dependent and at sub-
micromolar protein concentration we saw little basal activity (0.83 Pi/min/VPS4B) 
(Figure 3.1A.  With the addition of LIP5, we observed a dramatic stimulation of 
the activity to 8.54 Pi/min/VPS4B.  However, when the minimal LIP5 binding 
element of CHMP5 was included with LIP5 in the assay, a pronounced inhibitory 
effect was observed.  Addition of CHMP5 reduced the LIP5 stimulated VPS4B 
ATPase activity to 0.67 Pi/min/VPS4B, which was near its basal level.  To 
determine whether this inhibitory effect depended upon CHMP5 binding to LIP5, 
we used a previously described LIP5-binding deficient mutant of CHMP5 
(L163D/L167D/L170D/L174D or L4D) (47).  In Figure 3.1A, we saw that inclusion 
of the quadruple leucine mutant in the assay failed to reproduce a similar 
inhibitory effect (4.94 Pi/min/VPS4B).  These data showed that while human 
CHMP5 regulates VPS4 ATPase activity in a LIP5-dependent manner, it has an 
opposite effect as compared to its yeast counterpart suggesting a potentially 
different mechanism of regulation.  Interestingly, addition of the minimal LIP5 
binding element of CHMP1B to the assay had little effect on VPS4B ATPase 
activity (Figure 3.1B).  This suggested that CHMP1B and CHMP5 play different 
roles in regulating LIP5 function. 
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Figure 3.1 ESCRT-III proteins regulate the stimulatory activity of LIP5 on 
VPS4. 
(A) CHMP5 MIM inhibits the stimulatory activity of LIP5.  ATP hydrolysis by 0.5 
µM VPS4B%MIT (intrinsic, first column) was assayed under conditions of 2 mM 
ATP at 37°C (see Experimental procedures).  In addition, the following proteins 
were incubated with Vps4: 0.5 µM LIP5 (second column), 2 µM CHMP5 MIM 
(third column), 0.5 µM LIP5 plus 2 µM CHMP5 MIM (fourth column), and 0.5 µM 
LIP5 plus 2 µM CHMP5 MIM L4D (fifth column).  (B) CHMP1B MIM has no effect 
on LIP5 activity.  The following proteins were incubated with Vps4: 0.5 µM LIP5 
(second column), 2 µM CHMP1B MIM (third column), and 0.5 µM LIP5 plus 2 µM 
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CHMP1B MIM (fourth column).  Each experiment was done in triplicate; all 
experiments were repeated a minimum of three times. 
3.3.2 The crystal structure of LIP5NTD-CHMP1B-CHMP5 
Since CHMP5 has a clear role in regulating the ability of LIP5 to stimulate 
VPS4 ATPase activity, we asked what the structural basis of this regulation is.  In 
a previously determined NMR structure of LIP5NTD-CHMP5 binary complex, 
there is no discernable conformational change in LIP5NTD upon CHMP5 MIM 
binding (47).  We reasoned that CHMP5-binding induced LIP5 conformational 
change might be small and transient thus not easily observable in the solution 
structure.  To that end, we embarked on determining the crystal structure of the 
ternary complex of LIP5NTD-CHMP1B-CHMP5.  The presence of CHMP1B led 
to the formation of crystals that diffracted to a very high resolution of 1.0 Å.  The 
structure was determined and refined with an R-factor of 16.5% and a free R-
factor of 18.1% (Table 3.1).  The final model consists of LIP5 residues 4-162, 
CHMP1B residues 185-199 and CHMP5 residues 151-190. 
In the ternary complex structure, CHMP1B forms a small helix that binds 
to the MIT1 domain of LIP5 and CHMP5 forms a loop-helix-turn-helix structure 
that wraps around the MIT2 domain but also makes significant contacts with the 
MIT1 domain (Figure 3.2A).  Overall, the modes of both ESCRT-III proteins’ 
binding to LIP5 largely mirror those observed in their respective binary complex 
structures (47).  The interface between LIP5 and CHMP5 is extensive with a 
measured buried surface area to be 1505 Å2.  The CHMP5 conformation in the 
complex structure can be divided into three major parts (Figure 3.2B).  Residues 
151-159 adopt an extended loop conformation and bind across the surface of 
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 Table 3.1 Crystallography statistics 
 LIP5NTD/CHMP1B/CHMP5 
 Native 
Data Collection  
Space group P21 
Unit cell parameters:  
a, b, c (Å) 34.2, 60.5, 52.0 
!, #, & (°) 90.0, 90.5, 90.0 
Molecules/ASU 1 
Wavelength (Å) 0.9998 
Resolution (Å) 1.0 
Unique reflections 99846 
Redundancy1 4.5 (3.5) 
Completeness (%) 87.4 (46.1) 
Average I/' (I) 50.6 (5.4) 
Rmerge  0.05 (0.27) 
Refinement  
Residues in the structure  
LIP5 4-162 
CHMP1B 185-199 
CHMP5 151-190 
Resolution range (Å) 50.0-1.0 
Rwork (%) 16.5 
Rfree (%) 18.1 
RMS deviations  
Bond lengths (Å) 0.008 
Bond angles (°) 1.28 
B-factor average (A2) 8.5 
Ramachandran plot  
Most favored (%) 98.8 
Allowed (%) 1.2 
Outliers (%) 0.0 
PDB accession code 4TXR 
 
helices 5 and 7 of LIP5NTD.  Residues 160-176 form a long helix that binds 
across helices 6 and 7 of LIP5NTD as well as make extensive contacts with helix 
1.  Following a three-residue turn, residues 181-189 form a short helix that binds 
across the surface of helices 5 and 6 of LIP5NTD.  When binding to the helices 
of the MIT2 domain, these CHMP5 structural elements all bind at a nearly 
perpendicular angle. 
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Figure 3.2 The crystal structure of LIP5NTD-CHMP1B-CHMP5 complex. 
(A) An overview of the LIP5NTD-CHMP1B-CHMP5 complex structure.  Cartoon 
representation of LIP5NTD (residues 1-162) in complex with CHMP1B (residues 
176-199) and CHMP5 (residues 151-190) in front (left panel) and back (right 
panel) views.  Coloring and labeling schemes are the same as in Figure 1A 
except that CHMP5 is colored in magenta.  (B) CHMP5 makes extensive 
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contacts with LIP5NTD.  The interface is divided and shown in three separate 
panels based on three sequence segments of CHMP5: 151-159 (left), 160-176 
(center) and 176-190 (right).  CHMP5 is shown as a magenta coil.  LIP5NTD is 
shown as a semi-transparent surface along with stick representation of side 
chains that contribute to van der Waals interactions.  Surface and sticks are 
colored using the following schemes: carbon atoms of MIT1, cyan; carbon atoms 
of MIT2, green; oxygen, red; nitrogen, blue.  (C) Trp147 of LIP5 flips upon 
binding CHMP5.  Zoom-in cartoon representation showing the conformation of 
Trp147 before (pale green) and after (green) binding CHMP5 (magenta). 
Interactions between CHMP5 and LIP5 are largely mediated by van der 
Waals interactions (Table 3.2).  As noted previously, CHMP5 contains a “leucine-
collar” that consists of six leucine residues, Leu158, Leu163, Leu167, Leu170, 
Leu174 and Leu183 (Figure 3.3) (47).  These residues are highly conserved in 
metazoan CHMP5 (Figure 3.4).  They bind to a conserved hydrophobic LIP5 
surface that is formed by aromatic side chains and aliphatic portions of basic 
residues (Figure 3.2B).  For example, the highly conserved Trp147 of LIP5 has 
been previously shown to be essential for high-affinity binding (47).  Comparison 
between the LIP5NTD-CHMP1B and LIP5-CHMP1B-CHMP5 structures showed 
that the imidazole ring of the Trp147 side chain adopts a different rotamer 
conformation upon CHMP5 binding.  It swings around the C#-C& bond by 180° to 
make room for CHMP5 binding (Figure 3.2C).  There are only a few specific 
hydrogen bond interactions between CHMP5 and LIP5.  CHMP5 residues 
involved in these interactions are clustered either at the N-terminal loop (Arg151 
and Tyr153) or at the short linker between the two helices (Asp177, Asp179, 
Tyr182 and Asp184) (Figure 3.5).  These residues are invariant among metazoan 
CHMP5 (Figure 3.4).  There has been speculation that charge-charge interaction 
might contribute to high-affinity binding between the two molecules given that 
CHMP5 is acidic and LIP5 is basic (47).  However, except for the few residues 
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Table 3.2 Intermolecular interactions in the CHMP5-LIP5-CHMP1B structure 
CHMP5 LIP5 CHMP1B 
Hydrogen bond interactions   
 R57 NH1 D186 OD1 
 R57 NH2 D186 OD2 
 E68 OE2 R191 NE 
 E68 OE1 R191 NH2 
 D65 OD1 R191 NH2 
 K71 NZ L195 O 
 E83 OE2 R196 NE 
 E83 OE1 R196 NH1 
 Q44 OE1 R196 NH2 
 V130 O R196 NH2 
 E83 N Q198 OE1 
R151 NH1 D102 OD2  
R151 NH1 N103 OD1  
S152 O R106 NH2  
Y153 OH D102 OD2  
E166 OE1 N154 ND2  
D177 OD2 K116 NZ  
D177 O R22 NH2  
D179 O K116 NZ  
Y182 OH E26 OE2  
Y182 OH T120 OG  
D184 OD2 R30 NE  
A186 O K96 NZ  
A189 O K96 NZ  
Van der Waals interactions   
 M47, R57, L60, S61, M64 L188 
 M64 R191 
 L40, M43, Q44, M47, M64 L192 
 Y36, L40, M64, L67, K71 L195 
 L40 R196 
Y153 F98, L99, R106, H141, Y144  
T155 K143, W147  
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CHMP5 LIP5 CHMP1B 
P156 W147  
L158 W147  
L163 R146, T150  
E166 T150, N154  
L167 Y119, R146, T150  
L170 I115, Y119, A149, H153  
G171 Y119, H19  
D172 H19  
L174 R22, Y119, T120  
L175 N18, H19, R22  
Y182 N113, K116, S117  
L183 H27, R30, M97, Y93  
E185 Y100, N113  
A186 Y100  
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mentioned above, most of the acidic residues of CHMP5 point away from the 
interface hence unlikely to contribute directly to binding. 
                             
Figure 3.3 “Leucine collar” of CHMP5 mediates hydrophobic binding to 
LIP5. 
LIP5-CHMP1B-CHMP5 complex structure is shown as a cartoon representation.  
Side chains of “leucine collar” residues are shown as stick models along with 
their van der Waals surfaces.  Same coloring scheme is used throughout the 
manuscript. 
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Figure 3.4 Sequence alignment of CHMP5/Vps60. 
“Leucine collar” residues are colored magenta.  Tyr182 is colored red. 
                           
Figure 3.5 Specific hydrogen bond interactions between CHMP5 and LIP5. 
CHMP5 residues involved in these interactions are clustered either at the N-
terminal loop (Arg151 and Tyr153) or at the short linker between the two helices 
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(Asp177, Tyr182 and Asp184).  Same coloring scheme is used throughout 
Chapter 3. 
3.3.3 Conformational change in LIP5 associated with CHMP5 binding 
The availability of high-resolution LIP5 complex crystal structures enabled 
us to examine structural change in LIP5 associated with CHMP5 binding.  
Overall, a moderate conformational adjustment was observed in LIP5, where the 
MIT2 domain moves relative to the MIT1 domain due to the presence of CHMP5 
at the MIT1-MIT2 interface (Figure 3.6A).  Helices 5 and 7 of the MIT2 domain 
are pushed outwards by about 2 Å.  In the absence of CHMP5 binding, there are 
a number of hydrogen bonds between the two MIT domains.  In particular, Glu26 
of the MIT1 domain interacts with Lys116 of the MIT2 domain.  Upon CHMP5 
binding, the distance between Glu26 and Lys116 increases from 2.9 Å to 9.0 Å 
(Figure 3.6B).  These residues would now form new interactions with the bound 
CHMP5.  In the LIP5NTD-CHMP1B-CHMP5 structure, Glu26 forms hydrogen 
bonds with the side chain of Tyr182.  Lys116 forms hydrogen bonds with the side 
chain of Asp177 and with the main chain carbonyl oxygen of Asp179 (Figure 6c).  
There are also additional interactions between CHMP5 and LIP5NTD in the 
vicinity including His19, Arg22 and Arg30 that stabilize the new conformation of 
LIP5NTD (Table 3.2). 
Of particular interest is Tyr182 of CHMP5, which stands out as the 
potential culprit of the conformational change.  In the ternary complex structure, 
Tyr182 drives itself between the LIP5 MIT1 and MIT2 domains, where it makes 
both hydrogen bond and van der Waals interactions with LIP5.  In the NMR 
structure of the LIP5NTD-CHMP5 binary complex, five out of the ten structure  
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Figure 3.6 Conformational change at the LIP5 MIT domain interface. 
(A) Superimposition of LIP5NTD-CHMP1B structure with LIP5NTD-CHMP1B-
CHMP5 structure.  The coloring scheme used is the same as in Figures 1a and 
4a (the binary complex has a pale color tone).  The view in the right panel is 
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nearly orthogonal to that of the left panel and highlights the movement of the MIT 
domain.  Helices are shown as cylinders and loops in the right panel are omitted 
for clarity.  (B) K116-E26 salt bridge is broken in the ternary complex structure.  
Side chains are shown in stick representation.  Carbons atoms are colored using 
the same scheme as in (A).  (C) K116 and E26 are engaged in new interactions 
in the ternary complex structure.  The left panel is a zoom-in view of interactions 
involving K116 and E26 before and after CHMP5 binding.  Residues involved are 
shown as sticks and labeled.  New hydrogen bonds are denoted as dashed lines 
with distances indicated.  The right panel omits the binary complex structure but 
shows 2Fo-Fc electron density (2.0!) associated with interacting residues in the 
ternary complex structure.  (D) Insertion of Tyr182 at the MIT domain interface.  
The left panel shows superimposition of LIP5NTD-CHMP1B-CHMP5 structure 
with LIP5NTD-CHMP5 structure (only one of the ten NMR structure assemblies 
is shown).  The right panel shows the conformation of Tyr182 in the two 
structures.  Tyr182 in the ternary complex structure adopts a “flipped in” 
conformation.  Tyr182 in the binary complex structure can adopt either a “flipped 
in” or “flipped out” conformation. 
ensembles have the Tyr182 pointed into the LIP5 MIT domain interface and the 
other five are oriented towards the solvent (Figure 3.6D)(47).  These data 
suggest that Tyr182 can exist in equilibrium between a “flipped in” or a “flipped 
out” conformation.  Binding of CHMP1B appears to have stabilized Tyr182 in the 
“flipped in” conformation at the LIP5 MIT domain interface as evidenced by the 
well-defined electron density associated with the residue (Figure 3.6C).  
Interestingly, Tyr182 of CHMP5 and Glu26 of LIP5 are strictly conserved in 
metazoan protein sequences suggesting a potentially conserved mechanism in 
higher eukaryotes (Figure 3.4, 3.7). 
We looked to see whether insertion of Tyr182 into the MIT domain 
interface might be structurally related to the inhibitory function of CHMP5 on 
LIP5.  A significant loss of the inhibitory effect of CHMP5 was observed when 
Tyr182 is mutated to alanine (Figure 3.8A).  Interestingly, this mutation has little 
effect on CHMP5 binding to LIP5 as GST-CHMP5Y182A can still bind a similar 
amount of LIP5 as the wild-type protein (Figure 3.8B).  These data suggested 
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Figure 3.7 Sequence alignment of LIP5/Vta1. 
Glu26 and Lys116 are colored red.  Trp147 is colored yellow. 
that the mere binding of CHMP5 to LIP5 is not sufficient for its inhibitory effect on 
LIP5 function.  Instead, the inhibitory effect is predicated on the conformational 
change in LIP5 associated with insertion of Tyr182 at the MIT domain interface. 
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Figure 3.8 Tyr182 of CHMP5 is important for its inhibitory activity. 
(A) CHMP5 Y182A abolishes its inhibitory activity towards LIP5.  Protein 
concentration used in the ATPase assay: VPS4B"MIT, 0.5 µM; LIP5, 0.5 µM; 
and CHMP5, 2 µM.  (B) CHMP5 Y182A still binds LIP5.  GST-SUMO, GST-
SUMO-CHMP5MIM, or GST-SUMO-CHMP5MIM, Y182A was used to analyze its 
interaction with LIP5.  GST-SUMO was used as a tag since GST-CHMP5MIM runs 
at a position similar to that of LIP5. 
3.3.4 LIP5NTD is directly involved in stimulation of VPS4 activity 
 Studies in yeast suggested that the stimulatory effect of Vta1 on Vps4 is 
attributed to the binding of its C-terminal VSE and VSL domains to Vps4 (38,42).  
The unstructured linker of Vta1 acts to inhibit the function of VSE and this 
inhibition is relieved upon binding of the regulatory ESCRT-III proteins to the N-
terminal domain of Vta1 (42).  To probe whether a similar mechanism is utilized 
in metazoan LIP5, we generated a LIP5 truncation mutant (LIP5215-307) that would 
include the putative VSE and VSL domains (Figure 3.9A).  A similar yeast Vta1 
truncation mutant displayed an increased stimulatory activity towards Vps4 when 
compared with the wide-type Vta1(42).  To our surprise, LIP5215-307 had very low 
 123 
activity towards VPS4B even though its binding affinity to VPS4B did not appear 
to be compromised (Figure 3.9B, 3.9C). 
A 
B  
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D 
 
Figure 3.9 Both terminal domains of LIP5 are required for its VPS4 
stimulatory activity.  
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(A) Schematic showing the LIP5 constructs used in the assay.  (B) Various LIP5 
truncation mutants or mutant combinations were assayed for their VPS4 
stimulatory activity.  Note that LIP5"166-215 is equivalent to adding the two terminal 
domains in cis.  (C) Various LIP5 truncation mutants were assayed for their 
binding affinity for VPS4B.  GST-SUMO was used as a tag since some of the 
GST-LIP5 constructs run at a position similar to that of VPS4B"MITE233Q.  
Binding analyses were performed in the presence or absence of ATP.  (D) The 
inhibitory activity of CHMP5 does not depend on the linker region of LIP5.  LIP5, 
LIP5"166-215 and LIP5165-307 were assayed for their abilities to stimulate VPS4B 
activity in the absence or presence of CHMP5. 
This observation suggested that residues beyond the C-terminal region of 
LIP5 are required for LIP5 activity.  To further map the location of these residues, 
we examined the activity of the following truncation mutants of LIP5 towards 
VPS4B: LIP5165-307, LIP5D166-215 and LIP51-162 (Figure 3.9A).  The results showed 
that deletion of LIP5NTD (LIP5165-307) led to a loss of stimulation, but deletion of 
the linker region (LIP5D166-215) had no negative effect on the activity of LIP5 
(Figure 3.9B).  In fact, deletion of the linker region produced a mutant that was 
even more active (11.10 Pi/min/VPS4B) than the wild-type protein (8.54 
Pi/min/VPS4B), suggesting an inhibitory role for this portion of the linker.  
Furthermore, LIP5NTD (LIP51-162) alone was not sufficient in stimulating VPS4.  
Hence, the two terminal domains of LIP5 are both required for the high 
stimulatory activity towards VPS4B while the linker region sequence is 
dispensable.  Interestingly, only when the two terminal domains of LIP5 were 
added in cis but not in trans would the stimulatory activity be reproduced (Figure 
3.9B).  These results suggested that although the C-terminal domain is 
responsible for high affinity VPS4B binding, the stimulatory activity of LIP5 is 
likely the work of the N-terminal domain.  Binding of the C-terminal domain to 
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VPS4B recruits the N-terminal domain to the site of action due to the physical 
linker between the two parts of LIP5. 
 
Given that the activity of LIP5 does not depend on the LIP5 linker 
sequence, we explored whether CHMP5 still displayed the same inhibitory effect 
on LIP5 activity in the absence of the linker sequence.  We observed a similar 
degree of inhibitory effect towards LIP5 activity for LIP5D166-244 (Figure 3.9D).  As 
a control, there was no reduction in the moderate ATPase activity generated by 
LIP5165-307 when CHMP5 was added.  Therefore, regulation of VPS4B activity by 
CHMP5 binding to LIP5NTD is unlikely mediated through the linker region, as 
has been suggested in the yeast (42).  Instead, CHMP5 binding is more likely to 
modulate the interaction between LIP5NTD and VPS4B through a mechanism 
that involves the conformational change in LIP5NTD as seen in the ternary 
complex structure. 
3.4 Discussion 
Given the structural and functional complexity of the ESCRT machinery, it 
is not surprising that ESCRT assembly is under tight spatial and temporal control 
at multiple steps.  Vps4 is the only energy-consuming enzyme within the ESCRT 
machinery and has long been viewed as the master regulator of the system.  
Vps4 engages in three types of protein-protein interactions: with itself, with 
ESCRT-III, and with Vta1.  These interactions represent three general 
mechanisms that are used to control the activity of Vps4 in the cell: (a) ATP-
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states, (b) recruitment to the site of action through specific protein-protein 
interactions, and (c) protein cofactors that promote or inhibit its activity. 
 
Vps4 is a member of the AAA-ATPase family and it cycles between two 
different quaternary structures depending on the status of its bound nucleotide 
(35).  In the absence of ATP, it exists as an inactive monomeric or dimeric 
species.  Upon ATP binding, it forms a high molecular weight ring-shaped 
oligomeric structure, which recent evidence suggests is likely a hexamer (36).  
This cycle, however, appears to be highly inefficient if the ATPase has to 
undergo the assembly-disassembly process each time it binds and hydrolyzes 
ATP.  In yeast, the cofactor Vta1 has been shown to bind Vps4 in an ATP-
dependent manner and activate its ATPase activity (23,39).  The action of Vta1 
has been attributed to the structural features near the C-terminus as the N-
terminal truncation mutant of Vta1 can recapitulate the full activity of Vta1 (42). 
3.4.1 Stimulation of VPS4 by LIP5 requires both terminal domains connected in 
cis 
While we demonstrated that human LIP5 stimulates the ATPase activity of 
VPS4, the mechanism of action appears to be different in the two systems.  
Although the C-terminal domain of LIP5 is both necessary and sufficient for 
binding VPS4, the C-terminal domain alone is not sufficient to reproduce the 
stimulatory activity of LIP5.  Instead, the full-scale activity requires the presence 
of both terminal domains.  Furthermore, a physical connection between the two 
domains is necessary as the two domains added in trans are not active.  The 
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length as well as the sequence of the linker appears to be less critical.  This is 
consistent with the fact that the sequence conservation at the linker region 
appears to be very low (Figure 3.7).  We hypothesize that the C-terminal domain 
of LIP5 makes an initial binding to VPS4, likely to the conserved #-domain 
(Figure 3.10).  This interaction brings the N-terminal domain close to the ATPase 
as it is connected to the C-terminal domain through the linker.  This enables an 
additional interaction between the N-terminal domain and VPS4, which otherwise 
would not occur due to its weak inherent binding affinity.  The activity of the full-
length LIP5 to VPS4 is likely the result of the combined actions of the two 
domains.  At this point, it is not clear how it exactly occurs but we suspect that 
LIP5 could promote the oligomerization of the ATPase as well as increase its 
catalytic efficiency. 
       
Figure 3.10 A model of VPS4 regulation by LIP5-CHMP5 complex. 
The C-terminal domain of LIP5 makes an initial binding to VPS4.  This interaction 
brings its N-terminal domain close to VPS4, which enables an additional 
interaction between the N-terminal domain and VPS4.  The combined actions of 
the two domains lead to full activity of VPS4.  Binding of CHMP5 to LIP5 
weakens the interaction between the N-terminal domain and VPS4 and leads to 
an inhibition of LIP5 activity. 
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3.4.2 CHMP5 is potent inhibitor of LIP5 stimulation of VPS4 
In contrast to CHMP1B, binding of CHMP5 to LIP5 potently inhibits the 
stimulatory activity LIP5 displays towards the VPS4 ATPase.  This suggests that 
binding of CHMP5 could potentially serve as an allosteric power switch to 
spatially and temporally control the activity of VPS4.  Sequence comparison has 
shown that the LIP5 MIT2 has diverged significantly from other known MIT 
domain sequences, suggesting that it might function as a specific CHMP5-
binding domain (data not shown).  Although most of the CHMP5-binding occurs 
on the MIT2 domain, there is also significant binding to the MIT1 domain, 
particularly near the MIT1-MIT2 interface.  The latter is significant because it 
leads to the movement of MIT2 relative to MIT1, likely due to the insertion of a 
highly conserved Tyr182 of CHMP5 at the domain interface.  We suspect that 
these changes form the structural basis for the inhibitory effect of CHMP5 on 
LIP5 function.  As we have seen, the interaction between the N-terminal domain 
of LIP5 and VPS4 is required for the full stimulatory activity of LIP5.  Movement 
of MIT2, induced by CHMP5 binding, could conceivably alter the interaction 
between LIP5 and VPS4 and hence the inhibition (Figure 10). 
 
While most ESCRT-III proteins promote the activity of Vps4, it is not 
unprecedented for one of them to exhibit an inhibitory function.  Early work 
studying the role of ESCRT in HIV-1 release found that siRNA silencing of 
CHMP5 in co-transfected human cells caused an increase in the release of 
infectious virus-like particles, suggesting a possible negative regulatory role for 
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CHMP5 in vivo (48).  Additionally, Ist1 inhibits Vps4 oligomerization and ATPase 
hydrolysis (45).  While Ist1 utilizes its C-terminal MIM for initial targeting to the 
MIT domain of Vps4, the subsequent association between the N-terminal 
ESCRT-III domain of Ist1 with Vps4 is responsible for the inhibition.  LIP5-
CHMP5 inhibition of VPS4B mirrors this mechanism, with the LIP5 VSL domain 
acting like the Ist1 MIM and the LIP5 NTD-CHMP5 MIM complex acting like the 
Ist1 ESCRT-III domain. 
 
In summary, we have performed structural and functional analyses of 
molecular interactions between VPS4B and its various associated regulators to 
gain mechanistic insights into the regulation of ESCRT machinery in higher 
eukaryotes.  The results show interesting mechanistic difference in yeast versus 
metazoan.  Although Vta1 and LIP5 can both stimulate their cognate Vps4 
ATPase activity, the structural requirement appears to be different.  The C-
terminal domain of Vta1 is sufficient for full activity in yeast (42) , whereas both 
terminal domains of LIP5 are required in metazoan.  Furthermore, the effect of 
the ESCRT-III proteins upon binding to the N-terminal domain of Vta1/LIP5 is 
also dramatically different in terms of their ability to up or down regulate the 
stimulatory activity of Vta1/LIP5 towards the ATPase.  Structural results from the 
current study, together with previous NMR structures of human LIP5-CHMP5 and 
yeast Vta1-Vps60 complexes (47,49), suggest that they are likely the results of 
different binding interactions.  Interestingly, residues at the interface of LIP5 and 
CHMP5 are highly conserved throughout the metazoan but much less so in yeast 
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(Figure 3.4, 3.7), suggesting that the allosteric regulatory mechanism of LIP5 by 
CHMP5 has diverged during evolution. 
3.5 Methods 
3.5.1 Cloning, Expression, and Purification 
DNA sequences encoding for various proteins and protein fragments were 
amplified from cDNAs (ATCC®) and cloned into a modified pET28b vector to 
generate N-terminal His6-SUMO tagged fusion proteins.  Point mutations were 
generated using a standard PCR mutagenesis protocol (Stratagene).  Proteins 
were expressed in Escherichia coli Rosetta(DE3), where cells were grown at 
37°C to log phase in standard LB media and induced with 0.2 mM Isopropyl #-D-
1-thiogalactopyranoside followed by an additional 16-20h growth at 16°C.  
Seleno-methionyl LIP51-162 derivative was expressed in E.  coli B834(DE3) using 
a minimal medium where methionines were replaced with seleno-methionines. 
 
All proteins were purified using a similar protocol with adjustment made 
when necessary.  Cells were pelleted and lysed by sonication in buffer A (25 mM 
Tris pH 8.0, 300 mM NaCl, 5 mM 2-mercaptoethanol, and 10 µg/mL (w/v) 
phenylmethylsulfonyl fluoride).  Cell lysate was cleared by centrifugation and 
supernatant was loaded onto a Ni2+-nitrilotriacetic acid affinity column, washed 
with buffer A and eluted with buffer A supplemented with 250 mM imidazole.  
Eluate was collected, digested with ULP1 to cleave the His6-SUMO tag while 
being dialyzed against 50 mM Tris pH 8.0, 25 mM NaCl overnight.  A moderate 
precipitation formed for LIP51-162 and LIP5"166-214 during dialysis, which was 
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determined to be nucleic acid and could be cleared by centrifugation.  Dialyzed 
protein mixture was passed over a second Ni2+-nitrilotriacetic acid column to 
remove the His6-SUMO tag.  Proteins that would be used for GST-pulldown 
analysis were stored directly in -80°C.  Proteins that would be used in ATPase 
assay were first concentrated using a Macrosep® (Pall Corporation) centrifugal 
device, diluted in ATPase buffer (100 mM Tris-HCl (pH 7.4), 20 mM KCl, 6 
mM MgCl2) and then stored at -80°C. 
 
Proteins used for crystallization were further purified.  LIP51-162  was further 
purified on a Source-S (GE Healthcare) cation exchange column using buffer C 
(50 mM HEPES pH 7.0, 50 mM NaCl, 1mM EDTA, 1mM DTT) as a loading 
buffer, and eluted via a gradient with buffer C supplemented with 1M NaCl.  
Fractions containing the protein was pooled, concentrated and loaded onto a 
HiLoadTM SuperdexTM 75 (GE Healthcare) column and eluted with buffer C.  With 
regards to the two protein complexes, purified ESCRT-III peptides were mixed 
with LIP51-162 in a saturating amount.  These mixtures were concentrated and 
loaded onto the SuperdexTM 200 column, and eluted with buffer C.  Complex 
formation was confirmed by elution position change from the gel filtration column.  
The two ESCRT-III peptides were not detectable by Coomassie blue staining. 
3.5.2 Crystallization and Data Collection 
Complex crystals of LIP5-CHMP1B were grown by sitting drop vapor 
diffusion method at 4°C.  Protein complex at 12.7 mg/ml was mixed in a 1:1 ratio 
with a solution of 16% MPD, 0.1 M Tris pH 9.0 and equilibrated against 500 µl of 
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a reservoir solution of 8% MPD, 0.1 M Tris pH 9.0.  Two crystals with different 
morphology appeared.  Long needle-like crystals would appear instantly and 
dissolve over time.  Stable diamond-like crystals would appear later and were 
ultimately used for data collection.  Crystals were micro-dialyzed (Hampton 
Research) against 30% MPD, 0.1 M Tris pH 9.0 for 16-24h before flash-frozen 
under liquid nitrogen.  Data were collected at Advanced Photon Source beamline 
21-ID, and processed and scaled using HKL2000 (HKL Research Inc.).  Complex 
crystals of LIP5-CHMP1B-CHMP5 were grown by sitting drop vapor diffusion 
method at 4°C.  Protein complex at 13.7 mg/ml was mixed in a 1:1 ratio with a 
reservoir solution of 19% PEG4000, 25 mM sodium acetate pH 5.5 and 
equilibrated against 500 µl of the reservoir solution.  Large diamond shaped 
crystals would appear after a few days, which were then micro-dialyzed against 
25% PEG4000, 20% ethylene glycol, 25 mM sodium acetate pH 5.5 before flash-
frozen under liquid nitrogen.  Data were collected at Advanced Photon Source 
beamline 21-ID, and processed and scaled using HKL2000. 
3.5.3 GST Pull-down Analysis 
GST pull-down analysis was performed following standard procedures in 
phosphate-buffered saline (PBS) solution supplemented with 1 mM DTT and 
0.1% (v/v) Tween 20(33).  Specific samples were also supplemented with 2 
mM ATP as indicated.  Purified proteins were incubated with GST alone, GST-
SUMO alone or GST-tagged proteins immobilized on glutathione-agarose beads 
for 1 h at 4 °C.  The beads were then washed extensively with the buffer before 
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bound proteins were analyzed on SDS-PAGE and visualized by Coomassie blue 
staining. 
3.5.4 Malachite Green ATPase Assay 
Malachite Green assay was used to measure the stimulation of 
VPS4B"MIT by various protein mixtures as previously described with 
modifications (39).  LIP5-binding ESCRT-III fragments instead of full-length 
ESCRT-III proteins were used in the assay due to difficulties in purifying full-
length proteins.  Briefly, 0.5 µM VPS4B"MIT was incubated with buffer or 0.5 µM 
LIP5 (or LIP5 truncation mutation), and with additional 2 µM ESCRT-III peptides 
(all final concentrations) where indicated, in a 15 µl protein mixture.  The reaction 
was started with the addition of 2 mM ATP (final concentration) to a final reaction 
volume of 25 µl.  The reaction was allowed to proceed for 1h, 80 µl of Malachite 
green reagent was then added and finally quenched with the addition of 10 µl of 
32% sodium citrate.  The samples were mixed and incubated at 37 °C for 10 min 
before A620 was measured on a SpectraMax M5 microplate reader (Molecular 
Devices, Sunnyvale, CA).  To account for background ATP hydrolysis, the signal 
from identically treated sample lacking VPS4B"MIT was subtracted.  Likewise, 
the background activities of LIP5 proteins or ESCRT-III peptides were subtracted 
from samples with an identical composition but lacking VPS4"MIT.  Each 
experiment was done three times in triplicate, where error bars represent 
standard error from the mean.  Significances in the data were assessed using 
one-way ANOVA in Prism5 (GraphPad). 
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Chapter 4 Vfa1, a Novel Vps4 regulator, binds to the N-terminal MIT 
domain of the AAA-ATPase 
4.1 Abstract 
The endosomal sorting complexes required for transport (ESCRTs) are 
responsible for multivesicular body (MVB) biogenesis, membrane abscission 
during cytokinesis, and retroviral budding. They function as transiently-
assembled molecular complexes on the membrane and their disassembly 
requires the action of the AAA-ATPase Vps4. Vps4 is regulated by a multitude of 
ESCRT and ESCRT-related proteins. Binding of these proteins to Vps4 is often 
mediated via the microtubule interacting and trafficking (MIT) domain of Vps4. 
Recently, a new Vps4-binding protein Vfa1 was identified in a yeast genetic 
screen, where overexpression of Vfa1 caused defects in vacuolar morphology. 
However, the function of Vfa1 and its role in vacuolar biology were largely 
unknown. Here, we provide a first detailed biochemical and biophysical study of 
Vps4-Vfa1 interaction. The MIT domain of Vps4 binds to the C-terminal 
seventeen residues of Vfa1. This interaction is of high affinity and greatly 
stimulates the ATPase activity of Vps4. The crystal structure of the Vps4-Vfa1 
complex shows that Vfa1 adopts a canonical MIT-interacting Motif 2 (MIM2) 
structure that has been previously observed in other Vps4-ESCRT interactions. 
These findings suggest that Vfa1 is a novel positive regulator of Vps4 function. 
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4.2 Introduction 
Controlling and remodeling membrane structure is a vital process for 
cellular homeostasis. Topologically related events such as multi-vesicular body 
(MVB) biogenesis, retroviral budding, and abscission between daughter cells 
during cytokinesis require the action of a class of proteins collectively known as 
the Endosomal Sorting Complexes Required for Transport (ESCRT)(1-9). The 
ESCRT proteins are unique in that they deform cellular membranes to generate 
curvature and bud away from the cytosol(7,10). The molecular mechanisms 
underlying the function of these proteins are similar but distinct in different 
cellular processes, and are best studied in the context of MVB biogenesis. 
 
The ESCRT proteins can be grouped into five distinct multi-meric protein 
complexes, ESCRT-0, -I, -II, -III and Vps4(11). It is believed that they work in a 
sequential manner to target cell surface receptors into MVB for eventual 
vacuolar/lysosomal degradation(12). Cargo molecules are first ubiquitinated and 
endocytosed into early endosome where they are recognized by ESCRT-0(13). 
Next, ESCRT-I and -II target and concentrate cargo molecules to the site of 
endosomal membrane deformation and may also directly cause change in 
membrane curvature (14). To complete the process of budding and vesicle 
formation, ESCRT-III oligomerizes and forms a filament structure on the 
endosomal membrane, which ultimately leads to scission of a forming 
vesicle(15,16). Ubiquitin tags are removed before cargo molecules are included 
in the vesicle. Finally, the ATPase Vps4 is recruited to the site of vesicle 
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formation. Through ATP hydrolysis, Vps4 is likely to drive the completion of 
vesicle formation in an irreversible direction and ultimately provide energy for the 
entire process(17,18). Biochemically, Vps4 catalyzes the removal of ESCRT-III 
oligomers from the endosomal membrane(19). This serves two critical functions: 
first, to provide proper temporal and spatial control of the ESCRT-III 
oligomerization, thus generating appropriately sized vesicles(20), and second, to 
recycle components of ESCRT-III to allow for continuous cargo trafficking(21). 
The role of the ESCRT proteins in MVB biogenesis is evolutionarily conserved in 
eukaryotic cells(6). 
 
Vps4 is a member of the AAA-ATPase (ATPase Associated with diverse 
cellular Activities) family. The crystal structure of Vps4 shows that it contains an 
N-terminal Microtubule Interaction and Trafficking (MIT) domain and a C-terminal 
AAA-ATPase domain connected by a flexible linker region(22-24). Vps4 exists in 
two quaternary structures, as a monomer in the absence of ATP binding and as a 
hexameric ring upon ATP binding(22,25). Oligomerization of Vps4 is mediated 
through the AAA-ATPase domain with ATP binding sites located at the subunit 
interface. The hexameric ring structure of Vps4 is a transient species in solution, 
only stable with ATP bound. Vps4 binds to many proteins in the cell, most of 
which are mediated through the MIT domain(26). The MIT domain adopts a 
three-helix bundle structure that serves as a binding partner for the MIT-
interaction motifs (MIMs) of ESCRT-III and ESCRT-III related proteins. The MIM 
was initially defined as a small sequence motif (~15-20 residues) at or near the 
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C-terminal end of ESCRT-III and ESCRT-III-related proteins(27). There have 
been speculations that the MIM binds to the ESCRT-III protein core structure in 
the auto-inhibited state of ESCRT-III. In the active state, it is exposed to the 
solvent and can be recognized by the MIT domain(28,29). Hence, the MIM 
serves as a bi-functional switch of ESCRT-III function. Based on the structure 
and the mode of interaction with the MIT domain, several different types of MIM 
have been described(30-36). For example, a MIM1 forms a small helix that binds 
between the second and third helices of the Vps4 MIT domain(30,31). 
Alternatively, a MIM2 adopts an extended structure that binds between the first 
and third helices(32). Binding of ESCRT-III to Vps4 can enhance the ATP 
hydrolysis by Vps4 although the mechanism of action is not clear(37). In addition 
to ESCRT-III and ESCRT-III-related proteins, there are also other regulators of 
Vps4 function. Vta1, a positive regulator of Vps4 ATPase, binds to a unique #-
domain within the AAA-ATPase domain and presumably activates Vps4 by 
stabilizing the hexameric ring structure required for ATP hydrolysis(38,39). 
 
A novel Vps4-binding protein, called Vps4 associated-1 (Vfa1), was 
recently identified in an overexpression study of all putative genes in 
Saccharomyces cerevisiae to look for vacuole morphology defects(40). 
Overexpression of Vfa1 caused altered vacuole size, indicative of MVB 
dysfunction. Most interestingly, Vfa1 was found to interact with Vps4. Given the 
lack of knowledge about Vfa1 and how essential Vps4 regulation is, we used 
biochemical and biophysical methods to show that Vfa1 binds to the Vps4 MIT 
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domain. We determined a high-resolution crystal structure of the Vps4 MIT 
domain in complex with a C-terminal Vps4-binding fragment of Vfa1, and 
identified residues important for binding. Vfa1 binds to Vps4 with high-affinity 
(~0.47 µM) and can stimulate Vps4 ATPase activity by more than 10-fold. These 
results suggest that Vfa1 is a bona fide regulator of Vps4 ATPase activity with a 
possible role in MVB regulation. 
4.3 Results 
4.3.1 Vfa1 binds to Vps4 in an ATP-independent manner 
We first sought to confirm the interaction between Vps4 and Vfa1 as 
reported by Arlt et al.(40) using Glutathione-S transferase (GST)-pull down 
analysis. Vps4 has been shown to exist in two oligomeric states, as a monomer 
and, upon binding ATP, as a hexameric ring(2,24). Many binding partners of 
Vps4, including ESCRT-III and ESCRT-III-related proteins, show an ATP 
dependence for Vps4 binding, suggesting that they only bind to the hexameric 
form of Vps4(22,39). To maintain Vps4 in a stable hexameric structure, we used 
an ATPase-deficient mutant (E233Q) of Vps4(44). We saw that Vfa1 could bind 
to Vps4 in both the absence and presence of ATP (Figure 4.1A). We further used 
size exclusion chromatography to validate the interaction between Vps4 and 
Vfa1. Different proteins or protein mixtures (Vfa1, Vfa1 with 2 mM ATP, Vps4, 
Vps4 with 2mM ATP, Vps4 plus Vfa1, and Vps4 plus Vfa1 with 2 mM ATP) were 
loaded onto a 120ml Superdex-200 column respectively. Compositions of elution 
peaks were examined by SDS-PAGE gel analysis. Regardless of the presence of 
ATP, Vfa1 co-eluted with Vps4 at a position that was distinct from Vfa1 alone, 
 145 
suggesting that it formed a stable complex with Vps4 in solution (Figure 4.1B). 
Therefore, Vfa1 can bind to either a monomeric or hexameric form of Vps4. 
 
Figure 4.1 Vfa1 binds to Vps4 in an ATP-independent manner 
(A) GST-SUMO or GST-SUMO-Vfa1 was used to pulldown Vps4E233Q.  GST-
SUMO was used as a tag since GST-Vfa1 runs at a position similar to that of 
Vps4E233Q.  Vps4E233Q oligomerizes in the presence of ATP.  Binding analyses 
were performed in the presence or absence of ATP to determine whether Vfa1 
binds to Vps4 monomer or oligomer.  Proteins retained on the beads were 
analyzed by SDS-PAGE and visualized by Coomassie staining. (B) Size-
Exclusion Chromatography (SEC) was used to compositions of molecular 
species in the following samples: Vfa1, Vfa1 + 2mM ATP, Vps4E233Q, Vps4E233Q + 
2mM ATP, Vfa1 + Vps4E233Q, and Vfa1 + Vps4E233Q + 2mM ATP.  Peak fractions 
were collected, analyzed by SDS-PAGE, and visualized by Coomassie stain.  
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The inset gel is a representation of the elution profile for the major peak in the 
Vfa1 + Vps4E233Q + 2mM ATP sample run as described above. 
4.3.2 Vps4-Vfa1 interaction is mediated through the N-terminal MIT domain of 
Vps4 
We next identified the minimal binding domains between the two proteins. 
Vps4 contains an N-terminal Microtubule Interacting and Trafficking (MIT) 
domain and a C-terminal canonical AAA-ATPase domain. Since most of the 
ESCRT-III and ESCRT-III-related proteins bind to the MIT domain, we reasoned 
that it might also be the site of binding for Vfa1. Indeed, deletion of the MIT 
domain (Vps4-"MIT) abolished the interaction between Vps4 and Vfa1. This was 
reminiscent of the interaction between Vps4 and Ist1, an ESCRT-III-related Vps4 
regulator that binds to Vps4 via the MIT domain in an ATP-independent 
manner(45), but different from another regulator Vta1 which binds to Vps4 in an 
ATP-dependent manner via the #-domain within the ATPase domain (Figure 
4.2A). ESCRT-III proteins bind to the MIT domain via C-terminal sequence 
motifs, known as the MIT-interacting motifs (MIMs)(46). Secondary structure 
prediction showed that Vfa1 was largely an $-helical protein with a C-terminal 
helix suggestive of a potential site for MIT interaction (data not shown). We 
therefore made a truncation mutant of Vfa1 (Vfa11-186) with the C-terminal 17 
residues deleted and tested whether it could still bind to Vps4. Removal of the C-
terminal sequence abolished its interaction with Vps4 (Figure 4.2B). These 
results show that Vps4-Vfa1 binding is mediated through the N-terminal MIT 
domain of Vps4. 
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Figure 4.2 Mapping the binding interface between Vps4 and Vfa1 
(A) The Vps4 MIT domain is necessary for Vfa1 binding.  GST, GST-Vta1, GST-
Ist1 and GST-Vfa1 were used to analyze their interactions with Vps4E233Q"MIT 
(residues 83-437) in the presence or absence of ATP.  Vta1 known to only bind 
to the oligomeric form of Vps4.  Ist1 is an ESCRT-III related protein that binds to 
the Vps4 MIT domain.  (B) The C-terminal sequence of Vfa1 is necessary for 
Vps4 binding.  GST-SUMO, GST-SUMO-Vfa1, or GST-SUMO-Vfa11-186 was 
used to analyze their interactions with Vps4E233Q in the presence or absence of 
ATP. 
4.3.3 Binding of Vfa1 stimulates the ATPase activity of Vps4 
When ESCRT-III and ESCRT-III-related proteins bind to Vps4, they often 
stimulate the ATPase activity of Vps4(37,47). To determine whether this was the 
case for Vfa1, we used the Malachite Green ATPase assay(41) to examine how 
Vfa1 might affect the ATPase activity of Vps4 (Figure 4.3). As a control, the 
addition of Bovine Serum Albumin (BSA) did not stimulate the ATPase activity of 
Vps4. Vta1, a known positive regulator of Vps4, was able to increase the rate of 
Vps4 ATP hydrolysis by three-fold when added in a 1:2 ratio. In comparison, 
addition of Vfa1 in a similar ratio increased the Vps4 ATPase activity by an 
approximate 10-fold as compared to the intrinsic activity of Vps4 even though 
Vfa1 itself had no ATPase activity. Vfa1 therefore appeared to be a much more 
potent activator of Vps4 than Vta1. To examine whether this stimulation was 
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dependent on the site of interaction we identified, we also included Vfa11-186 in 
the Vps4 ATPase assay. No stimulation was seen upon the addition of Vfa11-186 
demonstrating that stimulation by Vfa1 requires the specific interaction between 
Vps4 and Vfa1. 
       
Figure 4.3 Vfa1 stimulates Vps4 activity. 
ATP hydrolysis by 0.125 µM Vps4 (intrinsic, first column) was assayed under 
conditions of 1mM ATP at 37°C (see Experimental procedures). To observe 
stimulation of Vps4 activity, the following proteins (0.25 µM) were incubated with 
Vps4: Bovine Serum Albumin (second column), Vta1 (third column), Vfa1 (fourth 
column), Vfa11-186 (fifth column), Vfa1F198D (seventh column), and Vfa1V201D 
(eighth column). Each experiment was done in triplicate; all experiments were 
repeated a minimum of three times. Intrinsic ATPase activity for Vfa1 (0.25 µM) is 
shown in the sixth column. 
4.3.4 Crystal structure of Vps4 MIT and Vfa1 MIM 
To understand the structural nature of the Vps4-Vfa1 interaction, we 
determined the crystal structure of the Vps4-Vfa1 complex using the Vps4 MIT 
domain (residues 1-82) and a C-terminal fragment of Vfa1 that encompasses the 
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necessary Vps4-binding sequence (residues 183-203). The structure was 
determined by molecular replacement using the yeast Vps4 MIT domain 
structure as a search model(31) and refined to 2.3Å resolution (Table 4.1). The 
refined structure has an R-factor/Rfree of 23.6%/25.7% with excellent parameters 
for stereochemistry. There are two molecular complexes of Vps4-Vfa1 in the 
asymmetric unit. The r.m.s deviations for C$ positions between the two 
complexes are 0.039 Å and 0.672 Å for Vps4 and Vfa1, respectively. The 
average buried surface area at the interface of Vps4 and Vfa1 is approximately 
900 Å%. 
Table 4.1 Crystallographic data statstics  
Data Collection  
Space group P212121 
Unit cell parameters:  
a, b, c (Å) 38.5, 56.7, 84.2 
Molecules per asymmetric unit 2 
Wavelength (Å) 0.9998 
Resolution (Å) 2.3 
Unique reflections1 8662 (840) 
Redundancy 7.1 (7.3) 
Completeness (%) 99.9 (100.0) 
Average I/! (I) 34.6 (7.3) 
Rmerge  0.04 (0.34) 
Refinement  
Resolution range (Å) 35.00-2.30 
Rwork (%) 23.6 
Rfree (%) 25.7 
RMS deviations  
Bond lengths (Å) 0.011 
Bond angles (°) 1.40 
B-factor average (A2) 43.1 
Ramachandran Plot Regions  
Most favored (%) 95.9 
Allowed (%) 4.1 
Outliers (%) 0.0 
PDB ID code 4NIQ 
1Values in parentheses are for the specified high-resolution bin. 
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As shown in Figure 4.4A, the Vps4 MIT domain adopts a three-helix 
bundle fold (H1-H3). Binding of Vfa1 to Vps4 does not change the overall 
structure of the domain. The r.m.s deviations for C$ positions between the Vps4 
MIT domain structure in the Vfa1 complex and other previously reported Vps4 
MIT domain structures are in the range of 0.6-0.7 Å. The Vps4-binding sequence 
of Vfa1 can be divided into three regions: an N-terminal extended region 
(residues 183-188), a short 2-turn $-helix in the middle (residues 189-196) and a 
C-terminal extended region (residues 197-203). Interactions between Vps4 and 
Vfa1 are mediated through all three regions. The N-terminal extended region 
binds to the turn between the second and third helices of the MIT domain, while 
the middle helix and the C-terminal extended region binds predominantly 
between the first and third helices of the MIT domain. 
4.3.5 Molecular interactions between the C-terminal extended region of Vfa1 
fragment and Vps4 
Vps4 presents a hydrophobic binding pocket between the first and third 
helices. As shown in Figure 4.4B, this hydrophobic pocket includes side chains 
from residues Leu7, Ile11, Val14, Ile18 (helix one) and Leu55, Ile56, and Tyr63 
(helix three). In addition, the aliphatic portions of side chains from residues Lys59 
and Arg66 also contribute to the pocket hydrophobicity, which allows for discrete 
interactions with the following Vfa1 residues: Leu192, Leu193, His196, Phe198, 
Pro199, Val201, and Pro202 (Figure 4.4B). A number of specific hydrogen bond 
interactions are also present at the interface. For example, the side chain of Vfa1 
residue His196 forms a hydrogen bond with the main chain carbonyl oxygen of 
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Vps4 residue Gly4. A complete list of molecular interactions observed at the 
interface is tabulated in Table 4.2. 
 
Figure 4.4 The crystal structure of the Vps4-Vfa1 complex. 
(A) An overview of the Vps4-Vfa1 complex structure. Ribbon representation of 
Vfa1 (residues 183-203) in complex with Vps4 (1-82) in two orthogonal views. 
Vfa1 is colored in cyan, and the three helixes of the Vps4 MIT domain are 
colored red, green and blue, respectively.  The N- and C- termini of the two 
proteins are labeled. (B) The C-terminal extended region of Vfa1 binds in a 
 152 
hydrophobic pocket formed by helices 1 and 3 of the Vps4 MIT domain. Left 
panel is a surface representation of the Vps4 MIT domain and the Vfa1 binding 
pocket is selectively colored based on the underlying atoms: carbon, yellow; 
oxygen, red; and nitrogen, blue. Residues that contribute to binding are labeled 
in black. Right panel is the same surface representation with Vfa1 showing in 
cyan. Critical hydrophobic residues utilized by Vfa1 for binding Vps4 are labeled 
in cyan. (C) The C-terminal extended region of Vfa1 binds like a “MIM2”. Top 
panels show ribbon and surface representations of the Vps4-Vfa1 complex and 
the hVPS4A-CHMP6 complex (PDB: 2K3W). Bottom panels show zoom-in views 
of the interactions within the two complex structures. Critical residues from the 
MITs are labeled in black. Residues that make close contacts from the MIM2s 
are in cyan for Vfa1 and orange for CHMP6. (D) Sequence alignment of various 
MIM2s. 
Table 4.2 Detailed interactions between Vps4 and Vfa1 
Vps4 Vfa1 
Hydrogen bond interactions  
G4 O H196 OE2 
Y46 O S185 N 
E47 OE1 T187 OG1 
E47 OE2 T187 N 
K48 N S185 O 
N49 ND2 T187 O 
N49 ND2 D188 OD1 
S52 OG T187 O 
E62 OE2 V201 N 
Y63 OH P199 O 
Van der Waals interactions  
L7 L192, H196, F198 
I11 F198, P199 
V14 P199 
I18 P199, V201, P202 
L40 F198 
K51 P189 
L55 P189, L192, L194, F199 
I56 L192, F198 
K59 F198 
Y63 F198, P199, V201 
R66 V201, P202 
 
The interaction between Vps4 and the C-terminal extended region of the 
Vfa1 fragment is of particular interest. It is reminiscent of the MIT-MIM interaction 
as seen in the structure of human VPS4A and CHMP6, the human homolog of 
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Vps20 (a core ESCRT-III protein)(32). The MIM involved in this type of 
interaction has been termed as MIM2. In both the Vps4-Vfa1 and the VPS4A-
CHMP6 complexes, the MIT domains adopt similar structures. When the 
conformations of the bound peptides in the two complexes are compared, it is 
clear that the C-terminal extended region of Vfa1 fragment adopts a conformation 
similar to that of the CHMP6 MIM2 (Figure 4.4C). Moreover, both peptides utilize 
hydrophobic residues including two signature prolines within their sequences to 
bind to Vps4. Specifically, CHMP6 MIM2 residues (Leu170, Pro171, Val173 and 
Pro174) fit into the hydrophobic pocket within the helical groove between helices 
one and three in a nearly identical fashion as the Vfa1 fragment. 
 
Previous studies defined MIM2 as a MIT-binding motif that contains a 
conserved LP(E/D)VP sequence(32). In the Vps4-Vfa1 structure, Vfa1 utilizes a 
slight different 198FPSVP202 sequence at the core of the binding interface. By 
aligning the MIT-binding motif of Vfa1 with other MIM2 sequences, we arrived at 
a more general &PX&P motif (where & represents a hydrophobic residue) that is 
required for a peptide sequence to bind as a MIM2 (Figure 4.4D). Based on the 
structure shown here, the hydrophobic residues from the Vfa1 “MIM2” make 
contact with the hydrophobic pocket presented by the Vps4 MIT domain helices 
one and three. The variable residue X tends to be polar and always seems to 
point into solvent in different structures. 
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4.3.6 Additional interaction between Vfa1 MIM and Vps4 
While the MIT-MIM2 interactions are similar in the two complex structures, 
CHMP6 does not contain sequence N-terminal to the MIM2 that makes additional 
contacts with VPS4A MIT. In Vfa1, these contacts include the N-terminal 
extended region and the middle helix. The middle helix is amphipathic and binds 
to the hydrophobic pocket formed by the first and third helices of the MIT domain 
via Pro189, Leu192 and Leu193 as described above (Figure 4.5). Interactions 
between the N-terminal extended region and Vps4 are largely polar. Vfa1 forms 
several hydrogen bond interactions with the backbone atoms from the turn 
between the second and third helices of the Vps4 MIT domain (Figure 4.5). 
Specifically, Vfa1 residues 185-186 and Vps4 residues 46-48 form parallel #-
sheet like main chain hydrogen bonds. The side chain of Vps4 Glu47 forms 
bidentate hydrogen bonds with the side chain and the main chain atoms of Vfa1 
Thr187. The amide nitrogen of Vps4 Asn49 side chain forms bifurcated hydrogen 
bonds with the main chain carbonyl oxygen atom of Vfa1 Thr187 and the side 
chain carboxyl oxygen atom of Vfa1 Asp188. 
 
Figure 4.5 Additional interactions between Vps4 and Vfa1 
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Cartoon representation of Vfa1 (cyan) making contacts with Vps4 (grey) beyond 
the “MIM2” sequence. (A) Interactions involving the middle helix; (B) Interactions 
involving the N-terminal extended region. Residues that make distinct contacts 
are shown as stick models and labeled in cyan for Vfa1, black for Vps4. 
Hydrogen bonds are denoted as dashed lines. 
4.3.7 Functional relevance of Vps4-Vfa1 interaction 
We used site-directed mutagenesis and GST-pull down analysis to evaluate the 
contribution of interface residues to the overall stability of the complex. 
Interactions between Vps4 and MIM2-containing ESCRT-III proteins have been 
previously shown to be disrupted by mutation of Ile18, a residue located at the 
hydrophobic pocket formed by helices one and three of the Vps4 MIT 
domain(48).  Since Ile18 is also located at the Vps4-Vfa1 interface, we reasoned 
that this mutant should also prevent Vfa1 from binding. Indeed, I18D failed to 
bind to GST-Vfa1 in our GST pull-down analysis, suggesting that Ile18 is 
essential for high-affinity binding interaction (Figure 4.6A). In contrast, mutation 
of Leu64 of Vps4, a residue important for interactions between Vps4 and MIM1-
containing ESCRT-III proteins(30), had no effect on Vfa1 binding (Figure 4.6A). 
Moreover, Vfa1 mutants F198D and V201D also failed to bind to Vps4. As 
mentioned above, Phe198 and Val201 are part of the MIM2 sequence. 
Collectively, these results confirm the importance of Vfa1 MIM2 sequence to the 
overall stability of the complex. 
 
Using Isothermal Titration Calorimetry (ITC), we measured the binding 
affinity between the Vps4 MIT domain and Vfa1. The MIM2-type MIT-MIM 
interaction has been previously characterized to have a low micromolarity 
dissociation constant (KD ~5-10 µM)(32). Here, we saw that full-length Vfa1 
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bound to the Vps4 MIT domain with a significantly higher affinity (KD = 0.47 µM ± 
0.12) (Figure 4.6B). This is approximately 10-fold higher in affinity as compared 
to the CHMP6-hVPS4A interaction.  This increase in affinity may have been due 
to the additional contacts between Vps4 and Vfa1 beyond the interaction that 
involves the C-terminal MIM2 sequence, which are not available in CHMP6. The 
contribution of Vfa1 sequence beyond MIM2 to the overall binding affinity of the 
complex was corroborated by the observation that Vps4 mutant E47A/N49A had 
a significantly decreased affinity for Vfa1 based on GST-pull down analysis 
(Figure 4.6C). 
 
To further study the functional relevance of Vps4-Vfa1 interaction, we 
examined how point mutations within the Vps4-Vfa1 binding interface might 
affect the ability of Vfa1 to stimulate Vps4 ATPase activity. Two Vfa1 mutants 
F198D and V201D, which had drastically reduced affinities for Vps4 by both 
GST-pull down analysis and ITC, were unable to stimulate the ATPase activity of 
Vps4 (Figure 4.3). This again suggests that the specific interaction between Vfa1 
and Vps4 is important for its role as a potential positive regulator of Vps4. 
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Figure 4.6 Critcal residues at the Vps4-Vfa1 binding interface 
(A) Vfa1 binds in the first and third helical groove of Vps4 MIT as a “MIM2”. Top 
panel, GST, GST-Vfa1, and GST-Vfa11-186 were used to analyze their respective 
interactions with Vps4-MIT and Vps4I18D-MIT. Middle panel, GST, GST-Vfa1, and 
GST-Vfa11-186 were used to analyze their respective interactions with Vps4-MIT 
and Vps4L64D-MIT. Bottom panel, GST, GST-Vfa1, GST-Vfa1F198D, and GST-
Vfa1V201D were used to analyze their respective interactions with Vps4-MIT.  (B) 
Binding affinities of Vps4-MIT to wild-type and mutant Vfa1 as determined by 
isothermal titration calorimetry (ITC) assay. A representative ITC enthalpy plot for 
the binding of Vps4-MIT to wild-type Vfa1 is also shown. (C) Region outside Vfa1 
MIM2 contributes to Vps4 binding. GST, GST-Vfa1, and GST-Vfa11-186 were used 
to analyze their respective interactions with Vps4-MIT and Vps4E47A/N49A-MIT. 
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4.4 Discussion 
Oligomerization of ESCRT-III proteins on the endosomal membrane is a 
critical step in generating intra-luminal vesicles during MVB biogenesis. This step 
is terminated by the removal of ESCRT-III proteins from the membrane through 
the action of the AAA-ATPase Vps4. Activity of Vps4 is tightly regulated in the 
cell by a multitude of proteins that specifically bind to Vps4. A newly identified 
protein, Vfa1, which causes defects in vacuolar morphology upon overexpression 
in yeast, has been previously shown to bind to Vps4. In order to understand the 
molecular mechanism of Vfa1 function, we embarked on a detailed structural 
study of the interaction between Vps4 and Vfa1. We have confirmed that Vfa1 
binds to Vps4 in an ATP-independent manner(40). In addition, the crystal 
structure of Vps4-Vfa1 complex reveals that Vfa1 binds to the N-terminal MIT 
domain of Vps4, utilizing a conserved &PX&P binding motif (MIM2) that is 
shared among some ESCRT-III and ESCRT-III-related proteins. Moreover, 
binding of Vfa1 to Vps4 significantly stimulates the ATP hydrolysis activity of 
Vps4. These data strongly suggest that Vfa1 is a positive regulator of Vps4 in the 
MVB pathway. 
4.4.1 Vfa1 binds to the Vps4 MIT domain using a canonical MIM2 
The MIT domain is a protein-protein interaction domain mostly found in 
proteins involved in membrane trafficking (Vps4, AMSH, UBPY, Vta1, Spastin 
and Spartin)(26,49). Protein sequence motifs that specifically bind to the MIT 
domain are collectively termed as MIMs. They are often found at the C-terminal 
ends of ESCRT-III and ESCRT-III-related proteins and can bind to the MIT 
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domain in a variety of manners, utilizing different binding surfaces on the MIT 
domain. The MIT domain of Vps4 contains two MIM-binding surfaces. In the 
crystal structure of Vps4-Vps2 complex, the Vps2 C-terminal sequence forms a 
small helix that binds between helices two and three of the Vps4 MIT 
domain(31). In the solution structure of hVPS4A-CHMP6 complex, the C-terminal 
sequence of CHMP6 adopts an extended conformation and binds between 
helices one and three of the hVPS4A MIT(32). These two structures help define 
that any MIM that binds in a similar fashion (same orientation, with conserved 
binding interactions) would be a MIM1 (between helix 2/3) or a MIM2 (between 
helix 1/3). The complexity in binding illustrates the mechanism by which MIT 
domains discriminate specific binding partners. In the current work, we show that 
the C-terminal sequence of Vfa1 binds to the Vps4 MIT domain in a manner 
similar to that of CHMP6. Therefore, the structure should be classified as a 
MIM2. This finding strongly suggests that Vfa1 plays a role related to the function 
of Vps4 in the MVB pathway. 
 
Beyond the MIM2 sequence, the molecular interfaces within the hVPS4A-
CHMP6 complex and the Vps4-Vfa1 complex are significantly different. hVPS4A 
makes additional interactions with CHMP6 residues C-terminal to the MIM2. 
These interactions do not exist in Vfa1, as its MIM2 sequence is located at the 
very C-terminal end. For Vfa1, the sequence N-terminal to the &PX&P motif 
makes additional contacts with Vps4 in the form of a short helix and an extended 
loop. As shown by mutagenesis and GST-pull down analysis, these interactions 
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do contribute to the overall stability of the complex. The CHMP6 fragment used in 
the structural study does not include additional sequence N-terminal to the MIM2. 
It is possible that the small helix seen in the Vfa1 structure may also exist in 
CHMP6 if more residues were included in the structural study. Indeed, secondary 
structure prediction of CHMP6 indicated the possibility of a small helix upstream 
of the MIM2 sequence. Nevertheless, the binding mechanism beyond the 
canonical MIT-MIM2 interface is likely to be distinct between the two complex 
structures. These differences suggest that interactions outside the consensus 
MIM2 sequence may provide a mechanism for MIT domains to distinguish 
among their various binding partners. Hence, regulation of Vps4 (and other 
ESCRT proteins) via MIT-MIM interaction can be more finely tuned than 
previously thought.  More MIT-MIM complex structures will be needed to properly 
decipher the MIT-MIM ‘binding code.’ 
4.4.2 Regulation of Vps4 by Vfa1 
As previously noted, overexpression of Vfa1 in yeast cells leads to an 
alteration in vacuolar morphology(40). Since Vfa1 can bind to Vps4 in both in 
vivo and in vitro assays(40), these data seem to suggest that Vfa1 has an 
inhibitory role in Vps4 regulation. We have now shown that Vfa1 binds to the 
Vps4 MIT domain and contains a MIM2 sequence that has been previously 
identified in some ESCRT-III proteins. Binding of Vfa1 to Vps4 is ATP-
independent and can greatly stimulate the ATPase activity of Vps4. Therefore, 
our biochemical and biophysical analysis instead suggest a positive regulatory 
role for Vfa1. 
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How does one reconcile the difference between the biochemical and 
biological data? The binding affinity of Vfa1 to Vps4 is about 10-20 fold higher 
than those of core ESCRT-III MIM2s to Vps4(32). While in cytosol, Vfa1 can form 
a complex with Vps4, which may stabilize the Vps4 oligomer, and is then 
recruited to the endosomal membrane. Due to an avidity effect of the ESCRT-III 
oligomer, while individually having a weaker affinity for Vps4 than Vfa1, the 
ESCRT-III oligomer can displace Vfa1 from Vps4 to allow for ESCRT-III 
disassembly. In a Vfa1 overexpression system, however, Vfa1 would outcompete 
the ESCRT-III proteins and block their binding to Vps4, thus preventing the 
proper function of Vps4.  
 
Deletion of Vfa1 in yeast has no observable phenotype on vacuolar 
morphology. It is possible that other ESCRT-III-related proteins may have 
overlapping function with Vfa1. Vfa1 does not seem to be essential for ESCRT-III 
filament disassembly, but more likely plays a role in the temporal and spatial 
control of Vps4 function. Many known regulators of Vps4 have weak or no 
phenotype in their respective deletion strains (Vta1, Vps60, Did2, Ist1)(50). It is 
only when two or more of these genes are deleted do we see a synthetic 
phenotype of vacuolar morphology(47,51). Moreover, EM tomography has often 
revealed more subtle effects on MVB biogenesis in a single gene deletion strain 
of these proteins(20). Taken together, the lack of a distinct phenotype on 
vacuolar morphology suggests that Vfa1 acts at a similar level as other 
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regulators of Vps4. It will be interesting to see whether a synthetic phenotype 
exists when Vfa1 is deleted in conjunction with other ESCRT-III-related proteins. 
Yeast-two hybrid analysis showed that Vfa1 could bind to Vta1 and preliminary 
biochemical characterization suggested that other ESCRT-III and ESCRT-III-
related proteins may also bind to Vfa1((52), data not shown). How Vfa1 works 
together with other ESCRT proteins to regulate Vps4 is a critical next step in 
understanding ESCRT function. 
4.5 Methods 
4.5.1 Cloning, Expression, and Purification 
DNA fragments encoding Vfa1 and Vps4, and their various fragment 
constructs were amplified from the S. cerevisiae genomic DNA. These proteins 
were expressed in E. coli Rosetta(DE3) cells using a modified pET28b vector 
with a SUMO protein tag inserted between a His6-tag and the respective protein 
coding region. The His6-SUMO-tagged protein was purified by Ni+2-NTA affinity 
chromatography following standard procedures. ULP1 protease was then added 
to remove the His6-SUMO tag, and the digested protein mixture was passed over 
a second Ni+2-NTA column. Proteins were further purified by ion exchange 
chromatography on a Source-S column (GE Healthcare) for Vfa1 proteins and a 
Source-Q column (GE Healthcare) for Vps4 proteins. The Vps4-Vfa1 complex 
was purified by mixing the two protein fragments in stoichiometric amounts 
followed by gel filtration chromatography using a HiLoadTM SuperdexTM 200 (GE 
Healthcare) column. 
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4.5.2 GST pull-down Analysis 
GST pull-down analysis was performed following standard procedures in 
Phosphate-buffered Saline (PBS) solution supplemented with 1mM DTT and 
0.1% (v/v) Tween-20(22). Specific samples were also supplemented with 2mM 
ATP as indicated. Purified proteins were incubated with either GST alone or 
GST-tagged proteins immobilized on glutathione agarose beads for 1 hr at 4°C. 
The beads were then washed extensively with the buffer before bound proteins 
were analyzed on SDS-PAGE and visualized by Coomassie staining. 
4.5.3 Isothermal Titration Calorimetry 
To measure the binding affinity between Vfa1 and the Vps4 MIT domain 
(residues 1-82), Vfa1 or Vfa1 mutants were titrated against the Vps4 MIT domain 
using a Nano ITCTM (TA instruments) or an ITC-200 microcalorimeter (GE 
Healthcare) at 25 °C. Data were processed using the NanoAnalyze software. All 
proteins were dialyzed against a buffer containing 50 mM HEPES (pH 7.5) and 
50 mM NaCl, centrifuged to remove any particulates, and degassed before 
binding analysis. Vfa1 proteins were injected at 0.23 mM (or greater for mutants) 
against 0.06 mM Vps4 MIT domain. The concentrations of all proteins were 
determined using UV spectral analysis. 
4.5.4 Malachite Green ATPase Assay 
The procedure was adopted from previous studies with modifications as 
indicated(41). The reaction buffer used included 100 mM Tris–HCl (pH 7.4), 
20mM KCl, 6mM MgCl2. Malachite green reagent was prepared as follows: 
malachite green (0.081% w/v), polyvinyl alcohol (2.3% w/v), ammonium 
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heptamolybdate tetrahydrate (5.7% w/v in 6 M HCl) and double distilled water 
were mixed at a 2:1:1:2 ratio, then stored at 4°C for at least 30 min. For Vps4 
stimulation experiments, a 15 µL protein mixture of 0.125 µM Vps4 and 0.25 uM 
of Vfa1, Vfa1 mutant, or Vta1 was incubated with 10 µL of 1.2 mM ATP (all final 
concentrations) at 37°C for 10 minutes in a 96-well plate. Protein concentrations 
were selected in order to see the stimulation of Vps4 hydrolysis and to avoid 
product inhibition. After the 10-minute incubation, 80 µL of malachite green 
reagent was added to each well. Immediately following this step, 10 µL 32% 
sodium citrate was used to inhibit the non-enzymatic hydrolysis of ATP. The 
samples were mixed thoroughly and incubated at 37 °C for 15 min before OD620 
was measured on a SpectraMax M5 (Molecular Devices, Sunnyvale, CA). To 
account for intrinsic hydrolysis, the signal from ATP in identically treated buffer 
lacking Vps4 was subtracted. 
4.5.5 Structural Study 
Vps4-Vfa1 complex crystals were grown using the sitting drop vapor 
diffusion method at 25°C. The protein complex (17 mg/mL) was mixed in a 1:1 
ratio with a reservoir solution of 26% (w/v) polyethylene glycol 4000, 10% (v/v) 
isopropanol and 0.1M HEPES, pH 6.5 in a final volume of 4 µL and equilibrated 
against 1 mL of reservoir solution. Clusters of sword-shaped crystals appeared 
after one day, and grew to full size after three days. Single crystals were isolated 
from the clusters and cryo-protected using the reservoir solution. 
Diffraction data were collected at the Advanced Photon Source Beamline 
21-ID-D. The Vps4-Vfa1 complex crystal diffracted to 2.3 Å. It belongs to the 
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space group of P212121 and contains two molecular complexes in the asymmetric 
unit. Data were indexed, integrated and scaled using HKL2000 (HKL Research). 
PHENIX software suite was used for structure determination and refinement. The 
structure was solved by molecular replacement as implemented in the AutoMR 
module(42), using the Vps4 MIT domain (PDB accession code 2V6X) as an initial 
search model. Non-crystallographic symmetry restraint was applied throughout 
refinement. Model building was done with COOT(43). 
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Chapter 5 Conclusions and Perspectives 
Understanding the molecular mechanism of membrane vesiculation by the 
ESCRT machinery has long been a goal for those in the protein trafficking, 
virology, and cancer biology fields.  While recent work has shown that 
restructuring of membrane by the ESCRT-III complex coupled with the hydrolysis 
of ATP by the AAA-ATPase Vps4 constitutes the final critical steps of 
vesiculation, there is a great gap in our knowledge about how Vps4 and ESCRT-
III work together in this process.  In particular, my thesis work has attempted to 
answer these questions by investigating how ESCRT-III proteins indirectly control 
Vps4 (in human: VPS4) activity by binding to its co-factor Vta1 (LIP5), namely 
Did2 (CHMP1B) and Vps60 (CHMP5).  Furthermore, I looked to answer how a 
novel ESCRT-III protein, Vfa1, directly controls Vps4 function.  While my thesis 
work has made gains in lessening this gap, there are still a significant amount of 
work that is needed to help us better understand this complicated mechanism. 
 
One clear deficiency in the ESCRT field is that much of our current 
knowledge with regard to ESCRT function has come from studies in yeast.  While 
I cannot stress enough how extremely fruitful and incredible insightful this work 
has been, until we test whether mechanisms in yeast are conserved within higher 
organisms it will be difficult directly to apply our knowledge about the ESCRT 
proteins to achieve therapeutic results.  In Chapter 2, I examined whether the 
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Vps4 co-factor, Vta1 and LIP5 – two homologs that have low sequence identity to 
each other - maintained structural similarity over the course of evolution.  I 
determined the crystal structure of the LIP5 N-terminal domain (NTD), and 
compared it to a previously determined crystal structure of Vta1NTD.  Like its 
yeast counterpart, LIP5NTD is comprised of two microtubule-interacting and 
trafficking (MIT) domains.  Overall, LIP5 and Vta1 adopt a similar fold, however 
the LIP5 MIT2 undergoes a 4 Å rotation relative to MIT1 when compared with the 
Vta1 MIT2.  I also investigated how the two ESCRT-III proteins, Did2 (CHMP1B) 
and Vps60 (CHMP5), bind to Vta1/LIP5.  It had been shown previously that the 
yeast ESCRT-III proteins bind to the second MIT domain.  However, I discovered 
that Did2 binds to the MIT1 and confirmed that the Vps60 binds to the MIT2.  
When testing how their human orthologs bind LIP5, CHMP1B, like Did2, was 
found to bind to the MIT1.  Interestingly, residues critical for Vps60 binding in 
Vta1 - while located at structurally analogous positions - are not essential for 
CHMP5 in human.  This strongly suggested that Vps60/CHMP5 binding to 
Vta1/LIP5 has diverged during evolution.  The fact that CHMP1B bound to the 
LIP5 MIT1 prompted me to determine the crystal structure of the minimal LIP5 
binding sequence, the CHMP1B MIT-interacting motif (MIM), with the LIP5NTD.  
As suspected, CHMP1B binds via a canonical MIT-MIM1 binding motif as seen in 
other MIT-ESCRT-III structures.  This indicates that all other ESCRT-III proteins 
that contain a MIM1 would bind LIP5 by a similar mechanism.   
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CHMP5 regulation of LIP5 has seem to have diverged from yeast, which 
made me question not only the mechanism of CHMP5 regulation of LIP5, but 
also whether LIP5 itself functions differentially in its direct role in VPS4 
regulation, as described in Chapter 3.  Using ATP hydrolysis as a functional 
readout, I saw that LIP5 does stimulate VPS4, as has been shown with yeast 
proteins, but CHMP1B MIM had no effect on LIP5 mediated stimulation of VPS4 
while CHMP5 actually inhibited LIP5 stimulation.  This was wholly unexpected, 
since both yeast proteins Vps60 and Did2 greatly stimulate Vps4 via Vta1.  By 
determining the crystal structure of the LIP5NTD-CHMP1B MIM-CHMP5 MIM 
complex, I proposed a model that explains the likely mechanism for CHMP5 
inhibition.  A previously determined solution structure of LIP5NTD and the 
CHMP5 MIM, showed that one residue of CHMP5, Tyr182, exists in a dynamic 
equilibrium.  Interestingly, I found that in the ternary complex crystal structure, 
this Tyr182 disrupts a conserved salt bridge between the MIT1-MIT2 interface, 
and causes a 2 Å shift in the MIT2 domain.  Although Tyr182 does not affect the 
affinity between LIP5 and CHMP5, it does relieve the inhibitory effects of CHMP5 
towards LIP5.  I reasoned that if regulation by ESCRT-III proteins is different for 
the human protein, it is then possible that LIP5 itself may utilize a different 
regulatory mechanism towards VPS4.  Indeed, unlike Vta1, which only requires a 
C-terminal VSL domain, LIP5 requires both its VSL and its NTD connected in cis 
for full activity.  While the physical connection is essential, the actual LIP5 linker 
sequence is dispensable for LIP5 stimulation.  Surprisingly, CHMP5 could also 
inhibit the LIP5 linker deletion mutant.  Together, this suggests a model of 
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regulation where the LIP5 VSL initially binds to VPS4 and through the physical 
linkage to NTD, brings it in close proximity to VPS4 for full activity.  When 
CHMP5 binds, the insertion of Tyr182 causes a conformational change in the 
LIP5NTD that precludes the stimulatory binding of LIP5NTD to VPS4. 
 
Chapter 4 is devoted to the regulatory property of a newly identified Vps4 
regulatory protein, Vfa1.  Initially, Vfa1 was only known to interact with Vps4, and 
upon its over-expression, could cause slight morphological defects in the yeast 
vacuole (presumed to be caused by dysfunction in endosomal pathway).  I found 
that Vfa1 not only binds Vps4, but this interaction dramatically potentiates Vps4 
ATPase activity.  I was able to map the binding interface between the two 
proteins and found that the Vps4 MIT domain interacted with the C-terminal 
portion of Vfa1.  The crystal structure of the complex showed that Vfa1 binds 
Vps4 using a canonical MIT-MIM2 interaction, as described from previous 
structural work with the ESCRT-III proteins and Vps4.  Perturbation to the binding 
interface ablates this high affinity MIT-MIM2 interaction, as well as prevented 
Vfa1 stimulation of Vps4 ATPase activity.  This structure showed that Vfa1 is a 
bona fide ESCRT protein, and has greatly expanded our understanding of 
ESCRT function by adding a new family member. 
 
While these results help us better appreciate the ESCRT-III/Vps4 
interaction, more effort is needed to achieve a comprehensive understanding.  
The number of distinct MIT-MIM interactions has continued to expand, with a 
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total of 5 different types of interactions being classified to date [appendix].  So 
far, three of these MIT-MIM interactions have been shown to be utilized by the 
Vps4/Vta1 complex.  The MIMs of the ESCRT-III proteins can also bind to other 
MIT domain containing proteins, thus encompassing the other two known MIT-
MIM interactions.  Yet, there are many other MIT containing proteins whose 
molecular interactions with the ESCRT-III proteins have not been classified.  In 
human, 13 proteins have been predicted to contain MIT domains, but only 7 of 
them have been analyzed for ESCRT-III binding properties (1).  The MIT-MIM 
interaction seems to be essential for the recruitment MIT containing proteins to 
the site of action.  If we were to fully comprehend all of the various MIT-MIM 
interactions, would it be possible for us to ‘decode’ MIT-MIM interactome?  This 
would allow us to selectively target certain MIT-MIM interactions to prevent a 
specific MIT containing protein from being recruited by the ESCRT-III proteins.  
In the context of therapeutic application, we could envision to essentially ‘turn off’ 
a single aspect of ESCRT function that has become deleterious, while allowing 
other ESCRT functions to continue normally. 
 
Although the interactions between the ESCRT-III proteins, Vta1 and Vps4 
have been studied in detail, the atomic resolution structure of a fully active Vps4 
oligomer has remained elusive.  Hence, we cannot fully apprehend the 
mechanism by which Vps4 converts the ESCRT-III proteins from a membrane 
bound conformation to a cytosolic one.  It is presumed that the dynamic nature of 
Vps4 structure, between a monomeric species and an ATP-bound oligomer, 
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makes the protein challenging to crystallize.  Other structural efforts using 
electron microscopy (EM), while thought to be initially successful, actually 
generated structures of Vps4 that were later proved to be non-physiological (2).  
However, improvements in cyro-EM technology and data collection may make it 
more feasible than ever to approach atomic level resolution for the Vps4 oligomer 
(3).  Furthermore, recent work using the Vps4 homolog from thermophillic yeast 
(Sulfolobus solfataricus) proved useful in resolving oligomeric complexes by size-
exclusion chromatography (2).  Combining these two experimental approaches 
may be the trick necessary for us to finally obtain a high-resolution structure of 
the Vps4 complex.  Another route may be using the lessons learned from 
obtaining the structure of another AAA protein, ClpX, where linkers were added 
to create one polypeptide encompassing all six subunits to force a stable 
oligomeric structure (4).  By linking Vps4 together, it may be possible to generate 
a high-resolution structure by preventing the dissociation of the oligomer. 
 
The prevailing model of Vps4 regulation is that the faster the enzyme can 
hydrolyze ATP, the better for its function in vivo.  It will be interesting to actually 
correlate the rate of ATP hydrolysis with its physiological function.  It has become 
quite successful in recent years to try to recapitulate ESCRT function using in 
vitro reconstitution (5), and I believe it is feasible to extend this further using a 
method developed by Saksena et al. (6).  In brief, they recapitulate ESCRT-III 
assembly on a liposome, where one of the ESCRT-III proteins is conjugated to a 
dye that has different spectroscopic characteristics depending whether it is in 
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solution or in a lipid environment.  Therefore, when Vps4 removes the ESCRT-III 
complex from the lipid membrane, the change in the spectroscopic property of 
the dye can followed kinetically.  Unfortunately, the researchers only use the core 
ESCRT-III proteins (Vps20, Snf7, Vps24, and Vps2) and Vps4 for their analysis, 
and it will be interesting to see how the inclusion of the other ESCRT-III proteins 
(Did2, Vps60, Ist1, and Vfa1) in conjunction with Vta1 or by themselves, can 
influence this process.  Did2, Vps60 and Vfa1 have all been shown to directly or 
indirectly stimulate Vps4 ATPase activity, and in contrast, Ist1 has been shown to 
inhibit Vps4 (7-9).  It will be fascinating to see what interplay exists between 
these proteins, and whether an increase of ATPase activity directly contributes to 
the expedition of ESCRT-III disassembly. 
 
One theme of this thesis work has been that some of our knowledge of the 
ESCRT system in yeast is not easily translatable to the human system.  
Unfortunately, study of ESCRT dysfunction in the metazoan MVB pathway in is 
challenging by conventional methods.  In metazoan, our current understanding of 
ESCRT function predominantly comes from observing the efficiency of viral 
release or cytokinesis.  While useful in their own right, ESCRT function is not 
ubiquitous for all processes.  The early ESCRT complex, ESCRT-I, seems to be 
dispensable for viral release and cytokinesis, and therefore studies in these 
systems cannot recapitulate what we currently understand about MVB 
biogenesis (10).  Furthermore, the yeast system is genetically tractable, while the 
metazoan experiments rely on siRNA to probe the function of a particular ESCRT 
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proteins.  There is a great need for developing new methods for the study of 
metazoan MVB biogenesis system in a more native context.  Recent work has 
begun to show the promise for C. elegans to be used as a model system for this 
exact purpose.  During embryogenesis, there is a large and systematic flux of 
materials that goes through the MVB pathway, and as such this allows for the live 
organism imaging for protein factors, like individual ESCRT components, or 
movement of cellular receptors into MVBs (11).  Taking advantage of the 
clustered, regularly interspersed, short palindromic repeats (CRISPR) RNA-
guided Cas9 nuclease for genetic manipulations has the potential to 
exponentially increase the ease and tractability of the C. elegan system (12).  
Observing MVB biogenesis in vivo and, most importantly, in a metazoan system 
has the potential to dramatically increase our understanding of ESCRT function. 
 
Until we can define mechanistic roles for all the ESCRT-III proteins and 
how they work together, it will be extremely challenging to fully comprehend the 
scission event carried out by this interplay.  In MVB biogenesis, the vesicle 
formation is uniform and precise, suggesting a tightly controlled process that is 
not spontaneous.  Even slight disruptions to ESCRT-III function can lead to 
improper development of MVBs.  Hopefully, the work presented in this thesis has 
helped resolve some of the ambiguity surrounding Vps4/Vta1 regulation by the 
ESCRT-III proteins, and provided useful clues to help address the next critical 
question in the field. 
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Appendix Structural basis of molecular recognition between ESCRT-
III-like protein Vps60 and AAA-ATPase regulator Vta1 in the 
multivesicular body pathway 
A.1 Abstract 
The AAA-ATPase Vps4 is critical for function of the multivesicular body 
sorting pathway, which impacts cellular phenomena ranging from receptor down-
regulation to viral budding to cytokinesis. Vps4 activity is stimulated by the 
interaction between Vta1 and Vps60, but the structural basis for this interaction is 
unclear. The fragment Vps60(128–186) was reported to display the full activity of 
Vps60. Vta1 interacts with Vps60 using its N-terminal domain (Vta1NTD). In this 
work, the structure of Vps60(128–186) in complex with Vta1NTD was determined 
using NMR techniques, demonstrating a novel recognition mode of the 
microtubule-interacting and transport (MIT) domain in which Vps60(128–186) 
interacts with Vta1NTD through helices $4' and $5', extending over Vta1NTD 
MIT2 domain helices 1–3. The Vps60 binding does not result in Vta1 
conformational changes, further revealing the fact that Vps4 ATPase is enhanced 
by the interaction between Vta1 and Vps60 in an unanticipated manner 
A.2 Introduction 
Membrane budding away from the cytosol controls a number of biological 
processes important to cellular homeostasis and defenses against aging (1-3). 
The machinery responsible for executing this function consists of several distinct 
multimeric complexes known as the endosomal sorting complexes required for 
transport (ESCRTs) (4-6), which were originally identified in yeast and have been 
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implicated in multivesicular body (MVB) biogenesis in plants, fungi, and animals 
(6,7). MVBs are formed when the late endosomal membrane invaginates and 
forms vesicles in the lumen, carrying selected transmembrane protein cargoes in 
the budding process (2,3). MVB biogenesis and fusion of an MVB with the 
lysosome in a later step represent a mechanism in which eukaryotic cells down-
regulate cell surface signaling via the endolysosomal degradation pathway (8). 
Components of the ESCRT machinery have been identified as potential tumor 
suppressors (9), mainly attributed to the involvement of the ESCRT machinery in 
mediating signal attenuation for activated receptors of growth factors, peptide 
hormones, and cytokines. The ESCRT machinery protects against age-related 
neurodegenerative diseases through either the canonical MVB pathway or 
autophagy (9,10). In addition, the ESCRT machinery also plays a pathological 
role in viral infection (2,11,12). 
 
At least five distinctive multimeric complexes are involved in MVB 
biogenesis: ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III, and Vps4 (13,14). Their 
structure and function are highly conserved in all eukaryotes (9,10). ESCRT-0 is 
responsible for clustering of ubiquitylated cargoes to the site of MVB formation. 
ESCRT-I and ESCRT-II together generate membrane curvature and budding, 
whereas assembly of ESCRT-III at the bud neck catalyzes scission of the 
membrane. Completion of the process requires the AAA-ATPase Vps4, which 
disassembles ESCRT-III polymers upon ATP binding and hydrolysis (15,16). 
This ATP-consuming reaction is the only step in MVB biogenesis that inputs 
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energy into the system, therefore providing the thermodynamic driving force for 
processing. Importantly, the role of Vps4 is conserved in all biological processes 
that depend on the action of the ESCRTs. Similar to other AAA-ATPases, Vps4 
functions as an oligomer whose structure likely contains two conformationally 
distinctive hexameric rings (17). The rings contain a central pore where ESCRT-
III subunits may physically interact and pass through during the disassembly 
process. Initial binding of Vps4 to ESCRT-III subunits requires its N-terminal 
microtubule-interacting and transport (MIT) domain (18). The MIT domain 
appears to specifically recognize short peptide sequence MIT-interacting motifs 
(MIMs) at or near the C-terminal end of ESCRT-III subunits (19-24). 
 
The in vivo activity of Vps4 is tightly regulated (25). To date, at least four 
proteins have been identified to bind to Vps4 and have roles in regulating its 
oligomerization and activity (26-29). Did2, Ist1, and Vps60 are ESCRT-III-related 
proteins whose mechanisms of action on Vps4 remain to be clarified. Vta1 is a 
positive regulator of Vps4 by promoting Vps4 oligomerization (26,30). Structural 
study of Vta1 has shown that it is a molecular dimer, with each subunit folded 
into two terminal domains linked by a flexible linker (29). Its C-terminal domain 
mediates dimerization and binds to a unique #-domain in the Vps4 AAA domain 
(31,32). Its N-terminal domain (residues 1–167; Vta1NTD) (Figure A.1) contains 
two tandem MIT domains, which specifically recognize Vps60 and Did2 but not 
other ESCRT-III subunits (27,29). The fragment Vps60(128-186) was reported to 
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display the full activity of Vps60, which stimulates Vps4 ATPase in a Vta1-
dependent manner (27). 
 
Figure A.1 Structural features of the Vta1NTD-Vps60(128–186) complex 
(A) schematic representation of Vta1 and Vps60, highlighting regions critical for 
interactions that contribute to increased Vps4 ATPase activity. VSL, 
Vta1/SBP1/LIP5; CTR, C-terminal region. (B) backbone view of the ensemble of 
the 20 lowest energy Vta1NTD-Vps60(128–186) NMR structures, where 
Vps60(128–186) is displayed in orange. (C) three-dimensional representative 
structure of Vta1NTD-Vps60(128–186). The helices are numbered. (D) structural 
comparison of five different recognition modes of the MIT domain with MIM. 
Vps60 interacts with the first, second, and third helices of the Vta1NTD MIT2 
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domain together, which is different from a previously reported MIT ligand 
recognition mode. 
In this work, to investigate how Vps60 interacts with Vta1NTD, we first 
measured the binding affinity of Vta1NTD for Vps60(128–186) (Kd ! 0.7 µM) 
using isothermal titration calorimetry assay and then determined the solution 
structure of Vta1NTD in complex with Vps60(128–186). To confirm the residues 
involved in the interaction between Vta1NTD and Vps60(128–186), site-directed 
mutations and GST pulldown experiments were performed. The structure reveals 
that Vps60(128–186) interacts with Vta1NTD through a novel MIT domain 
recognition mode distinct from any reported mechanism. 
A.3 Results 
A.3.1 NMR Structural Determination 
Initially, two basic sets of NMR mixed samples were made: 1) 13C and 15N 
isotope-labeled Vta1NTD with unlabeled Vps60(128–186) at a stoichiometric 
ratio of 1:1.2 and 2) 13C and 15N isotope-labeled Vps60(128–186) with unlabeled 
Vta1NTD at a stoichiometric ratio of 1:1.2, each of them for assignment of NMR 
signals belonging to the corresponding 13C- and 15N-labeled component and its 
structural determination. The intermolecular NOEs could be correctly assigned by 
confirming signals observed in three-dimensional 13C-F1-edited, 13C/15N-F3-
filtered NOESY spectra acquired on both complex samples. In total, assignments 
of >96% of the main chain and 95% of the side chain atoms of the residues in the 
complex were completed. The NMR chemical shift changes of Vta1NTD 
backbone atoms 1H and 15N in the absence and presence of Vps60(128–186) 
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reveal that Vps60(128–186) addition mainly induced Vta1NTD MIT2 domain 
amide 15N and 1H chemical shift variations in residues of the Vta1NTD MIT2 
domain (Figure A.2A), suggesting that Vps60-binding sites localize in these 
regions. This observation accords with the analysis of the electrostatic surface of 
Vta1NTD in its free state, which shows that the Vta1NTD MIT2 domain is more 
positively charged than the MIT1 domain (Figure A.2B and Figure A.2C), suitable 
for negatively charged Vps60 binding. 
 
Figure A.2 Vps60 interacts with the Vta1NTD MIT2 domain motif, resulting 
in conformation stabilization of Vps60 and Vta1 NTD helix !4  
(A) chemical shift changes in Vta1NTD backbone amide atoms 1H and 15N upon 
Vps60(128–186) binding, calculated using the following equation: "(av = (0.5 ) 
("((NH)2 + 0.2 ) "((15N)2))1/2. The secondary structures are indicated at the top 
based on the crystal structure of free Vta1NTD (Protein Data Bank code 2RKK). 
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(B and C) electrostatic potential surfaces between helices 1 and 3 (left), helices 2 
and 3 (right) of the MIT1 domain and between helices 1 and 3 (left) and helices 2 
and 3 (right) of the MIT2 domain, respectively. The electrostatic potential surface 
was generated based on the crystal structure of free Vta1NTD using DelPhi 
software and visualized by PyMOL. (D) superimposition of two-dimensional 1H-
15N HSQC spectra of Vps60(128–186) in the absence (blue) and presence (red) 
of Vta1NTD. (E) CD spectroscopy of free Vps60(128–186). (F) structural overlay 
of Vta1NTD in the free state (gray) and in complex with Vps60(128–186) (red). 
The N and C termini and the secondary structures are indicated. (G) interactions 
between the short N-terminal $-helix of Vps60(128–186) and helix $4 of 
Vta1NTD. The ribbon representation of Vta1NTD is colored in green for $2 and 
$3, red for $4, and blue for $5, with the N-terminal $-helix of Vps60(128–186) 
shown in orange. 
The solution structure of the Vta1NTD-Vps60(128–186) complex was 
determined by a conventional heteronuclear NMR method using 15N- or 13C/15N-
labeled protein. In total, 4469 distance restraints from NOE (286 intermolecular 
NOEs), 260 hydrogen bonds, and 390 dihedral angle restraints for backbone ! 
and * angles were used to calculate the solution structure. A best fit 
superposition of the ensemble of the 20 lowest energy structures represented in 
Figure A.1B is displayed, with root mean square deviations of 0.59 ± 0.13 Å for 
global backbone atoms and 1.07 ± 0.15 Å for global heavy atoms. The root mean 
square deviations were 0.46 ± 0.10 Å for the backbone atoms (N, C$, and CO) 
and 0.87 ± 0.12 Å for all heavy atoms in the well-ordered secondary structure 
regions. The Ramachandran plot displays 94.1% of the residues in the most 
favored regions and 4.8% residues in additionally allowed regions (Table A.1), 
indicating that the structures are reasonable. 
Table A.1 Experimental restraints and structural statistics for the Vta1NTD-
Vps60(128-186) complex 
NMR distance and dihedral constraints  
    Distance restraints from NOEs  
        Intramolecular  
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            Total 4183 
            Intraresidue (i + j = 0) 1215 
            Sequential (|i + j| = 1) 971 
            Medium-range (1 < |i + j| , 5) 1340 
            Long-range (|i + j| > 5) 657 
        Intermolecular 286 
    Hydrogen bonds 260 
    Dihedral restraints 390 
        ! 195 
        * 195 
 
Structural statisticsa  
    r.m.s.d.b versus mean structure (Å)  
        All backbone atoms 0.59 ± 0.13 
        All heavy atoms 1.07 ± 0.15 
        Backbone atoms (secondary structure) 0.46 ± 0.10 
        Heavy atoms (secondary structure) 0.87 ± 0.12 
    r.m.s.d. from experimental restraints  
        NOE distances (Å) 0.023 ± 0.0003 
        Dihedral angles 0.685 ± 0.0136° 
    r.m.s.d. deviations from idealized geometry  
        Bonds (Å) 0.0018 ± 0.000021 
        Angles 0.280 ± 0.0038° 
        Impropers 0.289 ± 0.0039° 
    Ramachandran analysis (%)  
        Residues in most favored regions 94.1 
        Residues in additionally allowed regions 4.8 
        Residues in generously allowed regions 1.1 
        Residues in disallowed regions 0.0 
"a Structural statistics were calculated from the 20 lowest energy XPLOR-NIH 
structures. 
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"b r.m.s.d., root mean square deviations. 
A.3.2 Vta1 Binding Stabilizes Vps60(128–186) Helix Conformation 
The two-dimensional NMR 1H-15N HSQC experiment with Vps60(128–
186) in its free state (Figure A.2D) suggests that Vps60(128–186) in its free state 
is disordered because the cross-peaks are not dispersed, localizing mainly in the 
region between 8.0 and 8.5 ppm. To confirm this observation, we preformed CD 
spectroscopy on free Vps60(128–186), where negative absorption at !200 nm 
shows a random coil conformation (Figure A.2E). Upon binding to Vta1NTD, the 
cross-peaks in two-dimensional NMR 1H-15N HSQC of Vps60(128–186) became 
dispersed (Figure A.2D), suggesting that Vps60(128–186) folds into an ordered 
structure, coinciding with the structure determined below. This demonstrates that 
Vta1NTD binding stabilizes Vps60 helix conformation. 
A.3.3 Overall Complex Structure 
The Vta1NTD-Vps60(128–186) structure shows that the bound Vta1NTD 
still has two MIT domains, each of them composed of three $-helices (MIT1: 
helices $1, $2 and $3; and MIT2: helices $5, $6, and $7) (Figure A.1C), almost 
similar to those observed in its free state (29). Helix $4 was much longer in 
Vta1NTD bound to Vps60(128–186) than in free Vta1NTD, which might have 
resulted from the conformational stabilization upon its binding to Vps60 (as 
demonstrated below), consistent with the secondary structure prediction based 
on the assignments of backbone atoms 13C$, 13C#, 13CO, 1H, and 15N (Figure 
A.3). The backbone atoms of bound Vta1NTD had a root mean square deviation 
of 1.07 Å from those of free Vta1NTD (Figure A.2F), indicating that Vps60(128–
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186) binding does not induce overall major conformational changes in Vta1NTD. 
The secondary structure prediction and perceived structural homology to 
ESCRT-III protein Vps24/CHMP3 suggest that Vps60(128–186) corresponds to 
the fourth and the fifth helices within the Vps60 structure (42). In the current 
complex structure, Vps60(128–186) indeed folds into two $-helices (denoted as 
$4' and $5'), and both helices are involved in the interaction with the MIT2 
domain of Vta1NTD (Figure A.1). The two $-helices of bound Vps60(128–186) 
adopt an overall V-shaped helix-turn-helix structure and straddle on the third 
helix ($7) of the Vta1NTD MIT2 domain. The longer helix $4' consists of residues 
140'–157' and interacts with $5 and $7, corresponding to the first and third 
helices of the Vta1NTD MIT2 domain. It runs diagonally from the N-terminal end 
of $5 to the C-terminal end of $7, maintaining a general direction parallel to both 
helices. The polypeptide chain crosses over to the other side of $7 near the C-
terminal end of $7 and continues as $5' (residues 168'–182'), running nearly 
vertical to helices $6 and $7. The Vta1-Vps60 complex buries a total of !3600-
Å2 surface area at the interface. In contrast to the MIT domains in Vps4, spastin, 
or AMSH (19-24), Vps60(128–186) interacts with Vta1NTD through helices $4' 
and $5', extending over Vta1NTD MIT2 domain helices 1–3. Thus, the Vta1NTD 
MIT2 domain displays a fifth and novel ligand recognition mode to bind to 
Vps60(128–186) (Figure A.1D and shown under “Discussion”). 
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Figure A.3 Chemical Shift Index between Vta1NTD free and Vta1NTD in 
complex with Vps60 
Graphs of the consensus plots of chemical shift index (CSI) based on the 1H$, 
13C$, 13C# and 13CO chemical shifts of Vta1NTD in free (A, upper) and bound (B, 
down) with Vps60128-186 
A.3.4 Vta1NTD Helix 4 Is Stabilized upon Vps60 Binding 
In our complex structure, there are no significant structural changes in 
Vta1NTD except in the region that connects the two MIT domains. In the free 
Vta1NTD structure (29), the linker adopts largely a random coil structure, with 
only a one-turn $-helix occurring at residues 80–84. In particular, residues 65–75 
appear to be disordered in the structure. Upon Vps60 binding, the linker 
becomes ordered. Residues 68–71 become a one-turn $-helix, and residues 73–
84 adopt a longer helical structure (Figure A2.F). This conformational change 
might be caused by the interactions between helix $4 (positions 73–84) of 
Structure of the Vta1-Vps60 structure 
!""
Structural basis of molecular recognition between ESCRT-III like protein Vps60 and AAA-ATPase 
regulator Vta1 in the multi-vesicular body pathway 
Zhongzheng Yang1, Cody Vild2, Jiaying Ju1, Xu Zhang3, Jianping Liu1, 4, Jie Shen1, Bin Zhao1, Wenxian 
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Supplementary figures legend 
Figure S1 Graphs of the consensus plots of chemical shift index (CSI) based on the 1H!, 13C!, 13C" and 
13CO chemical shifts of Vta1NTD in free (A, upper) and bound (B, down) with Vps60128-186.  
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 192 
Vta1NTD and a short N-terminal $-helix (positions 128–134) of Vps60(128–186) 
(Figure A.2G). The interaction is predominantly hydrophobic, involving Ile-128', 
Ile-130', and Leu-133' of Vps60, as well as Lys-74, Ser-75, Val-78, Met-79, Thr-
81, and Leu-82 of Vta1NTD helix $4. 
 
To confirm that the changes in helix $4 of Vta1NTD are generated due to 
Vps60(128–186) binding rather than crystallization, we assigned the chemical 
shifts of backbone atoms 13C$, 13C#, 13CO, 1H, and 15N of free Vta1NTD. The 
secondary structure prediction based on these assignments using the programs 
CSI (43) and TALOS (36-38) suggests that there are seven helices formed in 
free Vta1NTD, including $1 (Ala-2–Lys-17), $2 (Ile-23–Leu-36), $3, (Gln-43–Glu-
62), $4 (Asp-73–Met-79), $5 (Gln-86–Lys-109), $6 (Val-115–Leu-134), and $7 
(Thr-142–Lys-163), which are much similar to these observed in Vta1NTD bound 
to Vps60(128–186), except helix $4 (Figure A.3). 
A.3.5 Interface in the Vta1-Vps60 Complex Structure 
There are three major sites of interaction between the Vta1NTD MIT2 
domain and Vps60(128–186) (Figure A.4). The first binding site (Figure A.4A and 
Figure A.4B) on Vta1NTD is predominantly hydrophobic and is lined by Ile-91, 
Tyr-92, Leu-94, Phe-96, Met-98, Tyr-101, Leu-105, Leu-108, Tyr-153, and Tyr-
157 and the aliphatic chain of Lys-88, Lys-106, and Lys-109. The side chains of 
the residues located at Vps60(128–186) helix $4', including Met-140', Leu-141', 
Leu-143', Ile-144', Leu-150', Val-153', and Leu-154', are inserted into the groove 
of Vta1NTD helices 5 and 7. The Vps60(128–186) Ile-144' side chain has a 
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hydrophobic interaction with the Vta1NTD Ile-91, Leu-94, and Met-98 side 
chains, as Pro-171 functions in the complex Vps4A-CHMP6(168–179) (21). 
Besides the hydrophobic interactions, complementary salt bridges are also 
formed by two of the adjacent conserved Vps60(128–186) residues (Glu-149' 
and Glu-152') (Figure A.4B). Moreover, the side chains of Vta1NTD Asn-95 and 
Asn-102 may form hydrogen bond interactions with the main chains of Met-140' 
and Gln-146', respectively. The second site on Vta1NTD binds mainly to the 
linker between $4' and $5' of Vps60(128–186) (Figure A.4C), most prominently to 
the side chains of Leu-163' and Ile-166'. This site is also mainly hydrophobic and 
is lined by Tyr-153, Ile-156, and Tyr-157 and the aliphatic chains of Lys-149, Lys-
152, and Lys-160, except that the side chain of Glu-162' forms a complementary 
salt bridge with Lys-149. A previous alanine-scanning mutagenesis study showed 
that residues 139'–143', 144'–148', 154'–158', and 164'–168' of Vps60 are 
important for its interaction with Vta1 (27), which is consistent with our current 
structural observation. The third binding site on Vta1 contacts Vps60(128–186) 
helix $5' (Figure A.4D), including previously identified Vta1 residues important for 
Vps60 interaction, Trp-122 and Lys-152 (27-29). In addition, the side chains of 
polar residues Lys-118, Arg-119, Lys-155, Lys-160, and Lys-163, as well as 
residues Ile-125, Ile-156, Leu-158, and Ala-162, largely hydrophobic in nature, 
form salt bridges with those of Asp-168', Glu-170', Asp-172', Glu-174', Asp-176', 
Glu-181', and Asp-182' or have hydrophobic or stacking interactions with those of 
Leu-171', Leu-175', Leu-178', Ala-179', and F183'. A hydrogen bond interaction 
was observed between the side chain of Ser-159 and the main chain of Leu-171'. 
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Figure A.4 Detailed interactions between Vps60(128–186) and the Vta1NTD 
MIT2 domain 
(A and B), ribbon representation of Vta1NTD shown in blue, with Vps60(128–
186) helix $4' shown in orange. (C) ribbon representation of Vta1NTD shown 
in blue, with the linker between Vps60(128–186) helices $4' and $5' shown 
in orange. (D) ribbon representation of Vta1NTD shown in blue, with Vps60(128–
186) helix $5' shown in orange. 
A.3.6 Mutational Analyses of the Vta1-Vps60 Interaction 
Mutations were introduced into these observed binding sites to test the 
importance of the residues to the overall stability of the complex. As shown 
in Figure A.5 and Table A.2, our in vitro GST pulldown experiments and 
isothermal titration calorimetry assay demonstrated that of all the single alanine 
or aspartic acid substitutions of Vta1NTD Lys-88, Ile-91, Met-98, Leu-105, Lys-
106, Leu-108, Lys-109, Lys-118, Arg-119, Trp-122, Lys-149, Lys-152, Lys-155, 
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Ile-156, Leu-158, and Lys-163 have effects on Vps60(128–186) binding, 
confirming the energetic importance of all of these residues. Consistent with the 
large buried interface area of the Vta1-Vps60 complex, no single-site mutations 
could eliminate all detectable Vps60(128–186) binding. 
 
Figure A.5 Sequential and mutational analyses of the Vta1NTD-Vps60(128–
186) complex. 
(A) structure-based sequence alignments of the Vta1NTD MIT2 domain from 
various organisms. The residues involved in the interactions are indicated (black 
ovals). (B) GST pulldown assay of the Vta1NTD-Vps60(128–186) complex. GST 
or GST-tagged Vps60(128–186) was used to pull down wild-type or mutant 
ta1NTD as indicated. Proteins retained on the beads were analyzed by SDS-
PAGE and visualized by Coomassie Blue staining. (C) sequence alignment of 
Vps60(128–186) helices $4' and $5' from various organisms. The residues 
involved in the interaction are indicated (black ovals). 
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Table A.2 Binding affinities of Vps60(128-186) for wild-type and muntant 
Vta1NTD determined by isothermal titration calorimetry assay. 
Vta1NTD Kd 
 µM 
WT 0.7 ± 0.1 
K88A 1.2 ± 0.3 
I91A 0.9 ± 0.2 
M98A 0.9 ± 0.2 
L105A 3.1 ± 0.5 
K106D 1.1 ± 0.2 
L108A 1.4 ± 0.1 
K109D 0.8 ± 0.1 
K118D 1.7 ± 0.1 
R119D 1.05 ± 0.04 
W122A 1.4 ± 0.3 
W122D 4.7 ± 0.3 
K149A 1.0 ± 0.2 
K149D 1.9 ± 0.1 
K152A 3.9 ± 0.4 
K155A 2.3 ± 0.1 
I156A 1.5 ± 0.2 
L158A 1.5 ± 0.1 
K163A 1.1 ± 0.3 
 
Based on the sequence alignment (Figure A.5A and Figure A.5C), the 
Vta1NTD MIT2 domain derived from S. cerevisiae has low sequence similarity to 
the other organisms, whereas Vps60(128–186) is highly conserved. The highly 
conserved Vta1NTD MIT2 domain residues Trp-122, Lys-152, and Ile-156 play 
more important roles in the Vta1-Vps60 interactions. Compared with the wild 
type, the binding affinities of the W122A, W122D, K152A, and I156A mutants for 
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Vps60(128–186) are reduced by !2.0-, 6.7-, 5.6-, and 2.1-fold, respectively. Most 
notably, the non-conserved hydrophobic residues Leu-105 and Leu-108 in helix 
$5 of Vta1NTD are important as well; the L105A and L108A variants display an 
!4.4- to 2.0-fold reduction in the binding affinities for Vps60(128–186). This 
demonstrates that Vps60(128–186) helix $5' binds in a more conserved surface 
groove of Vta1NTD compared with Vps60(128–186) helix $4' (Figure A.5A), 
indicating that the interactions between Vps60(128–186) helix $5' and Vta1NTD 
are more common in all organisms, whereas the interactions between 
Vps60(128–186) helix $4' and Vta1NTD make the interactions between Vta1NTD 
and Vps60(128–186) in yeast unique from those in other organisms. Thus, the 
Vta1NTD-Vps60(128–186) complex structure provides a structural basis for a 
previous study that showed that LIP5 (Vta1 in yeast) bound efficiently to a 
fragment of CHMP5 (Vps60 in yeast) that contained $5 but not $4 (44). 
A.4 Discussion 
A.4.1 Novel Mode of MIT-MIM interaction 
The MIT domain is a versatile protein-protein interaction domain identified 
in proteins that have a role in vesicle trafficking, including Vps4, Vta1, AMSH, 
and UBPY, where they mediate interaction within the ESCRT-III complex (45). 
The MIT domain recognizes sequence motifs called the MIMs primarily within the 
ESCRT-III subunits. It has been suggested that the interaction between the MIT 
domain and MIM acts in regulating the disassembly of ESCRT-III, as well as in 
targeting specif
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MIM (MIM1, MIM2, MIM3, and MIM4) were reported to bind to different sites on 
the MIT domain (Figure A.1) (19-24). 
 
MIM1 contains a sequence-conserved amphipathic helix 
((D/E)xxLxxRLxxL(K/R)) along the groove between MIT domain helices $2 and 
$3 observed in the Vps4-Vps2(183–232) (19) and Vps4-CHMP1A(180–196) (20) 
complexes. MIM2 is a proline-rich sequence (L170P(E/D)VP174 and 
R183xLxPxLPxPP193) along the groove between MIT domain helices $1 and $3 
found in the Vps4-CHMP6(168–179) (21) and Saci1372-Saci1337(183–193) (22) 
complexes, respectively. MIM3 is a highly specific mode along the groove 
between MIT domain helices $1 and $3 found in the spastin MIT-CHMP1B(148–
196) complex (23) but with an interface twice large as that of the MIT domain of 
the Vps4-CHMP complex. MIM4 is a mainly polar sequence 
(E203xxxExx-xx-xxRLxTLR221) along a groove made up of helices 3 (Vps4 MIT 
domain helix 2) and 4/5 (Vps4 MIT domain helix 3) indentified in the AMSH"C-
CHMP3"N complex (24). Although the MIM4-binding site resembles the MIM1-
binding surface, the contacts between the AMSH MIT domain and MIM4 are 
mostly polar interactions, whereas hydrophobic interactions play an important 
role in the Vps4 MIT-MIM1 and Vps4 MIT-MIM2 complexes. 
 
Vta1NTD contains two tandem MIT domains as identified in its crystal 
structure (29), which mediate the interaction between Vta1 and the ESCRT-III-
related proteins Vps60 and Did2. Our NMR structure of Vta1NTD-Vps60(128–
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186) shows that Vps60 MIM binds exclusively to the second MIT domain of Vta1. 
Unlike other MIMs, the Vps60 MIM sequence (residues 140–186, defined as 
MIM5) is much longer and forms two helices ($4' and $5'). The significant 
difference from the other MIMs is that Vps60 MIM5 can bind both surfaces made 
up of helices 5 and 7 (Vps4 MIT domain helices 1 and 3) and helices 6 and 7 
(Vps4 MIT domain helices 2 and 3) of the Vta1 MIT2 domain. The Vta1 MIT2-
Vps60 MIM5 contacts are a mixture of polar and hydrophobic interactions, as is 
the case for spastin MIT-MIM3. Thus, the structure of the Vta1-Vps60 complex 
provides a novel recognition mode of the MIT domain with its ligand and extends 
the diversity of MIT domain interaction surfaces for peptide ligands. 
A.4.2 Vps60 Enhances Vta1 Stimulation of Vps4 in a Complex Manner 
The dynamic assembly and disassembly of the ESCRT-III polymer play a 
critical role in ESCRT-mediated membrane deformation events and alterations of 
Vps4 ATPase activity. To address how Vps60 and Did2 binding enhances Vta1 
stimulation of Vps4 ATPase activity, two models were presented (27). One is that 
their binding to the MIT2 domain results in conformation changes in Vta1; the 
other is that the interaction between Vta1 and Did2 or Vps60 increases the local 
concentration of Vta1-Vps4 in vitro. It was reported that removal of the two Vta1 
tandem MIT domains (Vta1(165–330)) does not enhance the basal activation of 
Vps4 by Vta1, implying that Vta1 MIT domains do not autoinhibit Vps4 activation 
(27). The current NMR structure of the Vta1NTD-Vps60(128–186) complex 
provides further evidence that Vps60 binding does not induce overall 
conformational changes in the N terminus of Vta1 (Figure A.2F) and thus might 
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not lead to further structural arrangement in the C-terminal domain of Vta1. 
These observations suggest that Vps60 may not allosterically regulate Vta1 and 
thus could not potentiate its ability to activate Vps4. 
 
The residues within Vps60(128–186) helix $5' in the interface are 
composed of the sequence D168'xxL171'xx(E174')L175'xxL178'(A179') (Figure A.6A), 
nearly identical to CHMP1A(180–196) MIM1 ((D/E)xxLxxRLxxL(K/R)) (19-20), 
except for Glu-174' and Ala-179' in contrast to the positively charged residues 
Arg-190 and Arg-195 in CHMP1A(180–196). In the Vta1NTD-Vps60(128–186) 
structure, the Vta1NTD MIT2 domain recognizes a new residue sequence 
(L143'(I144')xxxxE149'L150'xE152'V153'L154') within Vps60(128–186) helix $4', which has 
low sequence similarity to CHMP6 MIM2 (Figure A.6B) (21), although Leu-143', 
Glu-145', Glu-152', and Leu-154' are conserved. Therefore, the interactions 
between Vta1 and Vps60 implied by the current complex structure do not mimic 
the interactions between Vps4 and the ESCRT-III subunits CHMP1A(180–196) 
and CHMP6(168–179). Thus, it is plausible that the specific interaction between 
Vta1 and Vps60 increases the local concentration of Vta1-Vps4 in vitro to 
enhance Vta1-Vps4 binding and thereby stimulate Vps4 activity. 
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Figure A.6 Sequence alignments of Vps60(128–186) helices !4" and !5" with 
conserved MIM1 and MIM2. 
A, Vps60(128–186) helix $5' with MIM1 sequences. B, Vps60(128–186) helix $4' 
with MIM2 sequences. Sc, S. cerevisiae; HS, Homo sapiens. 
 
Taken together, the complex structure of Vta1NTD-Vps60(128–186) 
cannot account for all aspects of Vps4 activation, but it demonstrates a novel MIT 
recognition mode that has not been reported. Thus, to address how Vps4 
ATPase is activated, further studies of the dynamics of ESCRT-III assembly and 
disassembly will be performed to better understand the precise function of Vta1 
in the process of MVB sorting. The current structure further confirms that the 
interaction between Vps60 and Vta1 stimulates Vps4 ATPase in an unexpected 
manner. 
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A.5 Methods 
A.5.1 Cloning, Expression, and Purification 
DNA fragments encoding yeast Vta1 and Vps60 were amplified from 
Saccharomyces cerevisiae genomic DNA. Vta1NTD or Vps60(128–186) was 
expressed in Escherichia coli BL21(DE3) using a modified pET28b vector with a 
small ubiquitin-like modifier (SUMO) protein inserted between a His6 tag and the 
Vta1NTD or Vps60(128–186) coding region, respectively. His6-tagged SUMO-
Vta1NTD or His6-tagged SUMO-Vps60(128–186) was purified by nickel-
nitrilotriacetic acid affinity chromatography following standard procedures. Ulp1 
protease was then added to remove the His6-SUMO tag, and the protein mixture 
was passed over a second nickel-nitrilotriacetic acid column and further purified 
by anion exchange chromatography on a Resource Q column (GE Healthcare). 
For isotope labeling, M9 minimal medium was supplemented with 15NH4Cl 
(Cambridge Isotope Laboratories) or 15NH4Cl and 2 g/liter [13C]glucose 
(Cambridge Isotope Laboratories). Derivative proteins were purified in the same 
way as native proteins. 
A.5.2 NMR Sample Preparation and Data Collection 
Differentially labeled complex samples in 25 mM sodium phosphate (pH 
7.0), 100 mM NaCl, 5 mM DTT-d10, and 0.02% NaN3 were prepared as follows: 
1) 1.5 mMuniformly labeled 15N/13C-labeled Vta1NTD plus 1.8 mM unlabeled 
Vps60(128–186) and 2) 1.5 mM uniformly labeled 15N/13C-labeled Vps60(128–
186) in complex with 1.8 mM unlabeled Vta1NTD. All NMR experiments were 
performed at 20 °C on a Varian Unity Inova 600 NMR spectrometer (with cryo-
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probe) equipped with triple resonances and pulsed-field gradients or on a Bruker 
AVANCE III 800-MHz NMR spectrometer (with cryo-probe) equipped with four 
channels and z axis pulsed-field gradient. The standard suite of experiments for 
assigning the 1H,13C, and 15N backbone and side chain chemical shifts of 
bound 13C- and 15N-double-labeled Vta1NTD in complex with unlabeled 
Vps60(128–186) or of bound13C- and 15N-double-labeled Vps60(128–186) in 
complex with unlabeled Vta1NTD and for the collection of NOE-based distance 
restraints were measured (33,34), including two-dimensional 13C-edited 
heteronuclear single-quantum correlation (HSQC) in both aliphatic and aromatic 
regions and 15N-edited HSQC; three-dimensional HNCA, HNCO, HN(CO)CA, 
HNCACB, CBCA(CO)NH, and 15N-resolved HSQC- and HCCH-total correlation 
spectroscopy in both aliphatic and aromatic regions; 15N-resolved and 13C-
resolved HSQC-NOESY for both aliphatic and aromatic resonances; and two-
dimensional (H#)C#(C.C()H( and (H#)C#(C.C(C")H" spectra for correlation of 
C# and H( or H" in aromatic rings used in aromatic proton assignment (35). The 
intermolecular NOEs between labeled Vta1NTD or the Vps60(128–186) peptide 
and the unlabeled Vps60(128–186) peptide or Vta1NTD were obtained by 
analyzing three-dimensional 13C-F1-edited,13C/15N-F3-filtered NOESY spectra, 
respectively. All spectra were processed with the program NMRPipe (36) and 
analyzed with the SPARKY 3 software (37). The 1H chemical shifts were 
referenced to 2,2-dimethylsilapentane-5-sulfonic acid, and the 13C and 15N 
resonances were indirectly referenced to 2,2-dimethylsilapentane-5-sulfonic acid. 
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A.5.3 NMR Structure Calculation 
Calculations were carried out using a standard simulated annealing 
protocol implemented in the program XPLOR-NIH 2.19. Interproton distance 
restraints derived from NOE intensities were grouped into three distance ranges, 
1.8–2.9, 1.8–3.5, and 1.8–6.0 Å, corresponding to strong, medium, and weak 
NOEs, respectively. The dihedral angles - and * were derived from the 
backbone chemical shifts (HN, HA, CO, and CA) using the program TALOS (36-
38).  Slowly exchanging amide protons, identified in the two-dimensional 15N 
HSQC spectra recorded after a H2O buffer was exchanged with a D2O buffer, 
were used in the structure calculated with the NOE distance restraints to 
generate hydrogen bonds for the final structure calculation, as done in the 
literature (39). A total of 10 iterations (50 structures in the initial eight iterations) 
were performed. 100 structures were computed in the last two iterations; 20 
conformers with the lowest energy were used to represent the three-dimensional 
structures. In the ensemble of the simulated annealing 20 structures, there was 
no distance constraint violation of >0.3 Å and no torsion angle violation of >3°. 
The final 20 structures with the lowest energy were evaluated with the programs 
PROCHECK-NMR and PROCHECK (40) and are summarized in Table A.1. All 
figures were generated using the programs PyMOL and MOLMOL (41). 
A.5.4 Isothermal Titration Calorimetry 
To obtain a direct binding affinity between Vta1NTD (wild-type and 
mutants) and the Vps60(128–186) peptide, wild-type Vta1NTD and mutants were 
titrated with the Vps60(128–186) peptide using an iTC-200 microcalorimeter (GE 
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Healthcare) at 25 °C. All proteins and peptides were exchanged with buffer 
containing 20 mM sodium phosphate (pH 7.0) and 0.1 M NaCl by gel filtration 
chromatography, centrifuged to remove any particulates, and degassed. To 
obtain a direct binding affinity between Vta1NTD variants and the Vps60(128–
186) peptide, a solution of !0.1 mM wild-type and mutant Vta1NTD was titrated 
with 1.0 mM Vps60(128–186) peptide, respectively. The accurate concentrations 
of Vta1NTD and its mutants were determined using their A280 constants. 
A.5.5 Circular Dichroism Spectroscopy of Free Vps60(128–186) 
To probe the folding of free Vps60(128–186), the CD experiment was 
performed at 25 °C on a JASCO-715 spectropolarimeter (Jasco International Co., 
Tokyo, Japan). Data were collected at 0.1-nm intervals at a scan speed of 20 
nm/min, 1-nm bandwidth, and 0.25-s response time from 250 to 190 nm. Circular 
quartz cells of 1- and 0.1-cm path length were used for the far-UV regions. The 
CD intensities are expressed as molar residue ellipticities given in units of 
degrees cm2 mol+1. The concentration of Vps60(128–186) was !10 µM. The 
buffer conditions used for running CD spectra were 20 mM sodium phosphate 
and 50 mM NaCl (pH 7.5). 
A.5.6 GST Pulldown Experiments 
The experiments were performed following standard procedures in buffer 
containing 25 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 5 mM 2-
mercaptoethanol. Purified wild-type Vta1NTD and mutants were incubated with 
GST alone or with GST-tagged Vps60(128–186) immobilized on glutathione-
agarose beads for 3 h at 4 °C. The beads were then washed extensively three 
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times with the above buffer, and bound proteins were separated by SDS-PAGE 
and visualized by Coomassie Blue staining. 
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